quinazolines has been researched along with piperidines in 901 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 69 (7.66) | 18.7374 |
| 1990's | 77 (8.55) | 18.2507 |
| 2000's | 274 (30.41) | 29.6817 |
| 2010's | 431 (47.84) | 24.3611 |
| 2020's | 50 (5.55) | 2.80 |
| Authors | Studies |
|---|---|
| Schein, E; Voigt, WP | 1 |
| Dollery, CT; Follath, F; Kersting, F; Lewis, GR | 1 |
| Ferguson, AE; Leeson, S; Morrison, WD | 1 |
| Edgar, SA; Flanagan, C | 2 |
| Gescher, A; Stevens, MF; Turnbull, CP | 1 |
| Botros, S; Shaban, M | 1 |
| Anderson, A; Christopher, DH; Woodhouse, RN | 1 |
| Jackson, PG; Jennings, K; Jewitt, DE; Monaghan, M | 1 |
| Jackson, G; Jackson, PG; Jewitt, DE; Kitson, D | 1 |
| Jackson, PG; Jennings, K; Jewitt, D | 1 |
| Alabaster, CT; Blackburn, KJ; Joice, JR; Massingham, R; Scholfield, PC | 1 |
| Conely, JM; Hillis, WS; Hutton, I; Langhan, CE; Lawrie, TD | 1 |
| Cheng, CC | 1 |
| Ryley, JF; Wilson, RG | 1 |
| Dollery, CT; Follath, F; Kersting, F; Lewis, GR; Walden, RJ; Woolhouse, NM | 1 |
| Casey, NH; Crosley, RI; Roosendaal, B; Smith, GA | 1 |
| Casey, NH; Crosley, RI; Smith, GA | 1 |
| Rodríguez-Liñares, B; Walker, T; Watson, S | 1 |
| Bocek, P; Foret, F; Krivánková, L | 1 |
| Adams, MH; Cabel, MC; Colberg, M; Izat, AL; Reiber, MA; Skinner, JT; Stilborn, HL; Waldroup, PW | 1 |
| Bartov, I; Granot, I; Hurwitz, S; Pines, M; Plavnik, I; Wax, E | 1 |
| Daniels, H; Halvorson, JC; Hoffbeck, SL; Noll, SL; Waibel, PE | 1 |
| Chiba, S; Tsukada, M | 1 |
| Cabel, MC; Waldroup, PW | 1 |
| Cabel, MC; Norton, RA; Waldroup, PW; Yazwinski, TA | 1 |
| Hirata, T; Kubo, K; Nomoto, Y; Ohno, T; Takai, H; Teranishi, M | 1 |
| Kuang, Y; Liu, TP | 1 |
| de Vos, AJ; Shiels, I; Stewart, NP | 1 |
| de Chaffoy de Courcelles, D | 1 |
| Hirata, T; Kubo, K; Nakamura, J; Nomoto, Y; Obase, H; Ohno, T; Takai, H; Teranishi, M | 1 |
| de Chaffoy de Courcelles, D; De Clerck, F; Kennis, L; Roevens, P; Somers, Y; Van Belle, H | 1 |
| Ishida, R; Kudo, Y | 1 |
| Kinabo, LD; McKellar, QA; Murray, M | 1 |
| Aono, J; Ishizuka, N; Nabata, H; Sakai, K | 1 |
| Dolan, TT | 1 |
| Alabaster, VA; Campbell, SF; Danilewicz, JC; Greengrass, CW; Plews, RM | 1 |
| Baker, MN; Barrow, PA; Kirk, SJ; Simpson, JM | 1 |
| Conder, GA; Folz, SD; Lee, BL; Nowakowski, LH | 1 |
| Cagniant, E; Devaux, P; Tillier, C | 1 |
| Enueme, JE; Grant, RJ; Halvorson, JC; Waibel, PE | 1 |
| Damron, BL; Fell, RV; Grant, RJ; Hebert, JA; Hellwig, HM; Johnson, ZB; Primo, RA; Siccardi, FJ; Waldroup, PW | 1 |
| Behr, KP; Lüders, H; Plate, C | 1 |
| Blagburn, BL; Ernest, JA; Lindsay, DS; Sundermann, CA | 1 |
| McDougald, LR | 1 |
| Chapman, HD | 3 |
| Karasawa, A; Kasuya, Y; Kubo, K; Obase, H; Shigenobu, K; Shuto, K; Takai, H; Teranishi, M | 1 |
| Humke, R; Kiltz, HH | 1 |
| Grant, RJ; Kennedy, T; Mathis, GF; McDougald, LR; Quarles, CL; Schwartz, J | 1 |
| Grant, RJ; Quarles, CL; Spencer, GK; Waibel, PE; Waldroup, PW | 1 |
| Chhabra, MB; Ruprah, NS; Sanyal, PK | 1 |
| Hashikami, M; Karashima, N; Kasuya, Y; Kubo, K; Nakamizo, N; Obase, H; Shigenobu, K; Shuto, K; Takai, H; Teranishi, M | 1 |
| Kitaly, JI; Maiseli, NC; Mkonyi, PA; Mleche, WC; Njau, BC | 1 |
| Hayashi, E; Higashino, T; Ito, H; Watanabe, M | 1 |
| Chrusciel, TL; Isbell, H | 1 |
| Hagen, HE; Roth, HJ | 1 |
| DeStevens, G | 1 |
| Cheng, CC; Chien, PL | 1 |
| Nagasaki, T; Sato, Y; Tanaka, T | 1 |
| Grant, SJ; Jablons, D; Maas, JW; Swann, AC | 1 |
| Divo, AA; Geary, TG; Jensen, JB | 1 |
| Ahmed, JS; Rehbein, G; Zweygarth, E | 1 |
| Bhattacharyulu, Y; Gill, BS; Kaur, D; Singh, A | 1 |
| Angus, JA; Wright, CE | 1 |
| Heydorn, AO; Voigt, WP | 1 |
| McHardy, N; Morgan, DW | 1 |
| Mehlhorn, H; Moltmann, U; Schein, E; Voigt, WP | 1 |
| De Vos, AJ; Roos, JA | 1 |
| Maitra, SC; Mukherjee, SK; Murthi, PS; Rastogi, AK | 1 |
| Mathis, GF; McDougald, LR | 1 |
| Keshavarz, K; McDougald, LR | 1 |
| Bentley, GA; McLennan, PL | 1 |
| Chen, L; Dai, ZR; Li, GY; Zhang, XP | 1 |
| McDougald, LR; McQuistion, TE | 1 |
| Männer, K; Matuschka, FR | 1 |
| Anderson, A; Bliss, GW; Goodall, E; Woodhouse, RN | 1 |
| Atal, CK; Rao, PG; Zutshi, U | 1 |
| Norton, CC; Wise, DR | 1 |
| Bilgili, SF; Hess, JB; Pinion, JL | 1 |
| Bilgili, SF; Eckman, MK; Hess, JB; Pinion, JL | 1 |
| Rehg, JE | 1 |
| Adachi, H; Kodama, K; Mori, N; Saito, I | 1 |
| Adachi, H; Saeki, T; Saito, I; Souda, S; Takase, Y; Yoshitake, S | 1 |
| Brown, DM; Callow, AD; Choi, ET; Ryan, US; Sehgal, NL | 1 |
| Bollen, M; De Smedt, H; Himpens, B | 1 |
| Christensen, KD; Twining, P; Wyatt, CL; Zimmermann, NG | 1 |
| Granot, I; Halevy, O; Hurwitz, S; Pines, M | 1 |
| Chapman, HD; Hacker, AB | 1 |
| Isaka, N; Ito, M; Itoh, H; Konishi, T; Miyahara, M; Nakano, T; Shiraishi, T | 1 |
| Clarke, W; Cohen, AH; Fouty, B; Hanson, K; McMurty, IF; Morris, K; Rodman, DM | 1 |
| Buhr, RJ; Christensen, KD; Goodman, TN; Twining, PF; Wyatt, CL; Zimmermann, NG | 1 |
| Knopov, V; Levi-Schaffer, F; Nagler, A; Pines, M; Slavin, S | 1 |
| Hoyer, J; Papp, A | 1 |
| Cranfield, MR; Graczyk, TK; Hill, SL | 1 |
| Genina, O; Halevy, O; Levi-Schaffer, F; Nagler, A; Pines, M | 1 |
| Cotev, S; Feferman, R; Firman, N; Nagler, A; Pines, M; Shoshan, S | 1 |
| Nagler, A; Nyska, A; Nyska, M; Pines, M; Porat, S; Rivlin, E; Shoshan, S | 1 |
| Inoue, M; Kanda, T; Kobayashi, I; Kodama, K; Nagai, R; Suzuki, T; Takahashi, T | 1 |
| Ahn, HS; Chatterjee, M; Chintala, M; Chiu, P; Davis, H; Fawzi, A; Lin, CC; Sybertz, EJ; Tulshian, D; Vemulapalli, S; Watkins, RW | 1 |
| Ernst, RA; Kratzer, FH; Kuhl, HJ; Vohra, P | 1 |
| Matsumori, A; Nose, Y; Ono, K; Sasayama, S; Sato, Y; Shioi, T | 1 |
| Aingorn, H; Genina, O; Miao, HQ; Nagler, A; Pines, M; Vlodavsky, I | 1 |
| Brown, AD; Chintala, M; Chiu, PJ; Kurowski, S; Sybertz, EJ; Tetzloff, GG; Vemulapalli, S | 1 |
| Fujioka, M; Isaka, N; Ito, M; Miyahara, M; Nakano, T; Nishikawa, M; Shiku, H | 1 |
| Daugschies, A; Haberkorn, A; Rommel, M; Stephen, B | 1 |
| Barrington, M; Kotsonis, P; Majewski, H; Murphy, TV | 1 |
| Genina, O; Knopov, V; Lavelin, I; Nagler, A; Pines, M | 1 |
| Conway, AM; Pyne, NJ; Pyne, S; Tolan, D | 1 |
| Deng, XF; Mulay, S; Varma, DR | 1 |
| Aingorn, H; Condiotti, R; Genina, O; Katz, A; Miao, HQ; Nagler, A; Pines, M; Vlodavsky, I | 1 |
| Bursell, SE; Clermont, AC; Ishii, H; King, GL; Mori, F; Takagi, C; Takagi, H | 1 |
| Nagler, A; Pines, M | 2 |
| McDougald, LR; Seibert, BP | 1 |
| Genina, O; Lavelin, I; Levi-Schaffer, F; Nagler, A; Pines, M; Raphael, J; Rivkind, AI | 1 |
| Fukuchi, Y; Hanasato, N; Kira, S; Nishino, M; Oka, M; Yamaguchi, K | 1 |
| Daugschies, A; Gässlein, U; Rommel, M | 1 |
| Inoue, M; Iwamoto, A; Kanda, T; Kobayashi, I; Nagai, R; Sakamaki, T; Sato, K; Sumino, H; Takahashi, T | 1 |
| Adachi, H; Nishino, M | 1 |
| Fushiya, S; Murata, K; Oshima, Y; Takano, F | 2 |
| Mehlhorn, H; Schein, E | 1 |
| Adachi, H; Ishihara, H; Kabasawa, Y; Kodama, K; Matsukura, M; Miyazaki, K; Takase, Y; Watanabe, N | 1 |
| Díaz, E; Flores, I; Jones, DR; Martinez, C; Mérida, I | 1 |
| Hurttia, H; Leino, L; Saarinen, K | 1 |
| Abd-Elfattah, AS; Sholley, MM; Taher, MM | 1 |
| Abe, T; Goto, Y; Iijima, K; Kondon, K; Liu, K; Matsukawa, M; Sekine, S; Yamagishi, I | 1 |
| Hayakawa, H; Hirata, Y; Kakoki, M; Kikuchi, K; Nagano, T; Nagata, D; Nishimatsu, H; Omata, M; Suzuki, E; Suzuki, Y | 1 |
| Artemyev, NO; Cote, RH; D'Amours, MR; Granovsky, AE | 1 |
| Genina, O; Lavelin, I; Nagler, A; Ohana, M; Pines, M | 1 |
| Fukuchi, Y; Kira, S; Muramatsu, M; Ohnishi, M; Oka, M; Sato, K | 1 |
| Ciprés, A; Díaz-Flores, E; Flores, I; Jones, DR; Mérida, I; Sanjuan, MA | 1 |
| Curnutte, JT; Erickson, RW; Heyworth, PG; Langel-Peveri, P; Traynor-Kaplan, AE | 1 |
| Kurz, T; Richardt, G; Schneider, I; Tölg, R | 1 |
| Chiba, T; Kim, HS; Miura, M; Oshima, Y; Takaya, Y; Takeshita, M; Tanitsu, M; Tasaka, H; Uwai, K; Wataya, Y | 1 |
| Ariel, I; de-Groot, N; Elkin, M; Hochberg, A; Miao, HQ; Nagler, A; Pines, M; Vlodavsky, I | 1 |
| Dukarm, RC; Morin, FC; Perry, BJ; Russell, JA; Steinhorn, RH | 1 |
| Aingorn, E; de-Groot, N; Elkin, M; Hochberg, A; Nagler, A; Pines, M; Reich, R; Vlodavsky, I | 1 |
| Jiang, Y; Kanoh, H; Sakane, F; Walsh, JP | 1 |
| Albala, DM; Jahoda, A; Koleski, FC; Turk, TM; Wojcik, E | 1 |
| Bischoff, E; Jonas, U; Kühn, R; Lietz, B; Schramm, M; Stief, CG; Truss, MC; Uckert, S | 1 |
| Adachi, H; Ishibashi, K; Ishihara, H; Kabasawa, Y; Kakiki, M; Kodama, K; Matsukura, M; Miyazaki, K; Nishino, M; Ozaki, H; Takase, Y; Watanabe, N | 1 |
| Ahnen, D; Fetter, J; Li, H; Liu, L; Pamukcu, R; Piazza, GA; Sperl, G; Thompson, WJ; Zhu, B | 1 |
| Andersson, K; Fujiwara, M; Persson, K | 1 |
| Abramovitch, R; Dafni, H; Nagler, A; Neeman, M; Pines, M | 1 |
| Potter, DE; Thompson, WJ; Zhou, L | 1 |
| Ogasawara, K; Taniguchi, T | 1 |
| Genina, O; Gofrit, O; Nagler, A; Ohana, M; Pines, M; Pode, D | 1 |
| Nowak, RA | 1 |
| Foubert, TR; Jesaitis, AJ; Marodi, L; McPhail, LC; Palicz, A | 1 |
| Aingorn, E; Dou, HL; Elkin, M; Hemo, I; Miao, HQ; Nagler, A; Pines, M; Reich, R; Vlodavsky, I | 1 |
| Sule, SD; Wigley, FM | 1 |
| Black, CM; Denton, CP | 1 |
| Hezky, P; Krejcí, I; Proska, J; Rádl, S | 1 |
| Alfranca, A; Aragonés, J; Jones, DR; Landázuri, MO; Martin, S; Mérida, I; San Juan, MA; Vara, A; Vidal, F | 1 |
| Oka, M | 1 |
| Aeed, H; Alexiev, R; Avni, Y; Bruck, R; Genina, O; Nagler, A; Pines, M | 1 |
| Barabás, P; Egyed, O; Kardos, J; Kökösi, J; Kovács, I; Nagy, PI; Nyikos, L; Skuban, N; Szárics , E; Takács-Novák, K; Temesváriné-Major, E | 1 |
| Esumi, T; Hatakeyama, S; Iwabuchi, Y; Ooi, H; Urushibara, A | 1 |
| Berente, Z; Halmosi, R; Literati-Nagy, P; Osz, E; Sumegi, B; Toth, K | 1 |
| Kakinuma, Y; Miyauchi, T | 1 |
| Abe, H; Azuma, K; Harayama, T; Kim, HS; Koike, M; Nishioka, H; Takeuchi, Y; Wataya, Y | 1 |
| Du, X; Jiang, Y; Lu, X; Qian, W; Walsh, JP | 1 |
| Fukuda, K; Kato, T; Kodama, H; Miyoshi, S; Ogawa, S; Tahara, S | 1 |
| Alexiev, R; Domb, A; Genina, O; Inbar, J; Nagler, A; Ohana, M; Pines, M | 1 |
| Hagio, H; Hirabayashi, R; Kobayashi, S; Sugiura, M | 1 |
| Doods, HN; van Zwieten, PA; Wu, DM | 1 |
| Hayakawa, H; Hirata, Y; Homma, Y; Horie, S; Kawabe, K; Kitamura, T; Minowada, S; Nagai, R; Nagata, D; Nishimatsu, H; Ohta, N; Satonaka, H; Suzuki, E; Takeuchi, T | 1 |
| Covey, JM; Egorin, MJ; Eiseman, JL; Hamburger, DR; Parise, RA; Stecklair, KP | 1 |
| Bona, C; McGaha, TL; Phelps, RG; Spiera, H | 1 |
| Curwen, JO; Dukes, M; Hennequin, LF; Johnstone, C; Kendrew, J; Ogilvie, DJ; Plé, PA; Stokes, ES; Thomas, AP; Wedge, SR | 1 |
| Kardos, J; Kovács, R; Lasztóczi, B; Nyikos, L | 1 |
| Barak, V; Eshhar, Z; Gavish, Z; Nagler, A; Pines, M; Pinthus, JH; Ramon, J | 1 |
| Crompton, T; Martinez-A, C; Merida, I; Outram, SV; Varas, A | 1 |
| Nishioka, K; Yamamoto, T | 1 |
| Harris, AL; Streeter, EH | 1 |
| Hatakeyama, S; Hirai, S; Iwabuchi, Y; Kikuchi, H; Kim, HS; Ooi, H; Oshima, Y; Takaya, Y; Tasaka, H; Wataya, Y | 1 |
| Doods, HN; Schindler, M | 1 |
| Chern, JW; Choong, CM; Chueh, SC; Guh, JH; Teng, CM | 1 |
| Abe, H; Azuma, K; Harayama, T; Sasaki, K; Takeuchi, Y | 1 |
| Breuer, R; Goldstein, RH; Or, R; Segel, MJ; Tzurel, A | 1 |
| Alexiev, R; Anbinder, N; Genina, O; Mawasi, N; Paizi, M; Pines, M; Spira, G | 1 |
| Bigley, AL; Boffey, SJ; Chester, R; Curry, B; Curwen, JO; Dukes, M; Graham, GA; Hennequin, LF; Hughes, GD; Jackson, JA; Kendrew, J; Musgrove, HL; Ogilvie, DJ; Richmond, GH; Stokes, ES; Thomas, AP; Valentine, PJ; Wadsworth, PF; Wedge, SR | 1 |
| Eppinger, E; Meinhardt, G; Schmidmaier, R | 1 |
| Arndt, K; Doods, H; Schindler, M; Wu, D | 1 |
| Bona, CA; Kodera, T; McGaha, TL; Pines, M; Spiera, H; Stan, AC | 1 |
| Bona, C; Kodera, T; McGaha, T; Phelps, R; Pines, M; Spiera, H | 1 |
| Carlomagno, F; Ciardiello, F; Fontanini, G; Fusco, A; Guida, T; Ryan, AJ; Santoro, M; Tortora, G; Vecchio, G; Vitagliano, D | 1 |
| Rosen, LS | 1 |
| Doherty, JB; Hop, CE; Hunt, JA; Ita, I; Kallashi, F; Kumar, S; McCormick, SX; O'Keefe, SJ; O'Neill, EA; Pivnichny, JV; Porter, G; Ruzek, RD; Sinclair, PJ; Thompson, JE; Wang, Z; Woods, A; Zaller, DM | 1 |
| Daugschies, A; Joachim, A; Krull, T; Schwarzkopf, J | 1 |
| Hayakawa, H; Hirata, Y; Kakoki, M; Kangawa, K; Kitamura, T; Kurihara, H; Matsuo, H; Nagai, R; Nagata, D; Nishimatsu, H; Sata, M; Satonaka, H; Shindo, T; Suzuki, E; Takeda, R | 1 |
| D'Isanto, M; Finamore, E; Galdiero, M; Peluso, L; Vitiello, M | 1 |
| Berkelhammer, G | 1 |
| Cannavan, A; Elliott, CT; Kennedy, DG; Lövgren, T; Yakkundi, S | 1 |
| Arteaga, CL | 1 |
| Bianco, AR; Caputo, R; Carlomagno, F; Ciardiello, F; Damiano, V; Fontanini, G; Tortora, G; Troiani, T; Veneziani, BM; Vitagliano, D | 1 |
| Bernardino, CR; Chang, EL; Dartt, DA; Hodges, RR; Horikawa, Y; Rios, JD; Rubin, PA; Shatos, MA; Zoukhri, D | 1 |
| Ducreux, M; Köhne, CH; Schwartz, GK; Vanhoefer, U | 1 |
| Ishih, A; Miyase, T; Ohori, K; Terada, M | 1 |
| Nagler, A; Pines, M; Snyder, D; Yarkoni, S | 1 |
| Begum, K; Hirai, S; Kikuchi, H; Kim, HS; Miyazawa, Y; Oshima, Y; Tasaka, H; Wataya, Y; Yamamoto, K | 1 |
| SYRKINA-KRUGLIAK, SA; VERMEL', EM | 1 |
| Dafni, H; Gross, DJ; Nagler, A; Neeman, M; Pines, M; Reibstein, I; Slavin, S; Weiss, L | 1 |
| Ali-El-Dein, B; Bazeed, M; Hafez, AT; Jaidane, M; Mohsen, T; Ounaies, A | 1 |
| Bergh, A; Collin, O; Jonsson, A; Rudolfsson, SH; Wikström, P | 1 |
| Checkley, D; Kendrew, J; Tessier, JJ; Waterton, JC; Wedge, SR | 1 |
| Shiotsu, Y | 1 |
| Ishih, A; Miyase, T; Suzuki, T; Terada, M; Watanabe, M | 1 |
| Felici, A; Flanders, KC; Fujii, M; Javelaud, D; Mauviel, A; Mitchell, JB; Piek, E; Reiss, M; Roberts, AB; Russo, A; Samuni, AM; Sowers, A; Xavier, S; Yarkoni, S | 1 |
| Abu-Amara, SN; Bruck, R; Geiger, B; Genina, O; Gnainsky, Y; Monsonego-Ornan, E; Nagler, A; Paizi, M; Pines, M; Spira, G | 1 |
| Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; De Vita, F; Melisi, D; Tortora, G; Troiani, T | 1 |
| Bates, D | 1 |
| Doğusoy, G; Gümüştaş, K; Ozçelik, MF; Pekmezci, S; Saribeyoğlu, K; Unal, E | 1 |
| Durham, PL | 1 |
| Diener, HC; Goadsby, PJ; Hall, D; Husstedt, IW; Lesko, LM; Meier, U; Olesen, J; Pollentier, S | 1 |
| Houkin, K; Imai, S; Kai, M; Kanoh, H; Sakane, F; Tsushima, S; Yamada, K | 1 |
| Akaza, H; Blackledge, G; Carmichael, J; Isonishi, S; Kakeji, Y; Kurebayashi, J; Nakagawa, M; Nakamura, S; Ohashi, Y; Saijo, N; Sone, S; Tsuruo, T; Yamamoto, N | 1 |
| Al-Hendy, A; Copland, JA; Young, SL | 1 |
| Gear, RB; Heffelfinger, SC; LaDow, K; Schneider, J; Warshawsky, D; Yan, M | 1 |
| Carlomagno, F; Fusco, A; Hershman, JM; Melillo, RM; Motti, ML; Nikiforov, YE; Nikiforova, MN; Ryan, AJ; Santoro, M; Viglietto, G; Vitagliano, D | 1 |
| Alper, R; Ilan, Y; Nagler, A; Ohana, M; Pines, M; Shapira, MY; Shibolet, O; Vlodavsky, I | 1 |
| Anaganti, S; Billaud, M; Carlomagno, F; Fusco, A; Guida, T; Ryan, AJ; Santoro, M; Vecchio, G | 1 |
| Cadeddu, JA; Duchene, DA; Jacomides, L; Johnson, BD; Lindberg, G; Ogan, K; Pearle, MS | 1 |
| Andersson, U; Bergenheim, AT; Bergh, A; Henriksson, R; Johansson, M; Sandström, M | 1 |
| Keshavan, V; Shanthi, M; Tyagi, MG; Vikram, GS | 1 |
| Daeseleire, E; Delahaut, P; Huet, AC; Mortier, L; Van Peteghem, C | 1 |
| Ishih, A; Kobayashi, F; Miyase, T; Nagata, T; Terada, M | 1 |
| Covey, JM; Egorin, MJ; Grossi, IM; Merrill, JW; Parise, RA; Peggins, JO; Sparrow, BR | 1 |
| Bucana, C; Ellis, LM; Fan, F; Liu, W; Mansfield, PF; McCarty, MF; Ryan, AJ; Stoeltzing, O; Wey, J | 1 |
| COATNEY, GR; COOPER, WC; CULWELL, WB; IMBODEN, CA; WHITE, WC | 1 |
| de Waal, R; Heerschap, A; Küsters, B; Leenders, WP; Maass, C; Ruiter, D; Ryan, A; Verrijp, K; Wesseling, P | 1 |
| Fevery, J; Nevens, F; Roskams, T; Van de Casteele, M; Van der Elst, I; van Pelt, JF | 1 |
| Chambers, AF; Ellis, CG; Groom, AC; MacDonald, IC; Mackenzie, LT; Ryan, A; Varghese, HJ | 1 |
| Shi, W; Siemann, DW | 1 |
| Koh, Y; Koizumi, F; Nishio, K; Saijo, N; Taguchi, F; Tamura, T | 1 |
| Arao, T; Fukumoto, H; Nishio, K; Saijo, N; Takeda, M; Tamura, T | 1 |
| Brave, S; Kendrew, J; Stratford, IJ; Telfer, BA; Wedge, SR; Whittaker, L; Williams, KJ | 1 |
| Conaway, M; Gulding, K; Nicholson, B; Theodorescu, D; Wedge, SR | 1 |
| Carlomagno, F; Santoro, M | 1 |
| Bianco, R; Bianco, RA; Ciardiello, F; De Vita, F; Fontanini, G; Martinelli, E; Morgillo, F; Romano, M; Tortora, G; Troiani, T; Tuccillo, C | 1 |
| Bruno, W; Heller, L; Klitzman, B; Levin, LS; Meade, R; Olbrich, KC | 1 |
| Fang, D; Gettayacamin, M; Hansukjariya, P; Jiang, S; Lim, A; Okunji, CO; Tungtaeng, A; Wannaying, S; Zeng, Q; Zhu, S | 1 |
| Daeseleire, E; Delahaut, P; Elliott, C; Fodey, T; Huet, AC; Mortier, L | 1 |
| Acosta-Iborra, B; Aragonés, J; Castellanos, MC; Feijoo-Cuaresma, M; Landazuri, MO; Martín-Puig, S; Olmos, G; Temes, E | 1 |
| Barge, A; Baselga, J; Miller, KD; Rowbottom, J; Sledge, G; Trigo, JM; Wheeler, C | 1 |
| Baker, CH; Beaudry, P; Folkman, J; Force, J; Heymach, JV; Johnson, BE; Naumov, GN; Ryan, A; Soker, S; Wang, A | 1 |
| Cagan, R; Ryan, A; Vidal, M; Wells, S | 1 |
| Herbst, RS; Onn, A; Sandler, A | 1 |
| Drevs, J; Esser, N; Konerding, MA; Ogilvie, DJ; Ryan, AJ; Wedge, SR; Wolloscheck, T | 1 |
| Barge, A; Basser, R; de Boer, R; Eckhardt, SG; Green, M; Holden, SN; Hurwitz, HI; Rischin, D; Rosenthal, MA; Wheeler, C | 1 |
| Cascone, T; Ciardiello, F; De Vita, F; Eckhardt, SG; Laus, G; Morelli, MP; Orditura, M; Pepe, S; Tortora, G; Troiani, T | 1 |
| Heymach, JV | 1 |
| Ryan, AJ; Wedge, SR | 1 |
| Bradshaw, EL; Gustafson, DL; Long, ME; Zirrolli, JA | 1 |
| Ali, N; Fujita, Y; Ishizawa, K; Izawa, Y; Kanematsu, Y; Sone, S; Tamaki, T; Tsuchiya, K; Yano, S; Yoshizumi, M | 1 |
| Bartha, E; Czopf, L; Deres, P; Halmosi, R; Hantó, K; Hideg, K; Kálai, T; Kulcsár, G; Pálfi, A; Sümegi, B; Szabados, E; Tóth, A; Tóth, K | 1 |
| du Manoir, J; Francia, G; Hicklin, DJ; Kerbel, RS; Ma, L; Rak, J; Viloria-Petit, A | 1 |
| Abe, H; Azuma, K; Harayama, T; Oshige, M; Takeuchi, Y | 1 |
| Arao, T; Koizumi, F; Nishio, K; Shiratori, Y; Takeda, M; Takigahira, M; Yanagihara, K | 1 |
| Bianco, AR; Bianco, C; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Fontanini, G; Melisi, D; Raben, D; Ryan, A; Tortora, G | 1 |
| Cummings, JJ; Dukarm, RC; Lakshminrusimha, S; Russell, JA; Steinhorn, RH; Swartz, D | 1 |
| Awad, H; Hurwitz, H; Klitzman, B; Ko, J; Ross, J | 1 |
| Fridman, E; Genina, O; Mor, Y; Nagler, A; Pines, M; Pinthus, JH; Sheffer, Y | 1 |
| Arbell, D; Genina, O; Koplewitz, BZ; Nagler, A; Ohana, M; Pines, M; Udassin, R | 1 |
| Matsumori, Y; Muguruma, H; Nakataki, E; Sone, S; Yano, S; Yoshizumi, M; Zheng, R | 1 |
| Lee, D | 1 |
| Thompson, JE | 1 |
| Kurisu, K; Okamura, T | 1 |
| Hough, LB; Lu, Q; Montero, MJ; Nalwalk, JW; Shan, Z; Svokos, K; Wentland, MP | 1 |
| Soff, G; Zakarija, A | 1 |
| Hasegawa, H; Kojima, A; Matsui, K; Muraoka, M | 1 |
| Scheindlin, S | 1 |
| Buolamwini, JK; Kamath, S | 1 |
| Bigner, DD; Dimery, I; Friedman, HS; Graner, MW; Kaipainen, A; Keir, ST; Kieran, MW; Laforme, A; McLendon, RE; Rasheed, BK; Reardon, DA; Rich, JN; Ryan, AJ; Sathornsumetee, S; Wang, L; Wheeler, C | 1 |
| Antonaci, S; Azzariti, A; Giannelli, G; Paradiso, A; Porcelli, L; Sgarra, C | 2 |
| Edakuni, N; Goto, H; Kakiuchi, S; Matsumori, Y; Muguruma, H; Nakataki, E; Ryan, A; Sone, S; Tomimoto, H; Uehara, H; Yamamoto, A; Yano, S | 1 |
| Bianco, C; Ciardiello, F; Dimery, I; Frederick, B; Gustafson, D; Raben, D | 1 |
| Connolly, CM; Lawler, J; Pines, M; Yee, KO | 1 |
| Meng, L; Wei, L; Zhang, Q; Zhu, S | 1 |
| Cascone, T; Ciardiello, F; Gridelli, C; Morelli, MP; Troiani, T | 1 |
| Bauer, M; Niedobitek, E; Patsenker, E; Popov, Y; Schulze-Krebs, A; Schuppan, D | 1 |
| Cazzaniga, S; Gambacorti-Passerini, C; Mologni, L; Papinutto, E; Sala, E | 1 |
| Emri, Z; Héja, L; Kardos, J; Lasztóczi, B; Nyikos, L; Simon, A; Szárics, E | 1 |
| Ardizzoni, A; Franciosi, V; Tiseo, M | 1 |
| Govindan, R; Morgensztern, D | 1 |
| Bradshaw-Pierce, EL; Gustafson, DL; Merz, AL; Zirrolli, JA | 1 |
| Bianco, R; Cascone, T; Ciardiello, F; De Pacido, S; Eckhardt, SG; Fontanini, G; Morelli, MP; Normanno, N; Romano, M; Tortora, G; Troiani, T; Tuccillo, C; Veneziani, BM | 1 |
| Deres, P; Gallyas, F; Halmosi, R; Hanto, K; Hideg, K; Kalai, T; Kulcsar, G; Palfi, A; Sumegi, B; Szabados, E; Szereday, Z; Toth, A; Toth, K | 1 |
| Bozec, A; Fischel, JL; Milano, G | 1 |
| Haran, N; Leschinski, L; Pines, M; Rapoport, J | 1 |
| Eliashar, R; Maly, B; Nagler, A; Ochana, M; Pines, M; Sichel, JY | 1 |
| Brazelle, WD; Shi, W; Siemann, DW | 1 |
| Bièche, I; Blanc, JF; Dugot-Senant, N; Laurendeau, I; Pines, M; Rosenbaum, J; Rullier, A; Taras, D | 1 |
| Cahalon, L; Hecht, I; Leiba, M; Lider, O; Nagler, A; Sela, U; Shimoni, A; Vlodavsky, I; Zanin-Zhorov, A | 1 |
| Goto, H; Matsumori, Y; Nakataki, E; Ryan, AJ; Sone, S; Wedge, SR; Yano, S | 1 |
| Dong, RP; Eisenhauer, E; Kovacs, MJ; Marcellus, D; Mathews, S; Meyer, RM; Reece, DE | 1 |
| de Jonge, MJ; Dumez, H; Lacombe, D; Marréaud, S; Punt, CJ; Snyder, D; van Oosterom, A; Verweij, J; Yamaguchi, T; Yarkoni, S | 1 |
| Baribaud, F; Caudler, E; Fridman, JS; Friedman, SM; Gazdar, AF; Girard, L; He, B; Jablons, DM; Li, Y; Liu, C; Lo, Y; Mikami, I; Minna, JD; Newton, RC; Peyton, M; Reguart, N; Scherle, PA; Vaddi, K; Yang, G; Yao, W; Zhou, BB | 1 |
| Hariguchi, N; Hirai, S; Horoiwa, S; Kasahara, R; Kikuchi, H; Matsumoto, M; Oshima, Y; Yamamoto, K | 1 |
| Ciardiello, F; Eckhardt, SG; Lockerbie, O; Morrow, M; Troiani, T | 1 |
| McNeil, C | 1 |
| Attoub, S; Bruyneel, E; Emami, S; Gespach, C; Grijelmo, C; Nguyen, QD; Rivat, C; Rodrigue, CM; Rodrigues, S | 1 |
| Azzariti, A; Paradiso, A; Porcelli, L; Simone, GM; Xu, JM | 1 |
| Ali, N; Ishizawa, K; Kanematsu, Y; Ohnishi, H; Sone, S; Tamaki, T; Tsuchiya, K; Yano, S; Yoshizumi, M | 1 |
| Ikezoe, T; Koeffler, HP; Nishioka, C; Taguchi, H; Taguchi, T; Yang, Y; Zhu, WG | 1 |
| Burchert, A; Dietrich, C; Gläser, S; Hoffmann, S; Lingelbach, S; Müller, H; Rothmund, M; Wunderlich, A; Zielke, A | 1 |
| Rich, JN; Sathornsumetee, S | 1 |
| Bianco, C; Ciardiello, F; Cionini, L; Danesi, R; de Liguoro, M; Del Tacca, M; Eckhardt, G; Giovannetti, E; Mey, V; Nannizzi, S; Pasqualetti, F; Raben, D; Ricciardi, S; Tortora, G; Troiani, T | 1 |
| Golub, T; Halmos, B; Hetherington, CJ; Kobayashi, S; Lowell, AM; Meyerson, M; Monti, S; Shapiro, GI; Shimamura, T; Steidl, U; Tenen, DG | 1 |
| Bergh, A; Halin, S; Hammarsten, P; Henriksson, R; Rudolfsson, SH; Wikstöm, P | 1 |
| Fujita, K; Ishiguro, Y; Kawakami, M; Kimura, M; Matsuda, H; Nishimura, G; Sano, D; Tsukuda, M; Yamashita, Y | 1 |
| Herbst, RS | 1 |
| Herbst, RS; Heymach, JV; O'Reilly, MS; Onn, A; Ryan, AJ | 1 |
| Avezaat, CJ; de Vries, R; Garrelds, IM; Gupta, S; Lozano-Cuenca, J; MaassenVanDenBrink, A; Saxena, PR; van Kats, JP; Villalón, CM | 1 |
| Fidler, IJ; Herbst, RS; Isobe, T; Itasaka, S; Komaki, R; Langley, RR; O'Reilly, MS; Onn, A; Ryan, AJ; Shibuya, K; Shitani, T; Wu, W | 1 |
| Galzi, JL; Hachet-Haas, M; Kellenberger, E; Parmentier, M; Rognan, D; Springael, JY | 1 |
| Schneider, BP; Sledge, GW | 1 |
| de Waal, RM; Kats, G; Küsters, B; Leenders, WP; Roodink, I; Ruiter, DJ; Verrijp, K; Wesseling, P | 1 |
| Ikezoe, T; Koeffler, HP; Komatsu, N; Kuwayama, Y; Nishioka, C; Taguchi, H; Takeshita, A; Tasaka, T; Togitani, K; Yang, J; Yang, Y | 1 |
| Frederick, B; Gustafson, DL; Merz, AL; Raben, D | 1 |
| Ballabh, P; Braun, A; Csiszar, A; Goldman, SA; Hu, F; Lou, N; Nedergaard, M; Rivera, A; Smith, K; Ungvari, Z; Xu, H | 1 |
| Sequist, LV | 1 |
| Hanna, N | 1 |
| Ebi, H; Fujisaka, Y; Horiike, A; Jiang, H; Kawada, K; Minami, H; Murakami, H; Saijo, N; Sasaki, Y; Shimoyama, T; Shinkai, T; Tahara, M; Tamura, T; Yamada, Y; Yamamoto, N | 1 |
| Barge, A; Bruns, CJ; Conrad, C; Geissler, EK; Guba, M; Ischenko, I; Jauch, KW; Köhl, G; Ryan, AJ; Wedge, SR; Wiegand, U; Yezhelyev, M | 1 |
| Ardizzoni, A; Tiseo, M | 1 |
| Bradley, DP; Checkley, D; Kendrew, J; Kuribayashi, H; Tessier, JL; Waterton, JC; Wedge, SR | 1 |
| Kiselyov, AS; Milligan, D; Ouyang, X | 1 |
| Huang, W; Liu, QQ; Liu, R; Wu, J; Xiao, X; Zeng, M; Zhao, P; Zheng, L; Zhou, J; Zhu, X | 1 |
| Cabebe, E; Wakelee, H | 1 |
| Ahlman, H; Bernhardt, P; Jansson, S; Johanson, V; Kölby, L; Nilsson, O; Persson, F; Stenman, G; Stridsberg, M; Swärd, C; Wängberg, B | 1 |
| Császár, I; Juhász, G; Kovács, Z; Nyitrai, G; Palkovits, M; Papp, E; Puskás, L | 1 |
| Kibble, A | 1 |
| Hanrahan, EO; Heymach, JV | 1 |
| Advani, A; Advani, SL; Cox, AJ; Gilbert, RE; Gow, RM; Kelly, DJ; Marsden, PA; Marshall, SM; Rakoczy, PE; Steer, BM; Thai, K; White, KE; Zhang, Y | 1 |
| Armand, JP; Mir, O; Ropert, S | 1 |
| Belani, CP; Bodrogi, I; Csada, E; Gadgeel, S; Herbst, RS; Heymach, JV; Hou, J; Johnson, BE; Kennedy, SJ; Pesek, M; Prager, D; Roubec, J; Spásová, I | 1 |
| Alam, Y; Arnold, AM; Butts, C; Chan, A; Ding, K; Djurfeldt, M; Ellis, P; Findlay, B; Goss, G; Gregg, R; Langmuir, P; Lee, CW; Meharchand, J; Seymour, L; Shepherd, F; Smylie, M; Ung, Y; Whitehead, M | 1 |
| Ang, K; Herbst, RS; Itasaka, S; Jürgensmeier, JM; Komaki, R; Milas, L; O'Reilly, MS; Ryan, A; Shibuya, K; Shintani, T | 1 |
| Lou, L; Mi, Y | 1 |
| Ciardiello, F; Eckhardt, SG; Gustafson, DL; Henthorn, TK; Lockerbie, O; Long, M; Merz, A; Morrow, M; Serkova, NJ; Troiani, T | 1 |
| Ballabh, P; Braun, A; Chander, P; Csiszar, A; Hu, F; Kocherlakota, P; Nedergaard, M; Siegel, D; Ungvari, Z; Xu, H | 1 |
| Freshney, RI | 1 |
| Dowlati, A; Halmos, B; Kern, JA; Kluge, A; Nethery, D | 1 |
| Eckhardt, M; Fuchs, H; Guth, B; Himmelsbach, F; Langkopf, E; Lotz, R; Mark, M; Nar, H; Pfrengle, W; Sieger, P; Tadayyon, M; Thomas, L | 1 |
| Claes, A; Gambarota, G; Hamans, B; Heerschap, A; Leenders, W; Maass, C; van Tellingen, O; Wesseling, P | 1 |
| Claes, A; Heerschap, A; Jeuken, J; Leenders, WP; Maass, C; Wesseling, P | 1 |
| Andresson, T; Bedell, L; Bjornsson, JM; Bragason, G; Burghes, AH; Butchbach, ME; Coovert, DD; Gurney, ME; Haraldsson, M; Keyvan, M; Mishra, R; Pai, G; Palomo, M; Pease, B; Rao, M; Singh, J; Thosteinsdottir, M; Thurmond, J | 1 |
| Bergenheim, AT; Bergström, P; Henriksson, R; Johansson, M; Sandström, M | 1 |
| Beaudry, P; Folkman, J; Heymach, J; Nilsson, M; Poon, D; Prox, D; Rioth, M; Ryan, A; Ryeom, S; Xu, L; Zweidler-Mckay, P | 1 |
| Giordano, S; Petrelli, A | 1 |
| Goto, H; Hanibuchi, M; Ikuta, K; Kakiuchi, S; Nakataki, E; Nishioka, Y; Ogino, H; Ryan, A; Sone, S; Yamada, T; Yano, S | 1 |
| Eguchi, K; Fukuoka, M; Jiang, H; Kiura, K; Nakagawa, K; Nishio, K; Ohe, Y; Saijo, N; Seto, T; Shinkai, T; Tsuboi, M; Yamamoto, N; Yokota, S | 1 |
| Berrino, L; Cascone, T; Ciardiello, F; Heymach, JV; Kim, WY; Lee, HY; Morelli, MP; Morgillo, F; Pepe, S; Rodolico, G; Tortora, G | 1 |
| Lee, CB; Socinski, MA | 1 |
| Buhl, R; Fischer, B | 1 |
| Sherman, SI | 2 |
| Gettinger, S | 1 |
| Natale, RB | 1 |
| Prabhakar, S; Ramanjaneyulu, GS; Rao, BV; Sudhakar, N | 1 |
| Bernhard, JC; Ferrière, JM; Ravaud, A; Robert, G; Wallerand, H | 1 |
| Doody, JF; Hadari, YR; Katoch-Rouse, R; Kim, K; Kiselyov, AS; Ouyang, X; Piatnitski Chekler, EL; Sherman, D; Wang, Y | 1 |
| Fan, GJ; Wee, AG | 1 |
| Fukumura, D; Hoshida, T; Jain, RK; Kozak, KR; Kuo, AH; Liao, S; Lobo, J; Padera, TP | 1 |
| Albini, A; Benelli, R; Bianco, R; Ciardiello, F; Damiano, V; Daniele, G; De Falco, S; Garofalo, S; Gelardi, T; Melisi, D; Rosa, R; Ryan, A; Tarallo, V; Tortora, G | 1 |
| Kawabe, J; Ohsaki, Y; Osanai, S; Sasaki, T; Shibukawa, K; Tanno, S | 1 |
| Chen, WT; Cheung, M; Choi, S; El-Naggar, AK; Jasser, SA; Mao, L; Myers, JN; Ryan, AJ; Sano, D; Zhao, M | 1 |
| Cai, L; Hertz, L; Li, B; Nu, W; Peng, L; Zhang, H; Zhang, S | 1 |
| Bolshakov, S; Dicker, A; Korchin, B; Lahat, G; Lazar, A; Lev, D; Merritt, W; Nguyen, T; Pollock, RE; Ren, W; Sood, A; Wei, C | 1 |
| Bradshaw-Pierce, EL; Gustafson, DL; Raben, D; Steinhauer, CA | 1 |
| Bartha, E; Habon, T; Halmosi, R; Hideg, K; Kálai, T; Kalman, E; Kiss, GN; Kulcsár, G; Sumegi, B; Toth, K | 1 |
| Döme, B; Magyar, M | 1 |
| Bonomi, PD; Cohen, G; De Braud, F; Eberhardt, WE; Herbst, RS; Heymach, JV; Johnson, BE; Krebs, AD; Paz-Ares, L; Ranade, AA; Sandler, AB; Sebastian, M; Stewart, DJ; Trigo, JM; Vasselli, J | 1 |
| Gibbs, P; Godwood, A; Michael, M; Oliver, S; Smith, R; Tebbutt, N | 1 |
| Anaganti, S; Carlomagno, F; Guida, T; Kjaer, S; McDonald, NQ; Provitera, L; Ryan, AJ; Santoro, M | 1 |
| Ishih, A; Kobayashi, F; Miyase, T; Muregi, FW; Nagata, T; Ohori, K | 1 |
| Hamaguchi, W; Hattori, K; Igarashi, S; Ishikawa, N; Kawano, N; Koganemaru, Y; Masuda, N; Matsumoto, Y; Miyazaki, T; Ogino, S; Ohta, M; Takeuchi, M; Yamasaki, S; Yokoyama, K | 1 |
| de Boer, R; Godwood, A; Humblet, Y; Milenkova, T; Nogová, L; Ruffert, K; Smith, R; Vansteenkiste, J; Wolf, J | 1 |
| Balagtas, C; Bohlen, P; Doody, JF; Duncton, MA; Hadari, YR; Katoch-Rouse, R; Kawakami, JK; Kiselyov, AS; Kussie, P; Milligan, DL; Mitelman, S; Patel, SN; Piatnitski Chekler, EL; Rolster, RL; Sherman, D; Smith, LM; Surguladze, D; Tonra, JR; Wang, Y; Wong, WC | 1 |
| Godwood, A; Oliver, S; Peeters, M; Saunders, MP; Smith, R; Van Cutsem, E; Wilson, R | 1 |
| Bemis, LT; Flaig, TW; Li, Y; McCoach, C; Raben, D; Su, LJ; Varella-Garcia, M | 1 |
| Holmgren, L; Lu, L; Samén, E; Stone-Elander, S; Tegnebratt, T; Thorell, JO | 1 |
| Hirohashi, S; Kasai, S; Kokubu, A; Ochiya, T; Ojima, H; Shibata, T; Yoshikawa, D | 1 |
| Bodkin, D; Capó, A; Eberhardt, WE; Germonpré, P; Govindan, R; Kennedy, SJ; Natale, RB; Ranson, M; Rizvi, NA; Sleckman, BG; Stockman, PK | 1 |
| Bryce, J; De Feo, G; De Maio, E; Del Giudice, A; Di Maio, M; Falasconi, F; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC | 1 |
| Pakkala, S; Ramalingam, SS | 1 |
| Horn, L; Sandler, AB | 1 |
| Chen, LM; Dai, CL; Fu, LW; Li, YH; Liang, YJ; Mi, YJ; Tao, LY; To, KK; Wang, F; Yan, YY; Yang, AK; Zhang, X; Zheng, LS | 1 |
| Chen, JM; Huang, W; Jia, HY; Tan, L; Wu, JX; Yan, HJ; Yang, SP; Zeng, YX; Zhu, XF | 1 |
| Abratt, RP; Bodrogi, I; Federico, MH; Horti, J; Pover, GM; Sanders, N; Stenzl, A; Widmark, A | 1 |
| Cheng, AC; de la Cruz, E; Habeski, WM; Kablaoui, NM; Loh, C; Patel, SD | 1 |
| Samant, BS; Sukhthankar, MG | 1 |
| Bartha, E; Halmosi, R; Hideg, K; Kálai, T; Kereskai, L; Lantos, J; Magyar, K; Plozer, E; Solti, I; Sumegi, B; Szabados, E; Toth, K | 1 |
| Cho, YS; Choi, MJ; Choo, H; Jo, MN; Lee, BH; Nah, SY; Nam, G; Pae, AN; Rhim, H; Seo, HJ | 1 |
| Akslen, LA; Briggs, A; Byers, LA; Cascone, T; Engelman, J; Folkman, J; Halmos, B; Heymach, JV; Jänne, P; Johnson, BE; Kobayashi, S; Lifshits, E; Naumov, GN; Nilsson, MB; Straume, O; Tang, XM; Tenen, D; Wu, HK; Xu, L; Yeap, B | 1 |
| Hanrahan, EO; Herbst, RS; Heymach, JV; Johnson, BE; Kennedy, SJ; Langmuir, P; Mann, H; Natale, RB; Ryan, AJ | 1 |
| Gudise, C; Smith, E; Wei, L; Zeng, Y; Zhang, Q; Zhu, S | 1 |
| Ichihara, E; Kiura, K; Ogino, A; Ohashi, K; Osawa, M; Takigawa, N; Tanimoto, M | 1 |
| Azzariti, A; Berardi, F; Colabufo, NA; D'Incalci, M; Paradiso, A; Perrone, R; Porcelli, L; Quatrale, AE; Simone, GM; Xu, JM; Zucchetti, M | 1 |
| Fine, HA; Smith, JA; Yeh, S | 1 |
| Norris, CM; Ryan, A; Shi, W; Siemann, DW | 1 |
| Chang, CH; Chang, JW; Hui, CY; Yang, CH | 1 |
| Blaauw, RH; Botman, PN; Rutjes, FP; Schoemaker, HE; van Delft, FL; van den Berg, RJ; Wijdeven, MA; Wijtmans, R | 1 |
| Caprio, V; Clark, GR; Yang, SH | 1 |
| Dziadziusko, R; Fennell, D; Gridelli, C; Lacombe, D; Pallis, AG; Serfass, L; van Meerbeeck, JP; Welch, J | 1 |
| Addo-Yobo, SO; Jane, EP; Pollack, IF; Premkumar, DR | 1 |
| Hampton, T | 1 |
| Chen, W; Liebeskind, LS | 1 |
| Fine, HA; Kong, HH; Stern, JB; Turner, ML | 1 |
| Burd, R; Daskalakis, C; Dicker, AP; Ryan, A; Wachsberger, P | 1 |
| Berndt, A; Cesca, M; D'Incalci, M; Frapolli, R; Giavazzi, R; Kosmehl, H; Richter, P; Ryan, AJ; Scarlato, V | 1 |
| Ansiaux, R; Dewever, J; Feron, O; Gallez, B; Grégoire, V; Jordan, BF | 1 |
| Campiglia, P; De Falco, V; Fenzi, G; Illario, M; Monaco, S; Pastore, L; Rossi, G; Rusciano, MR; Salzano, M; Santoro, M; Sapio, MR; Vitale, M | 1 |
| Du, DZ; Hanrahan, EO; Heymach, JV; Johnson, BE; Kim, ES; Langmuir, P; Lee, JJ; Lin, HY; McKee, KS; Ryan, AJ; Tran, HT; Yan, S | 1 |
| Evans, P; McLaughlin, NP | 1 |
| Galle, PR; Gockel, I; Heidel, F; Lang, H; Lyros, O; Moehler, M; Mueller, A; Schimanski, CC | 1 |
| Gagel, RF; Gosnell, JE; Krebs, A; Moley, J; Pfister, D; Schlumberger, M; Skinner, M; Sosa, JA; Vasselli, J; Wells, SA | 1 |
| Annunziata, CM; Calvo, K; Choyke, P; Kimm, D; Kohn, EC; Kotz, H; Minasian, L; Steinberg, SM; Walker, AJ; Wood, BJ; Yu, M | 1 |
| Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P | 1 |
| Batchelor, TT; Ciampa, A; Doherty, LM; Drappatz, J; Gerard, M; Kesari, S; Lafrankie, DC; Ligon, KL; Muzikansky, A; Norden, AD; Phan, P; Sceppa, C; Schiff, D; Weiss, SE; Wen, PY; Wong, ET; Young, G | 1 |
| Dash, R; Fisher, PB; Mandal, M; Mazumdar, A; Sarkar, D; Sarkar, S | 2 |
| Hirte, H; Hotte, SJ; Kavsak, PA | 1 |
| Nair, BC; Vadlamudi, RK | 1 |
| Fang, W; Heymach, JV; Nilsson, MB; Palla, S; Zage, PE; Zeng, L; Zweidler-McKay, PA | 1 |
| Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Hoyer, D; Morissette, M; Ouattara, B | 1 |
| Fuse, E; Kodaira, H; Kusuhara, H; Sugiyama, Y; Ushiki, J | 1 |
| He, BF; Luo, RC; Miao, JX; Ruan, J; Shen, J; Zhao, P; Zheng, H | 1 |
| Kats-Ugurlu, G; Kiemeney, LA; Leenders, WP; Mulders, PF; Old, LJ; Oosterwijk, E; Oosterwijk-Wakka, JC | 1 |
| Haddad, R; Krebs, A; Paz-Ares, L; Robinson, BG; Vasselli, J | 1 |
| Cheng, SY; Chiou, SH; Feng, H; Hu, B; Lieberman, FS; Liu, KW; Ma, HI; Sarkaria, JN; Schornack, PA; Sengar, RS; Wiener, EC; Yiin, JJ | 1 |
| Brekken, RA; Carney, DN; Korpanty, G; Smyth, E; Sullivan, LA | 1 |
| Chan, AW; di Tomaso, E; Jain, RK; Kamoun, WS; Lahdenranta, J; McClatchey, AI; Plotkin, SR; Wong, HK | 1 |
| Cooper, JE; Wiseman, AC | 1 |
| Besson, V; Büki, A; Bukovics, P; Dóczi, T; Hernádi, I; Kövesdi, E; Lückl, J; Nyirádi, J; Pál, J; Sümegi, B | 1 |
| Huang, W; Jia, H; Ma, J; Tan, L; Wu, J; Yan, H; Yang, S; Zeng, M; Zhu, X; Zuo, Y | 1 |
| Biesma, B; Eberhardt, WE; Germonpré, P; Herbst, RS; Heymach, JV; Ichinose, Y; Johnson, BE; Kabbinavar, F; Kennedy, SJ; Langmuir, P; Li, L; Qin, S; Saijo, N; Sun, Y; Tada, H; Wang, J; Zhang, L; Zhou, C | 1 |
| Govindan, R; Stinchcombe, TE | 1 |
| Capó-Aponte, JE; Pan, Z; Reinach, PS; Wang, Z; Yang, H; Zhang, F | 1 |
| Andrews, GA; Fooshee, DR; Frederick, MJ; Galer, C; Milas, ZL; Morrow, PK; Myers, JN; Sano, D; Zhao, M | 1 |
| Dempsey, EC; Karoor, V; Le, M; Merrick, D; Miller, YE | 1 |
| Blackhall, FH; Kennedy, SJ; Milenkova, T; Nicolson, M; O'brien, M; Schmid, P; Taylor, P; Thatcher, N | 1 |
| Scheen, AJ | 2 |
| Langmuir, P; Martin, P; Molz, KH; Oliver, S; Read, J; Smith, R; Weil, A | 1 |
| Gerich, J | 1 |
| Flaig, TW; Li, Y; Su, LJ; Yang, X | 1 |
| Alferez, DG; Goodlad, RA; Ryan, AJ; Wilkinson, RW; Wright, NA | 1 |
| Antti, H; Bergenheim, AT; Henriksson, R; Johansson, M; Sandström, M; Wibom, C | 1 |
| Chen, X; Hoffman, L; Lee, TY; Ryan, AJ; Tai, JH; Tessier, J | 1 |
| Andreasson, I; Boér, K; Láng, I; Llombart-Cussac, A; Murray, E; Pover, GM; Sanders, N; Vivanco, GL | 1 |
| Bareford, MD; Dent, P; Eulitt, P; Hossein, H; Martin, AP; Mitchell, C; Nephew, KP; Yacoub, A; Yang, C | 1 |
| Baker, JN; Broniscer, A; Chin, TK; Davidoff, AM; Gajjar, A; Gilbertson, RJ; Kaste, SC; Kocak, M; Leung, W; Merchant, TE; Onar-Thomas, A; Pai Panandiker, AS; Panandiker, AP; Rowland, C; Stewart, CF; Tagen, M | 1 |
| Carlomagno, F; Chiappetta, G; Ciardiello, F; Coluzzi, S; De Falco, V; Fagin, JA; Ryan, AJ; Santoro, M; Tamburrino, A; Tortora, G; Troncone, G; Vitagliano, D | 1 |
| Bryce, J; Carillio, G; Carotenuto, P; Costanzo, R; Daniele, G; Di Maio, M; Giordano, P; La Rocca, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Doçi, CL; Hasina, R; Lingen, MW; Mankame, TP; Wroblewski, K; Zhou, G | 1 |
| Burtness, B; Psyrri, A | 1 |
| Chen, C; Damek, D; Fields, EC; Gaspar, LE; Kavanagh, BD; Lillehei, K; Liu, AK; Waziri, A | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| DeRyckere, D; Gore, L; Macy, ME | 1 |
| Daroczi, B; Dicker, AP; Lawrence, YR; Liu, Y; Wachsberger, PR; Xu, X | 1 |
| Amadori, A; Ancona, E; Balza, E; Borsi, L; Crescenzi, M; Esposito, G; Indraccolo, S; Persano, L; Ruol, A; Zulato, E | 1 |
| Bischoff, H; Kindermann, M; Reinmuth, N; Steins, MB; Thomas, M | 1 |
| Chilin, A; Conconi, MT; Guiotto, A; Marzaro, G; Parnigotto, PP; Tommasini, M; Tonus, F; Urbani, L; Zanusso, I | 1 |
| Goto, H; Li, Q; Nakataki, E; Nishioka, Y; Ogino, H; Sone, S; Takeuchi, S; Wang, W; Yamada, T; Yano, S | 1 |
| Bankson, JA; Chen, Y; Frederick, MJ; Galer, CE; Gule, MK; Henderson, YC; Jasser, SA; Lai, SY; Milas, ZL; Myers, JN; Sano, D; Schwartz, DL; Zhao, M; Zhou, G | 1 |
| Benz, MR; Bockisch, A; Czernin, J; Damoiseaux, RD; Hartung, V; Hildebrandt, IJ; Laing, RE; Phelps, ME; Walter, MA; Weber, WA | 1 |
| Allen, D; Cao, L; Chen, A; Chen, H; Choyke, P; Collins, J; Doroshow, JH; Gutierrez, ME; Horneffer, YR; Juwara, L; Kim, YS; Kummar, S; Melillo, G; Murgo, AJ; Trepel, J; Turkbey, IB; Yu, Y | 1 |
| Hong, J; Kim, H; Ying, Y | 1 |
| Barlesi, F; Tomasini, P | 1 |
| Abratt, RP; Arrieta, Ó; Blackhall, FH; Chan, V; de Boer, RH; de Marinis, F; Gottfried, M; Langmuir, P; Milenkova, T; Raats, J; Read, J; Vansteenkiste, JF; Wolf, J; Yang, CH | 1 |
| Barlesi, F; Ferry, D; Gogov, S; Goss, GD; Greco, FA; Langmuir, P; Mulatero, C; Natale, RB; Rowbottom, JA; Sunpaweravong, P; Thomas, M; Thompson, J; Thongprasert, S; Tsai, CM; Whorf, R | 1 |
| Batey, MA; de Brito, LR; Hall, AG; Irving, JA; Jackson, G; Leung, HY; Maitland, H; Newell, DR; Squires, MS; Zhao, Y | 1 |
| Claes, A; Hamans, BC; Heerschap, A; Jeuken, JW; Leenders, WP; Navis, AC; Wesseling, P | 1 |
| Hanna, EY; Heymach, J; Matsumoto, F; Milas, L; Molkentine, DP; Myers, JN; Papadimitrakopoulou, V; Sano, D; Takahashi, Y; Valdecanas, DR; Zhao, M | 1 |
| Friedrich, MJ | 1 |
| Takami, HE | 1 |
| Abe, M; Hashimoto, O; Inoue, K; Iwamoto, H; Kerbel, RS; Koga, H; Kurogi, J; Kuwahara, R; Nakamura, T; Niizeki, T; Sata, M; Torimura, T; Ueno, T; Yano, H | 1 |
| Cabebe, EC; Fisher, GA; Sikic, BI | 1 |
| Duvauchelle, T; Kennedy, SJ; Martin, P; Oliver, S; Read, J; Robertson, J | 1 |
| Brooks, S; Kong, HH; Linehan, WM; Srinivasan, R | 1 |
| Bourdel-Marchasson, I; Dejager, S; Schweizer, A | 1 |
| Alves, MM; de Groot, JW; Hofstra, RM; Links, TP; Osinga, J; Plukker, JT; Verbeek, HH | 1 |
| Beckman, JA; Burstein, HJ; Dallabrida, SM; Hannagan, K; Ismail, NS; Mayer, EL; Redline, WM; Rupnick, MA | 1 |
| Gallwitz, B | 1 |
| Acheson, KL; Baker, D; Barry, ST; Brave, SR; Hickinson, DM; Howard, Z; Jackson, L; James, NH; Lovick, SC; Marshall, GB; Odedra, R; Ratcliffe, K; Ryan, AJ; Smith, NR; Speake, G; Wainwright, A; Wilkinson, RW | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Gao, M; Lola, CM; Miller, KD; Sledge, GW; Wang, M; Zheng, QH | 1 |
| Brierley, R | 1 |
| Guan, Z; Jiang, Y; Li, S; Liao, H; Martin, PD; Smith, R; Zhan, J; Zhang, L; Zhang, Y; Zou, BY | 1 |
| Almendro, V; Ametller, E; Casas, I; Fernández-Nogueira, P; García-Recio, S; Gascón, P; Mayordomo, C; Pastor-Arroyo, EM; Vinyals, L | 1 |
| Fassnacht, M; Kreissl, MC; Schott, M; Spitzweg, C; Willhauck, MJ | 1 |
| Hu, MI | 1 |
| Bartha, E; Gero, D; Halmosi, R; Hideg, K; Kalai, T; Magyar, K; Olah, G; Solti, I; Sumegi, B; Szabados, E; Szabo, A; Szabo, C; Toth, K | 1 |
| Baudin, E; Borget, I; Brailly-Tabard, S; Brassard, M; Chanson, P; Leboulleux, S; Neraud, B; Salenave, S; Schlumberger, M; Trabado, S; Young, J | 1 |
| Baryawno, N; Ekström, TJ; Johnsen, JI; Larsson, C; Marino, AM; Sofiadis, A; Vukojević, V | 1 |
| Berrino, L; Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; Heymach, JV; Martinelli, E; Morgillo, F; Saintigny, P; Troiani, T; Tuccillo, C | 1 |
| Chastain, EM; Getts, DR; Getts, MT; Martin, A; Miller, SD; Shankar, S; Wood, K | 1 |
| Commander, H; Perry, C; Whiteside, G | 1 |
| Etienne-Grimaldi, MC; Fischel, JL; Lo Nigro, C; Merlano, M; Milano, G; Monteverde, M; Tonissi, F | 1 |
| Bai, F; Broniscer, A; Johnson, J; Stewart, CF; Wang, F; Yang, L | 1 |
| de Boer, RH; Wong, HL | 1 |
| Kennedy, KC; Qurollo, BA; Rose, BJ; Thamm, DH | 1 |
| Cerny, T; De Dosso, S; Koeberle, D; Renggli, V; Saletti, P; Sessa, C | 1 |
| Alecci, C; Assaraf, YG; Destro, A; Giancola, F; Gianoncelli, L; Giovannetti, E; Leon, LG; Lorenzi, E; Peters, GJ; Roncalli, M; Santoro, A; Smid, K; Zucali, PA | 1 |
| Ahn, J; Hyon, JY; Lee, JH; Wee, WR | 1 |
| He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Chevreau, C; Cottura, E; Garrido-Stowhas, I; Sibaud, V | 1 |
| Baudin, E; Dralle, H; Elisei, R; Fagin, JA; Gagel, RF; Jarzab, B; Langmuir, P; Read, J; Robinson, BG; Ryan, AJ; Santoro, M; Schlumberger, MJ; Vasselli, JR; Wells, SA | 1 |
| Rischin, D; Solomon, B | 1 |
| Langenkamp, E; Leenders, WP; Molema, G; Moorlag, HE; St Croix, B; Zwiers, PJ | 1 |
| Koch, L | 1 |
| Alter, M; Chaykovska, L; Fuchs, H; Heiden, S; Hocher, B; Klein, T; Rahnenführer, J; Runge, F; von Websky, K | 1 |
| Arpin, D; Ernesto, S; Nesme, P; Pérol, M | 1 |
| Langmuir, PB; Yver, A | 1 |
| Houvras, Y | 1 |
| Benoit, A; Cho, TH; de la Fouchardière, C; Derbel, O; Duplomb, S; Mechtouff-Cimarelli, L; Peix, JL | 1 |
| Ji, XL; Li, YL; Lin, MS; Song, SH; Tang, LD; Wu, CF; Yu, B | 1 |
| Chandrashekar, G; Chatterji, D; Meng, L; Robinson, K; Zhu, S | 1 |
| Bubley, GJ; Buckle, GC; Choueiri, TK; Eisenberger, MA; Hahn, NM; Hutson, TE; Jacobus, S; Kantoff, PW; Kim, WY; Morrissey, SC; Mortazavi, A; Petrylak, DP; Quinn, DI; Rosenberg, JE; Ross, RW; Ryan, CW; Sonpavde, G; Taplin, ME; Vaishampayan, U; Yu, EY | 1 |
| Clarke, D; Giles, P; Hutchison, M; Kennedy, SJ; Martin, P; Oliver, S; Partridge, E | 1 |
| Goozner, M | 1 |
| Chao, Y; Cheng, AL; Hsieh, RK; Hsieh, TY; Hsu, C; Huang, WT; Huo, TI; Hwang, WS; Meng, R; Yang, TS; Yu, CW | 1 |
| Gubish, CT; Henry, C; Rothstein, ME; Siegfried, JM; Stabile, LP | 1 |
| Ahn, SM; Christopoulos, A; Gooding, WE; Grandis, JR; Kim, S; Klein, JD | 1 |
| Guo, C; Lan, M; Li, S; Li, Y; Sun, X; Tang, Y; Zhan, D; Zhao, H | 1 |
| Cortese, JF; Dignam, JD; Edenius, M; Hendrick, M; Keller, TL; Kim, YJ; Lee, HK; Mazitschek, R; Rao, A; Sundrud, MS; Whitman, M; Wirth, DF; Yeo, CY; Yum, J; Zocco, D | 1 |
| Asaka, R; Hamanaka, W; Hatano, S; Ishikawa, Y; Lim Choi, Y; Mano, H; Nakagawa, K; Ninomiya, H; Okumura, S; Sakata, S; Satoh, Y; Soda, M; Suzuki, R; Takeuchi, K; Togashi, Y; Uehara, H | 1 |
| Arai, Y; Chiku, S; Enari, M; Furuta, K; Harris, CC; Haugen, A; Hiramoto, M; Ichikawa, H; Iwakawa, R; Kohno, T; Nammo, T; Ogawa, S; Ogiwara, H; Oike, T; Okayama, H; Sakamoto, H; Schetter, AJ; Sekine, I; Shibata, T; Shimada, Y; Skaug, V; Totoki, Y; Tsuda, H; Tsuta, K; Watanabe, S; Yamanaka, I; Yasuda, K; Yokota, J; Yoshida, T | 1 |
| Guo, L; Liu, Z; Meng, Q; Shi, H; Tang, J; Xu, L; Zhu, Y | 1 |
| Almeida, MQ; Hoff, AO | 1 |
| Bai, J; Chang, Y; Ding, C; He, J; Kang, E; Tang, L; Wu, S; Xu, X; Yue, L; Zang, J | 1 |
| Blajman, CR; Chen, YM; Emerson, L; Hirsh, V; Langmuir, P; Lee, JS; Manegold, C; Park, K; Perng, RP; Qin, S | 1 |
| Damse, A; Lacouture, ME; Rosen, AC; Sherman, E; Wu, S | 1 |
| Bai, C; He, J; Li, H; Qin, Y; Song, H; Wang, C; Wei, L; Wu, C; Wu, M; Xu, J; Zhang, X; Zhu, T | 1 |
| Döme, B; Török, S | 1 |
| Edwards, KL; Irons, BK; Stapleton, MR; Weis, JM | 1 |
| Tao, L; Yang, F; Zhu, B; Zhuo, W | 1 |
| Bénard, J; Bidart, JM; Farinotti, R; Forestier, F; Gil, S; Jovelet, C | 1 |
| Jo, MY; Joo, KM; Kim, HH; Kim, MH; Kim, Y; Kim, YG; Lee, SJ; Nam, DH | 1 |
| Pashankar, FD; Rapkin, L | 1 |
| Antalffy, G; Hegedüs, C; Kéri, G; Német, K; Orfi, L; Ozvegy-Laczka, C; Sarkadi, B; Settleman, J; Szakács, G; Truta-Feles, K; Váradi, A; Várady, G | 1 |
| Barbet, J; Chatal, JF; Goldenberg, DM; Kraeber-Bodéré, F | 1 |
| Antczak, C; Bhinder, B; Calder, PA; Djaballah, H; Mahida, JP | 1 |
| Azuma, T; Fujishiro, Y; Matsuzaka, K; Ochiai, H; Tonogi, M; Yamane, GY | 1 |
| Baudin, E; Chougnet, C; Leboulleux, S; Massicotte, MH; Nascimento, CL; Schlumberger, M | 1 |
| Boult, JK; Elvin, P; Gilmour, LD; Halliday, J; Jacobs, V; Jamin, Y; Robinson, SP; Ryan, AJ; Walker-Samuel, S; Waterton, JC | 1 |
| Brunstein, MC; Etienne-Grimaldi, MC; Fischel, JL; Formento, P; Guérin, O; Lattanzio, L; Lo Nigro, C; Maffi, M; Merlano, M; Milano, G; Monteverde, M; Ortholan, C; Pagès, G; Sudaka, A; Tonissi, F | 1 |
| Abe, M; Hashimoto, O; Inoue, K; Iwamoto, H; Koga, H; Masuda, H; Nakamura, T; Sata, M; Torimura, T; Ueno, T; Yano, H | 1 |
| Khurana, V; Minocha, M; Mitra, AK; Pal, D; Qin, B | 1 |
| Balakrishnan, S; Booth, B; Chattopadhyay, S; Dorsam, R; Duan, J; Garnett, C; Gehrke, B; Ghosh, D; Ibrahim, A; Justice, R; Kim, G; Liu, Q; Maher, VE; Marathe, A; Miksinski, SP; Moon, YJ; Murgo, A; Pazdur, R; Sarker, H; Skarupa, L; Song, P; Tang, S; Thornton, K; Verbois, L; Wilson, W; Zhu, H | 1 |
| Chu, CT; Kim, ES; Sada, YH | 1 |
| Chen, J; Cui, IH; Gong, Y; Jin, Y; Tang, C; Wu, X; Xu, Z; Zhang, X; Zhang, Y | 1 |
| Dempsey, EC; Fagan, KA; Karoor, V; Le, M; Merrick, D; Miller, YE | 1 |
| Abrams, TA; Ancukiewicz, M; Blaszkowsky, L; Chan, JA; Duda, DG; Elliott, M; Enzinger, PC; Goldstein, M; Jain, RK; Kulke, MH; Meyerhardt, JA; Regan, E; Schrag, D; Wolpin, BM; Zhu, AX | 1 |
| Frampton, JE | 1 |
| Aide, N; Bardet, S; Crouzeix, G; Michels, JJ; Sevin, E; Vaur, D | 1 |
| Ishikawa, M; Yamada, Y | 1 |
| Jia, HY; Li, J; Wang, ZY; Wu, XM; Zhou, Q | 1 |
| Bourgoin, S; Hamon, M; Kayser, V; Michot, B; Viguier, F | 1 |
| He, AN; Lin, F; Min, DL; Qi, WX; Shen, Z; Sun, YJ; Tang, LN; Yao, Y | 1 |
| Bible, KC | 1 |
| Awada, A; Bastholt, L; Bonichon, F; de la Fouchardiere, C; Gómez, JM; Krause, T; Leboulleux, S; Leenhardt, L; Licour, M; Schlumberger, MJ; Soufflet, C; Tennvall, J | 1 |
| Frampton, JE; Keating, GM; Lyseng-Williamson, KA | 1 |
| Furberg, CD; Moore, TJ | 1 |
| Bottai, G; Santarpia, L | 1 |
| Burstein, HJ; Chen, WY; Downing, SR; Gelman, R; Hannagan, K; Isakoff, SJ; Klement, G; Mayer, EL; Winer, EP | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Dolgin, E | 1 |
| Alden, C; Blumenschein, G; Davis, SE; Herbst, R; Hong, WK; Kim, E; Lee, JJ; Lippman, S; Liu, S; Stewart, D; Tang, XM; Tsao, AS; Wistuba, I | 1 |
| Fine, HA; Iwamoto, FM; Kreisl, TN; McNeill, KA; Shih, J; Sul, J | 1 |
| Aburatani, H; Endo, S; Fukayama, M; Ishikawa, S; Kanai, Y; Kataoka, H; Matsubara, D; Murakami, Y; Niki, T; Oguni, S; Ohara, S; Sakatani, T; Tamura, T; Yoshimoto, T | 1 |
| Baum, RP; Briest, F; Grabowski, P; Hörsch, D; Kulkarni, HR; Zaknun, JJ; Zeitz, M | 1 |
| Liu, HB; Lv, TF; Shi, Y; Song, Y; Xiao, YY; Yuan, DM; Zhan, P | 1 |
| Chang, AY; Wang, M | 1 |
| Campbell, MJ; Gosnell, J; Seib, CD | 1 |
| Chau, NG; Haddad, RI | 1 |
| Arnault, JP; Baudin, E; Brassard, M; Giacchero, D; Maksimovic, L; Mateus, C; Ramacciotti, C; Robert, C; Schlumberger, M; Tomasic, G; Wechsler, J | 1 |
| Acierno, R; Alberti, S; del Boccio, P; Giannelli, G; Maffia, M; Pieragostino, D; Sacchetta, P; Salzet, M; Simeone, P; Tinelli, A; Toto, C; Vergara, D | 1 |
| Schimmel, P; Sun, L; Yang, XL; Zhou, H | 1 |
| Ichihara, E; Kataoka, I; Kiura, K; Minami, D; Ochi, N; Ohashi, K; Takeda, H; Takigawa, N; Tanimoto, M | 1 |
| Beijnen, JH; Harmsen, S; Maas-Bakker, RF; Meijerman, I; Schellens, JH | 1 |
| Bakris, GL; Flynn, C | 1 |
| Cunnane, ME; Randolph, GW; Ross, DS; Sadow, PM; Wirth, LJ | 1 |
| Broniscer, A; Hillenbrand, CM; Kocak, M; Loeffler, RB; Sedlacik, J; Winchell, A | 1 |
| Bidart, JM; Broutin, S; Deroussent, A; Farinotti, R; Gil, S; Jovelet, C; Paci, A | 1 |
| Brekken, RA; Buettner, R; Chatterjee, S; Christofori, G; Frasca, D; Heukamp, LC; Koker, M; König, K; Meder, L; Neumaier, B; Peifer, M; Rauh, D; Schöttle, J; Siobal, M; Thomas, RK; Ullrich, RT; Wieczorek, C; Wolf, J | 1 |
| Burttet, LM; Cerski, MR; Dora, JM; Maia, AL; Scheffel, RS; Siqueira, DR | 1 |
| Armand, JP; Bahleda, R; Baselga, J; Berman, D; Calvo, E; Felip, E; Hanna, N; Harbison, CT; Herbst, RS; Kurland, JF; Laurie, SA; Park, JS; Pathak, AK; Shepherd, FA; Soria, JC; Vakkalagadda, B; Zhang, S | 1 |
| Park, JI; Starenki, D | 1 |
| Broniscer, A; Gajjar, A; Kaste, SC; Kaufman, RA | 1 |
| Baker, JN; Baker, SD; Broniscer, A; Chin, TK; Davidoff, AM; Gajjar, A; Huang, J; Kaste, SC; Merchant, TE; Onar-Thomas, A; Pai Panandiker, AS; Panetta, JC; Stewart, CF; Wetmore, C | 1 |
| Monneret, C | 1 |
| Antoun, S; Baracos, VE; Baudin, E; Borget, I; Broutin, S; Deroussent, A; Leboulleux, S; Massicotte, MH; Paci, A; Schlumberger, M | 1 |
| Adelstein, DJ; Bokar, JA; Dowlati, A; Fu, P; Halmos, B; Jia, Y; Juergens, R; Rodal, MB | 1 |
| Andriamanana, I; Duretz, B; Gana, I; Hulin, A | 1 |
| Robert, C; Sibaud, V | 1 |
| Esumi, H; Goto, K; Ishii, G; Kohno, T; Makinoshima, H; Matsumoto, S; Matsushima, K; Mimaki, S; Ochiai, A; Shibata, T; Suzuki, A; Suzuki, M; Suzuki, Y; Tsuchihara, K; Tsuta, K; Yoh, K | 1 |
| Alden, CM; Blumenschein, GR; Davis, SE; Herbst, R; Heymach, J; Hong, WK; Kim, E; Lee, JJ; Lippman, S; Liu, S; Tang, X; Tran, H; Tsao, AS; Wistuba, I | 1 |
| Aebi, S; Diebold, J; Gautschi, O; Hirschmann, A; Keller, FA; Strobel, K; Zander, T | 1 |
| Durante, C; Filetti, S; Paciaroni, A; Plasmati, K; Trulli, F | 1 |
| Banaszynski, ME; Kolesar, JM; Ton, GN | 1 |
| Charbonnel, B; Dejager, S; Schweizer, A | 1 |
| Fujita, S; Katsumura, S; Kobayashi, T; Sakaguchi, T; Tsuchikawa, H | 1 |
| Aisner, J; Dakhil, SR; Manola, JB; Schiller, JH; Sovak, MA; Stella, PJ | 1 |
| Adkins, D; Clark, J; Haddad, R; Jaffa, Z; Limaye, S; O'Neill, A; Posner, M; Riley, S; Zhao, S | 1 |
| Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N; Morissette, M | 1 |
| Aikin, A; Balis, FM; Chuk, MK; Dombi, E; Fox, E; Lodish, M; Marcus, L; Merino, MJ; Steinberg, SM; Wells, SA; Whitcomb, PO; Widemann, BC | 1 |
| Alafuzoff, I; Bergqvist, M; Blomquist, E; Edqvist, PH; Ekman, S; Gullbo, J; Jaiswal, A; Johansson, F; Lennartsson, J; Navani, S; Pontén, F; Popova, S; Sooman, L; Tsakonas, G | 1 |
| Fang, W; Li, A; Luo, S; Niu, X; Ruan, J; Shen, J; Tian, G; Zhao, P; Zheng, H | 1 |
| Bartsch, DK; Doll, D; Greene, BH; Hoffmann, S; Khoruzhyk, M; Ramaswamy, A; Roth, S; Wunderlich, A | 1 |
| Dall'acqua, S; Salvador, A; Vedaldi, D | 1 |
| Chen, S; Ding, W; Gu, J; Kim, S; Li, X; Pan, M; Tian, W; Zhang, L; Zheng, L | 1 |
| Baudry, C; Groussin, L; Paepegaey, AC | 1 |
| Postel-Vinay, S; Schlumberger, M; Soria, JC | 1 |
| Hu, W; Lu, X; Tu, Z; Wang, S; Xie, H; Xu, H; Yang, L; Zeng, L; Zeng, S; Zhang, G; Zhang, X; Zhao, X | 1 |
| Bhatt, DK; Gupta, S; Hay-Schmidt, A; Jansen-Olesen, I; Olesen, J; Ploug, KB; Ramachandran, R | 1 |
| du Bois, A; Elser, G; Harter, P; Hilpert, F; Kimmig, R; Kurzeder, C; Rau, J; Sehouli, J | 1 |
| Rodrigues, AD; Shen, H; Yang, Z; Zhang, Y; Zhao, W | 1 |
| Askeland, RW; Cyr, AR; Gillum, MP; Spanheimer, PM; Weigel, RJ; Woodfield, GW | 1 |
| Cagan, RL; Das, TK | 1 |
| Advani, A; Advani, SL; Connelly, KA; Gilbert, RE; Kelly, DJ; Thai, K; Zhang, Y | 1 |
| Ahn, JS; Ahn, MJ; Cho, EK; Kang, ES; Kang, JH; Kim, SW; Lee, DH; Lee, GW; Lee, JS; Lee, JW; Lee, KH; Park, K; Sun, JM | 1 |
| Kim, YS; Li, F; Li, Z; O'Neill, BE | 1 |
| Becker, MA; Farzan, T; Haluska, P; Harrington, SC; Hou, X; Kalli, KR; Krempski, JW; Weroha, SJ; Wong, TW | 1 |
| Mandal, M; Rajput, S; Sarkar, S; Tripathi, AK | 1 |
| Chen, Z; Chowdry, RP; Khuri, FR; Kim, S; Owonikoko, TK; Saba, NF; Shin, DM | 1 |
| Cass, CE; Damaraju, VL; Kuzma, M; Mowles, D; Ryan, AJ; Sawyer, MB; Scriver, T | 1 |
| Capdevila, J; Filetti, S; Grande, E; Kreissl, MC; Newbold, K; Reinisch, W; Robert, C; Schlumberger, M; Tolstrup, LK; Zamorano, JL | 1 |
| Bidart, JM; Broutin, S; Caillou, B; Commo, F; De Koning, L; Dubois, T; Dupuy, C; Lacroix, L; Marty-Prouvost, B; Ryan, AJ; Schlumberger, M; Talbot, M | 1 |
| Alghamdi, W; Cooper, MR; Shaheen, DJ; Steinberg, M; Yi, SY | 1 |
| Cohen, MS; Sim, MW | 1 |
| Baudin, E; Borson-Chazot, F; Hescot, S; Lombès, M | 1 |
| Das, S; Mandal, M; Mitra, A; Pradhan, R; Rajput, S | 1 |
| Bastian, G; Bourgoin, S; Hamon, M; Kayser, V; Michot, B | 1 |
| Bhang, HE; Chan, FC; Cooke, VG; Derti, A; Dietze, K; Dörken, B; Farsidjani, A; Frick, M; Fritsch, C; Gascoyne, RD; Hummel, M; Kauffmann, A; Kim, S; Korn, JM; Kovats, S; Kridel, R; Lenz, G; Meissner, B; Monahan, J; Morrissey, MP; Naylor, T; Pfister, E; Rahal, R; Rakiec, D; Romero, R; Ruddy, D; Sellers, WR; Stegmeier, F; Steidl, C; Tzankov, A | 1 |
| Cseh, S; Dobi, K; Dormán, G; Flachner, B; Hajdú, I; Lorincz, Z | 1 |
| Ding, X; Duan, W; Jin, X; Sun, Y; Wang, N; Wang, S; Xiang, L; Zhao, Z | 1 |
| Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M | 1 |
| Bao, J; Dai, Z; Lan, Y; Tu, W; Wei, T; Zhao, B | 1 |
| Anagnostis, P; Karras, S; Krassas, GE | 1 |
| Askeland, RW; Cyr, AR; De Andrade, JP; Kulak, MV; Park, JM; Spanheimer, PM; Sugg, SL; Thomas, A; Weigel, RJ; Woodfield, GW | 1 |
| Tibaldi, JM | 1 |
| Hariguchi, N; Horoiwa, S; Kasahara, R; Kikuchi, H; Matsumoto, M; Oshima, Y | 1 |
| Balis, FM; Derdak, J; Fox, E; Kebebew, E; Lodish, MB; Nella, AA; Quezado, MM; Stratakis, CA; Whitcomb, PO; Widemann, BC | 1 |
| Evans, P; McLaughlin, NP; Pines, M | 1 |
| Balogh, A; Bruszt, K; Deres, L; Eros, K; Gallyas, F; Halmosi, R; Hamar, J; Hideg, K; Magyar, K; Seress, L; Sumegi, B; Toth, K | 1 |
| Azad, AA; Beardsley, EK; Chi, KN; Chin, J; Ellard, SL; Hotte, SJ; Klotz, L; Kollmannsberger, C; Mukherjee, SD | 1 |
| Adamczak, J; Chatterjee, S; Florin, A; Franz, T; Heukamp, LC; Hinze, Y; Neumaier, B; Schöttle, J; Siobal, M; Ullrich, RT; Wieczorek, C | 1 |
| Brun, P; Dall'Acqua, S; Salvador, A; Vedaldi, D | 1 |
| Anderson, GL; Bonebrake, AJ; Chambers, SK; Coleman, RL; Delmore, JE; Hu, W; Markman, M; Moon, J; Sood, AK | 1 |
| Barni, S; Brandes, AA; Caffo, O; Cerea, G; Ciardiello, F; Crinò, L; Cruciani, G; De Marinis, F; Fasola, G; Favaretto, AG; Ferrari, S; Ferraù, F; Galetta, D; Genestreti, G; Gridelli, C; Grossi, F; Iannacone, C; Luciani, A; Novello, S; Zilembo, N | 1 |
| Funayama, S | 1 |
| Athyros, VG; Elisaf, MS; Filippatos, TD | 1 |
| Ito, K; Sugino, K; Takami, H | 1 |
| Chiou, TT; Gallacchi, D; Kwiatkowski, DJ; Lee, PS; Li, C; Malinowska, IA; Pereira, AM; Reynolds, SB; Robinson, L; Sun, Y; Yu, JJ; Zhang, EY | 1 |
| El-Shentenawy, A; Mohammed, AA | 1 |
| Alden, CM; Bashoura, L; Eapen, GA; Faiz, SA; Herbst, RS; Hong, WK; Jack Lee, J; Jimenez, CA; Liu, DD; Marom, EM; Massarelli, E; Mino, B; Morice, RC; Onn, A; Tran, HT; Wistuba, II | 1 |
| Califaretti, N; Chia, SK; Clemons, MJ; Cochrane, B; Dent, RA; Levine, MN; Parpia, S; Pond, GR; Pritchard, KI; Rayson, D; Robidoux, A; Song, X; Warr, D | 1 |
| Beuschel, SL; Hillegass, JM; MacPherson, MB; Macura, SL; Miller, JM; Mossman, BT; Perkins, TN; Sayan, M; Shukla, A; Thompson, JK | 1 |
| Ladizinski, B; Sankey, C | 1 |
| He, G; Hu, M; Li, J; Xu, Q; Ye, W; Zhang, Y; Zhong, G | 1 |
| Kong, L; Lai, ZW; Li, C; Liu, J; Sun, H; Wen, X | 1 |
| Bartha, E; Deres, L; Eros, K; Gallyas, F; Halmosi, R; Hideg, K; Kalai, T; Lantos, J; Palfi, A; Riba, A; Sumegi, B; Toth, K | 1 |
| Cohen, PR; Jalalat, SZ | 1 |
| Jain, V; Kikuchi, H; Oshima, Y; Sharma, A; Yogavel, M | 1 |
| Herbst, RS; Heymach, JV; Johnson, BE; Lockwood, SJ; Ryan, AJ | 1 |
| Imai, T; Ishigame, T; Kohno, T; Kumamoto, K; Saito, M; Tsuta, K | 1 |
| Bevilacqua, S; D'Alessio, A; De Luca, A; Frezzetti, D; Gallo, M; Maiello, MR; Morabito, A; Normanno, N; Perrone, F | 1 |
| Johansson, S; Leese, PT; Li, Y; Lisbon, E; Martin, P; Mathews, D; Oliver, S; Read, J; Steinberg, M | 1 |
| Fang, Y; Febles, NK; Ferrie, AM | 1 |
| Dai, B; Fang, B; Gao, W; Gold, KA; Heymach, JV; Hofstetter, WL; Lu, H; Minna, J; Ou, Z; Roth, JA; Swisher, SG; Wang, L; Wang, M; Wu, S; Zhang, L | 1 |
| Caro-Gutiérrez, D; Floristán Muruzábal, MU; Franco, AP; Gómez de la Fuente, E; López Estebaranz, JL | 1 |
| Cabanillas, ME; Hu, MI; Jimenez, C | 1 |
| Colao, A; Faggiano, A; Marotta, V; Sciammarella, C; Vitale, M | 1 |
| Baudin, E; Chougnet, CN; Leboulleux, S; Schlumberger, M | 1 |
| Jarzab, B; Krajewska, J | 1 |
| Chen, CR; Cohen, EW; Frank, SJ; Heymach, JV; Hirsch, FR; Jimeno, A; Lin, H; Lowe, ES; Myers, JN; Nedzi, L; Papadimitrakopoulou, VA; Raben, D; Tran, HT; Vasselli, JR | 1 |
| Bastida, CC; Falchook, GS; Gaido, L; Jackson, T; Karp, DD; Miller, VA; Ordóñez, NG; Stephens, PJ | 1 |
| Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L | 1 |
| Hong, T; Wang, C; Wang, F; Xia, L; Yang, S; Yang, Z | 1 |
| Huang, J; Ji, LJ; Liu, H; Liu, Y; Ma, W; Qi, X; Xu, M; Zhu, Y | 1 |
| Bellmunt, J; Choueiri, TK; Di Lorenzo, G; Federico, P; Mullane, S; Necchi, A; Pond, GR; Qu, AQ; Rosenberg, JE; Sonpavde, G | 1 |
| Kaelin, WG | 1 |
| Chen, V; Crooks, DR; Ghosh, S; Krishna, MC; Liao, PJ; Linehan, WM; Mannes, PZ; Matsumoto, S; Merino, M; Mitchell, JB; Neckers, L; Pendergast, AM; Ricketts, CJ; Rouault, TA; Sourbier, C; Srinivasan, R; Srivastava, G; Vocke, CD; Wei, MH; Yang, Y | 1 |
| Batchelor, TT; Beroukhim, R; Betensky, RA; Chheda, MG; Chi, AS; Drappatz, J; Eichler, AF; Gerstner, ER; Hochberg, FH; Norden, AD; Wen, PY; Yang, D | 1 |
| Chiba, M; Shibata, Y | 1 |
| Arrivas Bajardi, E; Barone, C; Bencardino, K; Buonadonna, A; Cartenì, G; Comandone, A; Ferrari, D; Ferrari, S; Foa, P; Gebbia, V; Milella, M; Personeni, N; Pressiani, T; Rimassa, L; Santoro, A; Testa, A; Tronconi, MC; Zaniboni, A | 1 |
| Ghosh, G; Guo, B; Wu, Y | 1 |
| Bardet, S; Bonichon, F; Borget, I; Chauffert, B; Chougnet, CN; Criniere, L; de la Fouchardiere, C; Drui, D; Leboulleux, S; Niccoli, P; Rohmer, V; Schlumberger, M; Schneegans, O; Schvartz, C; Zanetta, S | 1 |
| Chau, VM; Le, CV; Mai, HD; Nguyen, TL; Pham, VC; Phi, TD; Thanh, GV; Tran, VH; Truong, BN; Vu, VL; Vu, VN | 1 |
| Gianni, C; Loffi, M; Lombardi, F; Toffetti, L | 1 |
| Foltz, G; Harrison, JK; Hothi, P; Law, BK; Luo, D; Pham, K; Reynolds, BA; Siemann, DW | 1 |
| Cai, N; Chen, X; Kong, X; Liu, P; Xu, L; Zhang, Y; Zhou, Y; Zou, H | 1 |
| Fan, ZW; Li, J; Liu, Y; Xu, GG | 1 |
| Bigley, G; Blockley, L; Cresswell, C; Dale, A; Davies, A; de Boer, R; Donald, E; Elvin, P; Fan, S; Fu, H; Gladwin, A; Gray, N; Harrod, G; Herbst, RS; Ji, Q; Lee, JS; Morten, J; Platt, A; Read, J; Stevens, J; Su, X; Vasselli, J; Williams, V; Womack, C; Ye, Q; Zhang, T; Zheng, L | 1 |
| Curry, JL; Goldstein, J; Patel, AB; Piha-Paul, S; Subbiah, V | 1 |
| Kohno, T; Makinoshima, H; Matsushima, K; Sugano, S; Suzuki, A; Suzuki, Y; Tsuchihara, K | 1 |
| Alexander, BM; Ancukiewicz, M; Batchelor, TT; Beroukhim, R; Drappatz, J; Duda, DG; Gerard, M; Huse, JT; Jain, RK; Kaley, TJ; Lassman, AB; Lee, EQ; Ligon, KL; McCluskey, CS; Mikkelsen, T; Muzikansky, A; Norden, AD; Purow, BW; Ramkissoon, S; Schiff, D; Smith, KH; Weiss, SE; Wen, PY; Wong, ET | 1 |
| Del Giudice, P; Delord, JP; Hubiche, T; Roché, H; Sibaud, V; Tournier, E | 1 |
| Karedan, T; Perez, CA; Wang, E | 1 |
| Cupo, M; Mauritz, M; Mitulovic, G; Węsierska-Gądek, J | 1 |
| Ali, SM; Berry, J; Cascone, T; Guha-Thakurta, N; Heymach, JV; McMahon, C; Miller, V; Pai, S; Roxas, M; Subbiah, IM; Subbiah, V; Tang, Z | 1 |
| Bopp, SE; Clardy, J; Clish, CB; Cortese, JF; Derbyshire, ER; Estiu, G; Galinsky, K; Herman, JD; Keller, TL; Lindquist, S; Lukens, AK; Mazitschek, R; Mota, MM; Patel, V; Pepper, LR; Ribacke, U; Santos, SA; Schimmel, P; Sullivan, WJ; Whitman, M; Wiest, O; Wirth, DF; Zhou, H; Zuzarte-Luis, V | 1 |
| Ali, A; Anand, R; Culberson, C; Deng, Q; Greene, S; Kim, JH; Levorse, D; Lim, YH; Mullins, D; Parker, EM; Sherborne, B; Stamford, A; Tempest, P; Yu, Y; Zhang, X; Zheng, J; Zhou, W | 1 |
| Chen, JM; Chen, S; Du, W; Huang, W; Liu, J; Liu, RY; Pan, C; Shen, J; Wu, J; Zhou, L; Zhou, Y; Zhu, X | 1 |
| Fassnacht, M; Kreissl, MC; Mueller, SP | 1 |
| Antonelli, A; Benvenga, S; Di Bari, F; Fallahi, P; Ferrari, SM; Materazzi, G; Miccoli, P; Spisni, R | 1 |
| Cowan, N; Keiser, J | 1 |
| Cheng, X; Cheng, Y; Kuang, Y; Pan, X; Yang, X | 1 |
| Gemma, A; Miyanaga, A | 1 |
| Bueno, F; Cross, G; Lucas, S; Pitoia, F; Schmidt, A | 1 |
| Alias, Z; Feroz, SR; Kabir, MZ; Mohamad, SB; Mukarram, AK; Tayyab, S | 1 |
| Covell, LL; Ganti, AK | 1 |
| Darras, FH; Decker, M; Khan, N; Nurulain, SM; Saad, A; Sadek, B | 1 |
| Bradshaw, N; Davidson, R; MacGregor, FB; Narayanan, VK; Reed, N; Ronghe, M; Shaikh, MG; Welbury, R | 1 |
| Bandaru, S; Dunna, NR; Girdhar, A; Hussain, T; Kandula, V; Nayarisseri, A; Pudutha, A | 1 |
| Buck, AK; Grelle, I; Hänscheid, H; Herrmann, K; Higuchi, T; Lapa, C; Lückerath, K; Muegge, DO; Reiners, C; Schmid, JS; Werner, RA | 1 |
| Cui, Y; Li, X; Liu, H; Wang, D; Xu, T; Yin, B; Zhang, C; Zhang, Y | 1 |
| Diao, L; Fan, Y; Giri, U; Gudikote, J; Herbst, R; Heymach, JV; Johnson, BE; Koo, A; Lu, W; Nilsson, MB; Rowe, P; Ryan, A; Tang, X; Tong, P; Tran, H; Wang, J; Webster, A; Wistuba, II | 1 |
| Hadoux, J; Pacini, F; Schlumberger, M; Tuttle, RM | 1 |
| Cho, H; Choi, S; Kim, ND; Kwak, Y; Sim, T; Yoon, H | 1 |
| Bièche, I; Bonin, F; Château-Joubert, S; de Plater, L; Dieras, V; El Botty, R; Hatem, R; Labiod, D; Marangoni, E; Servely, JL; Vacher, S | 1 |
| Bradshaw-Pierce, EL; Eckhardt, SG; Eppers, S; Freas, E; Kane, MA; Kessler, ER; Leong, S; Lieu, CH; Messersmith, WA; Nallapreddy, S; O'byrant, CL; Pitts, TM; Spratlin, J; Weekes, C | 1 |
| Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Bretagne, M; Cabanes, L; Cessot, A; Chahwakilian, A; Coriat, R; Goldwasser, F; Huillard, O; Orvoen, G; Thomas-Schoemann, A; Tlemsani, C | 1 |
| De Andrade, JP; Gu, VW; Kulak, MV; Lorenzen, AW; Park, JM; Spanheimer, PM; Van Dorin, SE; Weigel, RJ; Woodfield, GW; Wu, VT | 1 |
| Bowler, KA; Burns, EM; Chapman, PJ; Fairweather, EE; Fritzl, SJR; Goldberg, KM; Hamilton, NM; Holt, SV; Hopkins, GV; Jones, SD; Jordan, AM; Lyons, AJ; Maguire, LA; McDonald, NQ; Mould, DP; Newton, R; Nikki March, H; Ogilvie, DJ; Purkiss, AG; Small, HF; Stowell, AIJ; Thomson, GJ; Waddell, ID; Waszkowycz, B; Watson, AJ | 1 |
| Abad, S; Auladell, C; Beas-Zarate, C; Camins, A; Ettcheto, M; Folch, J; García, ML; Olloquequi, J; Petrov, D; Sánchez-López, E | 1 |
| Chen, P; Liu, G; Wu, L | 1 |
| Ott, G; Rauert-Wunderlich, H; Rosenwald, A; Rudelius, M | 1 |
| Beckmann, L; Bender, R; Lange, S | 1 |
| Malik, R; Narula, A; Naskar, M; Pandey, RK; Prajapati, VK; Shah, P; Srivastava, S; Verma, P | 1 |
| Astsaturov, IA; Berger, AC; Boland, PM; Burtness, BA; Cheng, JD; Cohen, SJ; Cooper, HS; Davey, M; Lebenthal, A; Meyer, JE; Neuman, T; Olszanski, AJ; Scott, WJ | 1 |
| Vincenti, F; Webber, AB | 1 |
| Barbry, P; Belléannée, G; Blanck, O; Bonnetaud, C; Bordone, O; Bozec, A; Brest, P; Butori, C; Catargi, B; Guevara, N; Hénaoui, IS; Hofman, P; Hofman, V; Ilie, M; Lassalle, S; Lemaire, G; Long, E; Mari, B; Patey, M; Peyrottes, I; Popa, A; Sadoul, JL; Santini, J; Tissier, F; Trouette, H; Vielh, P; Zangari, J | 1 |
| Kumbhar, BV; Kunwar, A; Malik, R; Pandey, RK; Prajapati, VK; Srivastava, S; Sundar, S | 1 |
| Choi, YL; Han, J; I, H; Kim, J; Kim, RN; Kim, YD; Kim, YJ; Lee, CH; Lee, MK; Lee, MS; Lira, ME; Mao, M; Noh, KW; Oh, DY; Song, JY; Yang, JW | 1 |
| Au-Yeung, SC; Fei, R; Lam, AS; Poon, DC; To, KK; Wei, Y | 1 |
| Ajmera, S; Bollinger, KA; Bridges, TM; Bubser, M; Chang, S; Chase, P; Conn, PJ; Duggan, ME; Emmitte, KA; Engers, JL; Gregro, AR; Han, C; Hodder, PS; Hopkins, CR; Jones, CK; Lamsal, A; Lindsley, CW; Melancon, BJ; Niswender, CM; Noetzel, MJ; Smith, E; Tarr, JC; West, M; Wood, MR; Wood, MW | 1 |
| Ali, SM; Busaidy, NL; Chmielecki, J; Elvin, JA; Erlich, RL; Heilmann, AM; Khan, SA; Lipson, D; Miller, VA; Murthy, R; Nangia, C; Ross, JS; Shah, MH; Sherman, SI; Stephens, PJ; Subbiah, I; Subbiah, V; Sun, JX; Vergilio, JA; Wang, K; Yelensky, R | 1 |
| Bird, BH; Dodd, KA; Erickson, BR; Shrivastava-Ranjan, P; Spiropoulou, CF | 1 |
| Conklin, DS; Khan, F; Kokabee, L; Sevinsky, CJ; Sun, Y; Wang, X; Wong, J | 1 |
| Badziong, J; Führer, D; Herold, T; Schmid, KW; Tiedje, V; Ting, S; Walter, RF; Worm, K; Zwanziger, D | 1 |
| Learoyd, DL; Robinson, BG; Tsang, VH | 1 |
| Chabre, O; Dupuis, C; Durand, C; Piolat, C; Plantaz, D; Segura, D | 1 |
| Li, J; Liu, Z; Lu, D; Wang, H; Wang, J; Wei, X; Xie, H; Xu, X; Zheng, S; Zhuang, R | 1 |
| Chen, D; Coffman, TM; Jensen, BL; Johnsen, I; Madsen, K; Tinning, AR | 1 |
| Arora, D; Duan, H; Lee, JW; Li, Y; Lim, HY; Moon, SW; Wang, W | 1 |
| Ichihara, E; Kiura, K; Kubo, T; Ohashi, K; Osawa, M; Takata, M; Takata, S; Takigawa, N; Tanimoto, M | 1 |
| Guarino, M; Hanna, N; Jayaram, N; Masters, GA; Misleh, J; Patel, JD; Sanborn, RE; Stephens, A; Wu, J | 1 |
| Chen, Y; Dong, Y; Jiang, Z; Li, Y; Pei, H; Peng, Y; Shao, T; Sun, Z; Tang, W; Wang, J; Yi, Z; Zhou, W | 1 |
| Antonelli, A; Baldini, E; Biricotti, M; Fallahi, P; Ferrari, SM; Materazzi, G; Miccoli, P; Ulisse, S | 1 |
| Chen, AY; Ernani, V; Kumar, M; Owonikoko, TK | 1 |
| Collins, L; Corner, C; Goff, M; Gupta, A; Kelly, C; Lester, J; Love, S; Marshall, E; Middleton, MR; Nobes, J; Roberts, C; Salisbury, A; Tysoe, F; Wise, A; Wolstenholme, V; Woodward, M | 1 |
| Matsuhashi, N; Matsui, S; Okumura, N; Osada, S; Sasaki, Y; Takahashi, T; Tanahashi, T; Tanaka, Y; Yamaguchi, K; Yawata, K; Yoshida, K | 1 |
| Ahn, JS; Ahn, MJ; Choi, YL; Heo, DS; Jeon, YK; Keam, B; Kim, DW; Kim, TM; Lee, JK; Lee, SH; Min, HS; Park, K; Sun, JM | 1 |
| Horiuchi, K; Ito, Y; Komoda, M; Okamoto, T; Rito, K; Takahashi, S; Todo, T; Tomomatsu, J; Tsuji, A; Uchino, K | 1 |
| Goto, K; Ishii, G; Kohno, T; Matsumoto, S; Murakami, H; Nishio, M; Nogami, N; Nomura, S; Ohe, Y; Ohtsu, A; Sato, A; Satouchi, M; Seto, T; Tsuchihara, K; Tsuta, K; Yamamoto, N; Yoh, K | 1 |
| Chang, H; Kim, HS; Kim, JW; Lee, JS; Moon, SU; Sung, JH | 1 |
| Bañon-Maneus, E; Campistol, JM; Diekmann, F; Hierro-Garcia, N; Martina, MN; Moya Rull, D; Ramirez Bajo, MJ; Revuelta, I; Rovira, J | 1 |
| Carter, JJ; Fretwell, LV; Woolard, J | 1 |
| Alifano, M; Bienvenu-Perrard, M; Bricaire, L; Burnichon, N; Cochand-Priollet, B; Groussin, L; Lahlou, N; Louiset, E; Paepegaey, AC; Sarfati, PO | 1 |
| Bonsignore, R; Gentile, C; Lauria, A; Martorana, A | 1 |
| Aga, MA; Kumar, B; Nagaraju, PVVS; Rayees, S; Rouf, A; Sharma, A; Singh, G; Taneja, SC | 1 |
| Czuczman, P; Hagan, A; Lewis, AL; Lloyd, AW; Macfarlane, WM; Phillips, GJ | 1 |
| Craveiro, RB; Dilloo, D; Ehrhardt, M; Goetz, B; Olschewski, M; Pietsch, T; Velz, J | 1 |
| Abdolalizadeh, B; Amandi, N; Edvinsson, L; Pickering, DS; Pla, MV; Sams, A; Sheykhzade, M; Warfvinge, K | 1 |
| Campbell, F; Corrie, P; Costello, E; Cox, T; Coxon, F; Cunningham, D; Evans, A; Falk, S; Ghaneh, P; Greenhalf, W; Hickish, T; Jackson, R; Madhusudan, S; Middleton, G; Neoptolemos, JP; Palmer, DH; Propper, D; Rawcliffe, C; Ross, P; Shaw, VE; Valle, JW; Wadd, N; Wadsley, J; Wasan, H | 1 |
| Cohen, PR; Udkoff, J | 1 |
| Deres, L; Eros, K; Gallyas, F; Halmosi, R; Kalai, T; Magyar, K; Riba, A; Skazel, A; Sumegi, B; Toth, K; Vamos, Z | 1 |
| Dholakia, S; Fildes, JE; Friend, PJ | 1 |
| Edwards, A; Glass, JO; Li, Y; Patay, Z; Reddick, WE; Svolos, P; Sykes, A | 1 |
| Hong, SK; Park, JI; Starenki, D; Wu, PK | 1 |
| Cochin, V; Godbert, Y; Gross-Goupil, M; Le Moulec, S; Ravaud, A | 1 |
| Accardo, G; Avenia, N; Castaldo, F; Colantuoni, V; Conzo, G; Di Donna, C; Esposito, D; Gambardella, C; Giugliano, D; Mazzella, M; Pasquali, D; Polistena, A | 1 |
| Alsaid, MS; Ghorab, MM; Ragab, FA; Soliman, AM | 1 |
| Hedayati, M; Rajabi, S | 1 |
| Fisher, PB; Konar, S; Kumar, BNP; Mandal, M; Pathak, A; Prasad, PN; Rajput, S; Rao, RR; Sarkar, S | 1 |
| Danilov, AV; Hamilton, BJ; Jones, JD; Rigby, WFC; Skopelja-Gardner, S | 1 |
| Bengoetxea, H; Bulnes, S; Lafuente, JV; Requejo, C; Ruiz-Ortega, JA; Ugedo, L | 1 |
| Alias, Z; Ghani, H; Hamzah, NAB; Kabir, MZ; Mohamad, SB; Tayyab, S | 1 |
| Chen, X; He, Q; Li, H; Li, M; Liu, Y; Long, Y; Lu, L; Qiu, Y; Tang, J; Wang, X; Yu, Q; Zhang, Z | 1 |
| Hadoux, J; Schlumberger, M | 1 |
| Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Hou, S; Li, Y; Liu, Q; Liu, Y; Qi, M; Shao, L; Zhang, J | 1 |
| Feng, WH; Li, C; Liu, XQ; Liu, ZH; Wang, ZM; Yang, LX; Zhang, JY | 1 |
| Broniscer, A; Merchant, TE; Nguyen, R; Onar-Thomas, A; Patay, Z; Pierson, CR | 1 |
| Feng, WH; Li, C; Liu, XQ; Wang, ZM; Yang, LX; Zhang, JY | 1 |
| Akshintala, S; Balis, FM; Derse-Anthony, C; Dombi, E; Fox, E; Glod, JW; Kapustina, O; Kraft, IL; Lei, H; Lodish, M; Meltzer, PS; Merino, MJ; Shern, JF; Steinberg, SM; Waguespack, SG; Widemann, BC; Zhu, Y | 1 |
| Thieblemont, C | 1 |
| Kang, Y; Ma, W; Yang, L; Yang, T; Zhu, M | 1 |
| Komada, F | 1 |
| Barbeau, X; Boulanger, MC; Boutin, S; Forcellini, E; Lagüe, P; Lefebvre, CA; Mathieu, P; Paquin, JF; Rhéaume, G; Shayhidin, EE | 1 |
| Araki, M; Chauhan, R; Goto, K; Ichikawa, H; Ishii, G; Knowles, PP; Kohno, T; Matsumoto, S; McDonald, NQ; Mimaki, S; Nagatoishi, S; Nakaoku, T; Niho, S; Okuno, Y; Shimada, Y; Tsuchihara, K; Tsumoto, K; Yoh, K | 1 |
| Li, C; Wei, G; Yang, C | 1 |
| Droeser, R; Kouraklis, G; Patsouris, E; Tampaki, EC; Tampakis, A | 1 |
| Baple, EL; Brooke, A; Derse-Anthony, C; Glod, J; Newbold, K; Osborne, N; Sturley, R; Thomas, N; Vaidya, B | 1 |
| Antonelli, A; Baldini, E; Bocci, G; Di Desidero, T; Elia, G; Fallahi, P; Ferrari, SM; Fioravanti, A; La Motta, C; Materazzi, G; Miccoli, P; Orlandi, P; Paparo, SR; Patrizio, A; Piaggi, S; Ragusa, F; Ruffilli, I; Ulisse, S | 1 |
| Arriola-Villalobos, P; Benítez-Del-Castillo, JM; Benito-Pascual, B; Díaz-Valle, D | 1 |
| Duan, W; Feng, Y; Hei, YY; Mao, S; Shen, Y; Xin, M; Zhang, H; Zhang, SQ; Zhao, HY | 1 |
| Fan, XR; Feng, WH; Guo, ZT; Li, C; Liu, XQ; Wang, ZM; Yang, LX; Yu, XW; Zhang, JY | 1 |
| Abdel-Rahman, O; Elhalawani, H; Elsayed, Z | 1 |
| Byun, B; Chae, JH; Hyun, SA; Kim, KS; Lee, HA | 1 |
| Cáncela-Díez, B; Cuenca-Barrales, C; Galvez-Moreno, M; López-Delgado, D; Ruiz-Villaverde, R | 1 |
| Evans, P; McLaughlin, NP; Smullen, S | 1 |
| Das, SK; Emdad, L; Fisher, PB; Kumar, BNP; Kundu, SC; Mahto, MK; Mandal, M; Pathak, A; Puvvada, N; Rajput, S; Reis, RL; Sarkar, S; Yallapu, MM | 1 |
| Guo, J; Guo, T; Liu, D; Sun, Y; Wang, N; Zhu, X | 1 |
| Borchmann, S; Büttner, R; Dietlein, F; Florin, A; Golfmann, K; Hallek, M; Koker, M; Malchers, F; Meder, L; Rodrik-Outmezguine, V; Rosen, N; Tharun, L; Ullrich, RT; Volz, C | 1 |
| Kaufman, TS; Larghi, EL; Vargas, DF | 1 |
| Bumrah, C; Cote, GJ; Giordano, TJ; Knippler, CM; Miles, W; Ringel, MD; Saji, M; Valenciaga, A; Yilmaz, AS; Yu, L; Zhang, X | 1 |
| Balasubramaniam, S; Del Rivero, J; Edgerly, M; Fojo, T; Gramza, AW; Madan, RA; Ward, J | 1 |
| Bryant, A; Gaitskell, K; Goodall, RJ; Lyons, TJ; Morrison, J; Thoma, C; Wiggans, AJ | 1 |
| MacGregor, FB; Milner, TD; Reed, N; Ronghe, M; Shaikh, MG | 1 |
| Bauer, J; Grimm, D; Grosse, J; Infanger, M; Kopp, S; Krüger, M; Milling, RV; Wehland, M | 1 |
| Dagogo-Jack, I; Ferris, L; Gainor, JF; Lin, JJ; Nagy, R; Shaw, AT; Stevens, SE | 1 |
| Li, XF; Liu, GF; Miao, YY; Yu, SN; Zhang, SH | 1 |
| Colombo, C; De Leo, S; Di Stefano, M; Fugazzola, L; Persani, L; Vannucchi, G | 1 |
| Ali, SM; Chung, JH; DiClemente, F; Dolfi, SC; Ganesan, S; Gay, LM; Hirshfield, KM; Kulkarni, A; Lee, E; Leyland-Jones, B; Lin, S; Liu, C; Paratala, BS; Petrosky, W; Pham, K; Rodriguez-Rodriguez, L; Ross, JS; Schrock, AB; Williams, CB; Williams, K; Yao, M; Yilmazel, B | 1 |
| Krchňák, V; Pospíšilová, J; Schütznerová, E | 1 |
| Mohapatra, DP; Shepherd, AJ; Shutov, LP; Usachev, YM; Warwick, CA | 1 |
| Dedecjus, M; Druce, M; Elisei, R; Gagel, RF; Hu, MI; Kapiteijn, E; Krajewska, J; Locati, L; Pacini, F; Popovtzer, A; Weiss, R | 1 |
| Abelleira, E; Bueno, F; Jerkovich, F; Pitoia, F; Schmidt, A | 1 |
| Ferrari, M; Gu, J; Hamilton, DJ; Jiang, S; Li, F; Li, Z; Pettigrew, RI; Qiu, Y; Yang, Z | 1 |
| Al-Shakliah, NS; Bakheit, AH; Darwish, HW; Darwish, IA | 1 |
| Benhuri, B; Chaudhari, SP; Ciccolini, KT; Duran, J; Kim, J; Lacouture, ME; Lucas, AS; Wu, S | 1 |
| Balasubramanian, S; Carroll, C; Hamilton, J; Kaltenthaler, E; Moss, L; Tappenden, P; Wadsley, J; Wong, R | 1 |
| Adam, V; Arlt, VM; Heger, Z; Indra, R; Kolarik, M; Kopeckova, K; Stiborova, M | 1 |
| Britt, CJ; Russell, JO | 1 |
| Cai, J; Hilberg, F; Huang, Q; Liu, X; Mooers, BHM; Shen, T; Teng, P; Terzyan, SS; Wu, J; Zhou, M | 1 |
| Bascal, Z; Caine, M; Czuczman, P; Garcia, P; Hagan, A; Kilpatrick, H; Lewis, AL; Lloyd, AW; Macfarlane, WM; Phillips, G; Press, C; Tang, Y | 1 |
| Carter, JJ; Cooper, SL; March, J; Woolard, J | 1 |
| Doan, HQ; Goldstein, J; Hu, MI; Patel, AB; Piha-Paul, SA; Subbiah, V | 1 |
| Brocato, RL; Hooper, JW | 1 |
| Chu, PL; Chua, KLM; Chua, MLK; Liang, ZG; Low, KP; Nei, WL; Poon, DJJ; Ramaswamy, B; Shihabuddeen, WA; Soo, KC; Thong, PSP; Yeo, ELL | 1 |
| Qiu, XY; Yin, Y; Zhang, B; Zhang, YH | 1 |
| Arnaldez, FI; Derdak, J; Derse-Anthony, C; Dombi, E; Glod, J; Helman, L; Killian, JK; Linehan, WM; Meltzer, P; Miettinen, M; Spencer, M; Srinivasan, R; Steinberg, SM; Widemann, BC; Wiener, L | 1 |
| Gao, Y; Hou, H; Li, C; Ma, L; Pan, H; Su, P; Sun, J; Wang, F; Ye, Z; Zang, C; Zhang, G | 1 |
| Esmaeili, S; Fassihi, A; Fayyazi, N; Ghasemi, JB; Saghaie, L; Taheri, S | 1 |
| Kim, KW; Van den Abbeele, AD | 1 |
| Agate, L; Bottici, V; Cappagli, V; Ciampi, R; Elisei, R; Matrone, A; Molinaro, E; Piaggi, P; Ramone, T; Romei, C; Tacito, A; Valerio, L; Viola, D | 1 |
| Arulananda, S; John, T; Loh, Z; Mitchell, P | 1 |
| Adam, V; Arlt, VM; Eckschlager, T; Heger, Z; Indra, R; Jáklová, K; Kopečková, K; Pompach, P; Stiborová, M; Vavrová, K | 1 |
| Ahn, JS; Ahn, MJ; Chung, TY; Han, J; Jung, HA; Kang, WK; Lee, J; Lee, SH; Lim, DH; Nam, DH; Park, K; Shin, E; Sun, JM | 1 |
| Dai, Y; Geng, X; Gong, J; Liu, D; Ma, Z; Meng, H; Song, G; Song, Z; Yang, T; Zhou, B | 1 |
| Ahn, JS; Ahn, MJ; Ku, BM; La Choi, Y; Lee, J; Lee, SH; Park, K; Shim, JH; Sun, JM | 1 |
| Birtle, A; Casbard, A; Chester, J; Crabb, S; Elliott, T; Evans, L; Griffiths, G; Huang, C; Huddart, R; Jagdev, S; Jones, R; Lester, J; Madden, TA | 1 |
| Tang, C; Wu, J; Xu, J | 1 |
| Herbaut-Barres, B; Maret, D; Sibaud, V; Vigarios, E; Zerdoud, S | 1 |
| Su, Z; Tang, J; Wang, H | 1 |
| Forssell-Aronsson, E; Montelius, M; Nilsson, O; Sandblom, V; Shubbar, E; Spetz, J; Ståhl, I; Swanpalmer, J | 1 |
| Ayata, C; Danser, AHJ; de Vries, T; Ferrari, MD; Li, M; MaassenVanDenBrink, A; Mulder, IA; Qin, T; Sugimoto, K; van den Bogaerdt, A; van den Maagdenberg, AMJM; Wermer, MJH; Yanagisawa, T | 1 |
| Bastholt, L; Colzani, R; Elisei, R; Foster, M; Haddad, R; Hauch, O; Jarząb, B; Kreissl, MC; Robinson, B; Schlumberger, M; Weiss, R | 1 |
| Barros Freiria, X; Calabia Martínez, J; Castillo Devia, M; García Méndez, I; Martin Alemany, N; Merino Ribas, A; Noboa Paez, C; Pérez Bueno, F; Pilco Teran, M; Rubio Casadevall, J; Torguet Escuder, P | 1 |
| Baudin, E; Berdelou, A; Borget, I; Hecht, F; Leboulleux, S; Ramos, HE; Schlumberger, M | 1 |
| Balcı, Y; Çağlar Çıtak, E; Demir Gündoğan, B; Sağcan, F; Tuğ Bozdoğan, S; Tuncel Daloğlu, F | 1 |
| Akagunduz, B; Çoban, A; Guven, DC; Kara, AV; Mammadov, R; Ozcicek, F; Suleyman, B; Suleyman, H; Yazici, GN | 1 |
| Kaushik, AC; Wang, X; Wang, YJ; Wei, DQ | 1 |
| Adam, P; Allelein, S; Berg, E; Frank-Raue, K; Hoster, E; Koehler, VF; Kroiss, M; Raue, F; Schott, M; Spitzweg, C | 1 |
| Kitamura, S; Maeda, T; Yanagi, T | 1 |
| Chino, T; Ito, KI; Ito, T; Kanai, T; Maeno, K; Oba, T; Ono, M; Shimizu, T; Soma, A | 1 |
| Ahn, J; Jeon, MJ; Kang, HC; Kim, BH; Kim, HK; Kim, IJ; Kim, M; Kim, TY; Lim, DJ; Shong, YK; Yoon, JH | 1 |
| Ahn, HY; Chae, JE; Kim, SG; Moon, H; Noh, J; Park, YJ | 1 |
| Inui, KI; Masuda, S; Tanihara, Y | 1 |
| Bruszt, K; Deres, L; Eros, K; Gallyas, F; Halmosi, R; Horvath, O; Kalman, N; Kovacs, D; Ordog, K; Radnai, B; Toth, K; Toth, S | 1 |
| Adam, V; Heger, Z; Michalkova, H; Pribyl, J; Rex, S; Skladal, P; Skubalova, Z; Sukupova, M; Weerasekera, A; Zahalka, M | 1 |
| Amini, B; Bhatt, T; Cascone, T; Conley, AP; Drobnitzky, N; Falchook, GS; Fu, S; Hess, KR; Heymach, JV; Hong, DS; Janku, F; Karp, D; Meric-Bernstam, F; Naing, A; Piha-Paul, SA; Ryan, AJ; Sacks, RL; Sherman, SI; Subbiah, IM; Subbiah, V | 1 |
| Goto, K; Ikeno, T; Kohno, T; Matsumoto, S; Murakami, H; Nishio, M; Nogami, N; Nomura, S; Nosaki, K; Sato, A; Satouchi, M; Seto, T; Tsuta, K; Wakabayashi, M; Yamamoto, N; Yoh, K | 1 |
| Borghi, MO; Cantone, MC; Carra, S; Dicitore, A; Gaudenzi, G; Ghilardi, A; Hofland, LJ; Persani, L; Plebani, A; Saronni, D; Vitale, G | 1 |
| Ma, JL; Sheng, LQ | 1 |
| Eckschlager, T; Feglarová, T; Heger, Z; Hodek, P; Hraběta, J; Indra, R; Jáklová, K; Kolárik, M; Rex, S | 1 |
| Carter, R; Hagan, AE; Lewis, AL; Lloyd, AW; Macfarlane, WM; Phillips, GJ; Sharma, RA; Westhorpe, A; Znati, SA | 1 |
| Abdelhameed, AS; Al-Shakliah, NS; Alanazi, AM; AlRabiah, H; Attwa, MW; Hassan, ES | 1 |
| Bashir, A; Beck, AC; Erdahl, LM; Karwal, MW; Liao, J; Lizarraga, IM; Lorenzen, AW; Spanheimer, PM; Sugg, SL; Weigel, RJ | 1 |
| Li, PP; Wang, JP; Zhang, L | 1 |
| Abdelhameed, AS; Alanazi, AM; AlRabiah, H; Alruqi, OS; Attia, MI; Attwa, MW | 1 |
| Álvarez-Escolá, C; Castelo-Fernández, B; García-Moreno, RM; Moreno-Domínguez, Ó; Torres-Sánchez, I; Yébenes-Gregorio, L | 1 |
| Courtier, B; Hadoux, J | 1 |
| Jiang, D; Liu, J; Liu, X; Pan, Y; Qiu, Y; Shi, Y; Wan, H; Wang, P; Ying, K; Zhu, Y | 1 |
| Chen, X; Fu, H; Gao, Z; He, Q; Jin, Y; Luo, P; Pan, Z; Shen, X; Xu, Z; Yan, H; Yang, B | 1 |
| Brandenburg, T; Dralle, H; Führer, D; Muchalla, P; Schmid, KW; Theurer, S; Tiedje, V; Weber, F | 1 |
| Koehler, VF; Kroiss, M; Spitzweg, C | 1 |
| Batlevi, C; Biggar, E; Espeleta, JA; Kumar, A; Lam, HY; Matasar, M; Nichols, C; Owens, C; Qiu, A; Qualls, D; Salles, G; Seshan, V; Subzwari, S; Whiting, K; Younes, A | 1 |
| Hou, W; Li, S; Liao, H; Qiu, W; Yin, L; Zhan, J; Zhang, J | 1 |
| Atkinson, D; Bandula, S; Bascal, ZA; Beaton, L; Boucher, E; Chouhan, M; Clarkson, MJ; Cooper, S; Counsell, N; Czuczman, P; Davidson, BR; Forsyth, S; Hague, J; Hartley, JA; Jansen, M; Lewis, AL; Lowe, HL; Meyer, T; Munneke, G; Pollok, JM; Raja, J; Ryan, S; Sharma, D; Sharma, RA; Stuckey, DJ; Thin, MZ; Tregidgo, HFJ; Wilde, PE; Znati, SA | 1 |
| Cui, X; Li, C; Ma, J; Qiu, S; Shi, C; Sun, J; Xu, Y | 1 |
| Dai, B; Du, X; Gong, Z; Ji, Y; Li, S; Ma, W; Shi, X; Wang, B; Wang, Y; Yang, T; Zhan, Y; Zhang, D; Zhang, Y; Zhu, M | 1 |
| Hubalewska-Dydejczyk, A; Sokołowski, G; Suchmiel, M; Trofimiuk-Müldner, M; Wilczyńska, M | 1 |
| Bardet, S; Brose, MS; Capdevila, J; Elisei, R; Führer, D; Gao, M; Hadoux, J; Hoff, AO; Hu, MI; Isaev, P; Jarzab, B; Keam, B; Kopeckova, K; Lin, B; Lin, Y; Maeda, P; Robinson, BG; Sherman, EJ; Singh, R; Soldatenkova, V; Tahara, M; Wadsley, J; Wirth, LJ; Wright, J | 1 |
148 review(s) available for quinazolines and piperidines
| Article | Year |
|---|---|
The use of diacylglycerol kinase inhibitors for elucidating the roles of protein kinase C.
Topics: Animals; Blood Platelets; Diacylglycerol Kinase; Diglycerides; Enzyme Activation; Humans; Neutrophils; Phosphotransferases; Piperidines; Protein Kinase C; Pyrimidinones; Quinazolines; Quinazolinones; Rabbits; Receptors, Cell Surface; Second Messenger Systems; Thiazoles | 1990 |
Dependence liability of "non-narcotic" drugs.
Topics: Alcohols; Amphetamine; Barbiturates; Benzazepines; Carbamates; Chloral Hydrate; Dronabinol; Ephedrine; Esters; Ethers, Cyclic; Glycols; Hallucinogens; Halogens; Herbicides; Humans; Indoles; Phenethylamines; Piperidines; Plant Extracts; Quinazolines; Substance-Related Disorders | 1970 |
Halofuginone: a novel antifibrotic therapy.
Topics: Animals; Collagen; Fibrosis; Humans; Liver Cirrhosis; Piperidines; Postoperative Complications; Protein Synthesis Inhibitors; Pulmonary Fibrosis; Quinazolines; Quinazolinones; Skin; Tissue Adhesions | 1998 |
Novel therapy in the treatment of scleroderma.
Topics: Autoimmune Diseases; Bone Marrow Transplantation; Cysteine; Humans; Interferon-gamma; Nitric Oxide; Piperidines; Prostaglandins; Quinazolines; Quinazolinones; Relaxin; Scleroderma, Systemic; Tetracycline; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2001 |
Novel therapeutic strategies in scleroderma.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Minocycline; Nitric Oxide; Piperidines; Prognosis; Quinazolines; Quinazolinones; Relaxin; Scleroderma, Systemic; Treatment Outcome | 1999 |
[Endothelin receptor antagonist, phosphodiesterase inhibitor, thromboxane inhibitor].
Topics: Animals; Endothelin Receptor Antagonists; Enzyme Inhibitors; Humans; Hypertension, Pulmonary; Methacrylates; Phosphodiesterase Inhibitors; Piperidines; Purinones; Quinazolines | 2001 |
Angiogenesis in bladder cancer--prognostic marker and target for future therapy.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Cyclohexanes; DNA-Binding Proteins; Drug Combinations; Endothelial Growth Factors; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Lymphokines; Mice; Mice, Nude; Neovascularization, Pathologic; Nuclear Proteins; O-(Chloroacetylcarbamoyl)fumagillol; Piperidines; Quinazolines; Quinazolinones; Sesquiterpenes; Thymidine Phosphorylase; Transcription Factors; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Development and potential of non-peptide antagonists for calcitonin-gene-related peptide (CGRP) receptors: evidence for CGRP receptor heterogeneity.
Topics: Animals; Calcitonin Gene-Related Peptide Receptor Antagonists; Coronary Vessels; Male; Piperazines; Piperidines; Quinazolines; Rats; Receptors, Calcitonin Gene-Related Peptide; Swine; Vasodilation | 2002 |
Inhibitors of the vascular endothelial growth factor receptor.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Design; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Enzyme Inhibitors; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Phthalazines; Piperidines; Pyridines; Pyrroles; Quinazolines; Recombinant Proteins; RNA, Catalytic; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2002 |
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Cyclooxygenase 2; Deoxycytidine; Drug Administration Schedule; Enzyme Inhibitors; Flavonoids; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Isoenzymes; Leucovorin; Membrane Proteins; Organoplatinum Compounds; Oxaliplatin; Piperidines; Prostaglandin-Endoperoxide Synthases; Quinazolines; Thiophenes; Treatment Outcome | 2003 |
Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma.
Topics: Administration, Cutaneous; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Collagen Type I; Fibrosis; Graft vs Host Disease; Humans; Mice; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Scleroderma, Systemic | 2003 |
[Current screening for molecular target therapy of cancer].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib | 2003 |
ZD-6474. AstraZeneca.
Topics: Animals; Clinical Trials as Topic; Drugs, Investigational; Enzyme Inhibitors; Humans; Neoplasms; Piperidines; Quinazolines; Technology, Pharmaceutical | 2003 |
[Anti angiogenesis].
Topics: Angiogenesis Inhibitors; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclooxygenase 2; Female; Humans; Isoenzymes; Lung Neoplasms; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase Inhibitors; Membrane Proteins; Neoplasms; Neovascularization, Pathologic; Piperidines; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Quinazolines; Research Design; Thalidomide; Vascular Endothelial Growth Factor A | 2004 |
Potential nonhormonal therapeutics for medical treatment of leiomyomas.
Topics: Bexarotene; Female; Heparin; Humans; Interferon-alpha; Leiomyoma; ortho-Aminobenzoates; Piperidines; Pyridones; Quinazolines; Quinazolinones; Reproduction; Tetrahydronaphthalenes; Thiazolidinediones; Tocopherols; Uterine Neoplasms | 2004 |
Angiogenesis and lung cancer: prognostic and therapeutic implications.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Lung; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib | 2005 |
ZD6474--clinical experience to date.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A | 2005 |
ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity.
Topics: Administration, Oral; Biological Availability; Cell Survival; Drug Administration Schedule; ErbB Receptors; Humans; Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction | 2005 |
Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Taxoids | 2005 |
JAK protein kinase inhibitors.
Topics: Animals; Drug Design; Enzyme Inhibitors; Forecasting; Gene Expression Regulation; Humans; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Mannich Bases; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; TYK2 Kinase | 2005 |
[Molecular targeted therapy for malignant brain tumors].
Topics: Antineoplastic Agents; Benzamides; Brain Neoplasms; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Piperidines; Protein Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2005 |
Update on angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2005 |
Antiangiogenic drugs in non-small cell lung cancer treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Humans; Lung Neoplasms; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2006 |
Multi-target inhibitors in non-small cell lung cancer (NSCLC).
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Medical Oncology; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2006 |
Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Piperidines; Quinazolines; Randomized Controlled Trials as Topic | 2006 |
Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Humans; Neovascularization, Pathologic; Piperidines; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.
Topics: Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Molecular Structure; Neoplasms; Piperidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors | 2006 |
Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Drug Delivery Systems; Humans; Neovascularization, Pathologic; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2007 |
Drug insight: VEGF as a therapeutic target for breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Forecasting; Humans; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Vascular Endothelial Growth Factor A | 2007 |
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Morpholines; Organic Chemicals; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines | 2007 |
Combination of target agents: challenges and opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Drug Resistance, Neoplasm; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2007 |
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2007 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2007 |
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab | 2008 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome | 2007 |
[Lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drugs, Investigational; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Pneumonectomy; Pyridines; Pyrroles; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib | 2008 |
Early clinical studies of novel therapies for thyroid cancers.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Carcinoma; Clinical Trials as Topic; Drug Delivery Systems; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Thyroid Neoplasms | 2008 |
Targeted therapy in advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Neovascularization, Pathologic; Piperidines; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
[Targeted therapy for locally advanced and/or metastatic bladder cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Immunosuppressive Agents; Mutation; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Targeted Gene Repair; Trastuzumab; Urinary Bladder Neoplasms | 2008 |
[Tumor vasculature as a therapeutic target in non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Imidazoles; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Xanthones | 2008 |
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Therapy; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2009 |
Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2009 |
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2009 |
Targeted therapies in the treatment of advanced/metastatic NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Tyrosine kinase inhibitors and the thyroid.
Topics: Axitinib; Benzenesulfonates; Clinical Trials as Topic; Gefitinib; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Pharmaceutical Preparations; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Gland; Thyroid Neoplasms | 2009 |
Targeted molecular therapies in thyroid carcinoma.
Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms | 2009 |
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Lung Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2010 |
Novel immunosuppressive agents in kidney transplantation.
Topics: Abatacept; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Everolimus; Graft Rejection; Graft Survival; Humans; Immunoconjugates; Immunosuppressive Agents; Kidney Transplantation; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Recombinant Fusion Proteins; Sirolimus | 2010 |
ZD6474, a small molecule tyrosine kinase inhibitor, potentiates the anti-tumor and anti-metastasis effects of radiation for human nasopharyngeal carcinoma.
Topics: Animals; Apoptosis; Carcinoma; Chemotherapy, Adjuvant; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Neoplasm Metastasis; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2010 |
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
DPP-4 inhibitors: what may be the clinical differentiators?
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
Vandetanib: An overview of its clinical development in NSCLC and other tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Neoplasms; Piperidines; Quinazolines | 2010 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2010 |
Antiangiogenic therapies for malignant pleural mesothelioma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Line, Tumor; Disease Models, Animal; Humans; Mesothelioma; Mice; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic; Phenylurea Compounds; Piperidines; Pleural Effusion, Malignant; Pleural Neoplasms; Quinazolines; Quinolines; Thoracic Cavity; Vascular Endothelial Growth Factors | 2011 |
Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.
Topics: Anilides; Benzenesulfonates; Disease Progression; Humans; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Thyroid Neoplasms | 2011 |
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin | 2011 |
Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.
Topics: Administration, Oral; Animals; Boronic Acids; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Humans; Hypoglycemic Agents; Linagliptin; Piperidines; Purines; Quinazolines; Uracil | 2011 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
Current landscape for T-cell targeting in autoimmunity and transplantation.
Topics: Autoimmune Diseases; Calcineurin Inhibitors; Cell Differentiation; Cell Proliferation; Cytokines; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Janus Kinase 3; Organ Transplantation; Piperidines; Protein Kinase C; Pyrimidines; Pyrroles; Quinazolines; Receptors, Cytokine; T-Lymphocytes; Transplantation Immunology; Transplantation Tolerance | 2011 |
Vandetanib for the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Humans; Lung Neoplasms; Molecular Structure; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction | 2011 |
The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Middle Aged; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2011 |
[Dermatologic side effects induced by new angiogenesis inhibitors].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Drug Eruptions; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Skin; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Vandetanib for the treatment of thyroid cancer.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Humans; Piperidines; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2012 |
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain | 2012 |
Vandetanib (Caprelsa) for medullary thyroid cancer.
Topics: Carcinoma, Neuroendocrine; Drug Costs; Drug Interactions; Humans; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Thyroid Neoplasms | 2012 |
[Vandetanib treatment in refractory advanced lung adenocarcinoma patients: five cases and review of literature].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Piperidines; Quinazolines | 2012 |
Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Female; Humans; Male; Molecular Targeted Therapy; Mutation; Piperidines; Prognosis; Quinazolines; Signal Transduction; Thyroid Neoplasms; Time Factors; TOR Serine-Threonine Kinases | 2012 |
Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis.
Topics: Clinical Trials as Topic; Electrocardiography; Humans; Incidence; Middle Aged; Neoplasms; Odds Ratio; Piperidines; Quinazolines; Risk Factors | 2012 |
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Eruptions; ErbB Receptors; Female; Humans; Incidence; Lung Neoplasms; Male; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk; Severity of Illness Index; Small Cell Lung Carcinoma; Thyroid Neoplasms | 2012 |
Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2011 |
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib | 2012 |
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon-Like Peptide 1; Humans; Linagliptin; Male; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
[Vandetanib for advanced non-small cell lung cancer: a meta-analysis].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Quinazolines; Treatment Outcome; Young Adult | 2012 |
Management of thyroid carcinoma in children and young adults.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Female; Humans; Iodine Isotopes; Male; Piperidines; Quinazolines; Thyroid Neoplasms; Thyrotropin; Young Adult | 2012 |
Kinase inhibitors for advanced medullary thyroid carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Humans; Molecular Targeted Therapy; Patient Selection; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2012 |
Vandetanib for the treatment of lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Vascular Endothelial Growth Factor A | 2012 |
Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Lung Neoplasms; Neoplasms; Piperidines; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2012 |
Vandetanib: in medullary thyroid cancer.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease-Free Survival; Humans; Molecular Structure; Neoplasm Metastasis; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Thyroid Neoplasms | 2012 |
Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Hypertension; Incidence; Neoplasms; Piperidines; Publication Bias; Quinazolines; Risk | 2013 |
Vandetanib: a guide to its use in advanced medullary thyroid cancer.
Topics: Carcinoma, Neuroendocrine; Disease-Free Survival; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Piperidines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Thyroid Neoplasms | 2012 |
Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers.
Topics: Animals; Antineoplastic Agents; Drug Design; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib | 2013 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Vandetanib therapy in medullary thyroid cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Drug Interactions; ErbB Receptors; Humans; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms | 2012 |
Chemotherapy plus Vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Survival Rate | 2013 |
Vandetanib and the management of advanced medullary thyroid cancer.
Topics: Antineoplastic Agents; Carcinoma, Medullary; Clinical Trials as Topic; Humans; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Quinazolines; Thyroid Neoplasms | 2013 |
Vandetanib for the treatment of medullary thyroid cancer.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Humans; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2013 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
[Four new drugs on the market: abiraterone, belatacept, vandetanib and fidaxomycine].
Topics: Abatacept; Aminoglycosides; Androstenes; Androstenols; Anti-Bacterial Agents; Antineoplastic Agents; Clostridioides difficile; Clostridium Infections; Enzyme Inhibitors; Fidaxomicin; Humans; Immunoconjugates; Immunosuppressive Agents; Male; Piperidines; Prostatic Neoplasms; Quinazolines; Thyroid Neoplasms | 2013 |
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles | 2013 |
Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease Progression; Drugs, Investigational; Humans; Medical Oncology; Piperidines; Professional Practice; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2013 |
Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Fees, Pharmaceutical; Humans; Piperidines; Quinazolines; Thyroid Neoplasms | 2013 |
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Databases, Bibliographic; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2013 |
A Drosophila approach to thyroid cancer therapeutics.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drosophila; Drug Evaluation, Preclinical; Humans; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms | 2013 |
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.
Topics: Carcinoma, Neuroendocrine; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Diseases; Humans; Male; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Piperidines; Prognosis; Quinazolines; Risk Assessment; Thyroid Neoplasms; Treatment Outcome | 2013 |
Vandetanib for the treatment of medullary thyroid carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Interactions; Drug Labeling; Humans; Neoplasm Metastasis; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Thyroid Neoplasms | 2014 |
The discovery and development of vandetanib for the treatment of thyroid cancer.
Topics: Disease-Free Survival; Drug Discovery; Humans; Piperidines; Quinazolines; Thyroid Neoplasms | 2014 |
[Targeted therapies, prognostic and predictive factors in endocrine oncology].
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Disease-Free Survival; Endocrine Gland Neoplasms; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Prognosis; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome | 2013 |
Vandetanib for the treatment of thyroid cancer: an update.
Topics: Animals; Carcinoma, Neuroendocrine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Epidermal Growth Factor; Humans; Piperidines; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Thyroid Neoplasms; Transfection; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss | 2014 |
The chemistry and biology of febrifugine and halofuginone.
Topics: Antimalarials; Humans; Molecular Structure; Parasitic Sensitivity Tests; Piperidines; Plasmodium; Quinazolines; Quinazolinones; Structure-Activity Relationship | 2014 |
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin | 2014 |
Development of molecular targeted drugs for advanced thyroid cancer in Japan.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Japan; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms | 2014 |
Advanced thyroid cancers: new era of treatment.
Topics: Anilides; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; ErbB Receptors; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Lithium; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyridines; Quinazolines; Stilbenes; Thalidomide; Thyroid Neoplasms | 2014 |
Vandetanib as a potential treatment for breast cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2014 |
The evolving field of kinase inhibitors in thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms | 2015 |
[Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
Topics: Antineoplastic Agents; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Humans; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Rare Diseases; Thyroid Neoplasms | 2014 |
Novel therapies for thyroid cancer.
Topics: Anilides; Antineoplastic Agents; Clinical Trials as Topic; Diarrhea; Humans; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms | 2014 |
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Humans; Lung Neoplasms; Outcome Assessment, Health Care; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Vascular Endothelial Growth Factor A | 2015 |
Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Hypertension; Long QT Syndrome; Lung Neoplasms; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Risk | 2015 |
New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Iodine Radioisotopes; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Signal Transduction; Sorafenib; Thyroid Neoplasms; Treatment Failure | 2015 |
Systemic treatment of advanced differentiated and medullary thyroid cancer. Overview and practical aspects.
Topics: Anilides; Antineoplastic Agents; Drug Monitoring; Evidence-Based Medicine; Humans; Piperidines; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Thyroid Neoplasms; Tomography, Emission-Computed; Treatment Outcome | 2015 |
Selective use of vandetanib in the treatment of thyroid cancer.
Topics: Animals; Antineoplastic Agents; Disease-Free Survival; Humans; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Thyroid Neoplasms; Treatment Outcome | 2015 |
Risk of Gastrointestinal Events During Vandetanib Therapy in Patients With Cancer: A Systematic Review and Meta-analysis of Clinical Trials.
Topics: Antineoplastic Agents; Drug Monitoring; Gastrointestinal Diseases; Humans; Incidence; Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2017 |
[Anti-angiogenesis and molecular targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug Approval; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2015 |
Management of advanced medullary thyroid cancer.
Topics: Anilides; Antineoplastic Agents; Biomarkers; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Survival; Humans; Molecular Targeted Therapy; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms; Treatment Outcome | 2016 |
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Indoles; Kidney; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2016 |
Current Research Therapeutic Strategies for Alzheimer's Disease Treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzamides; Benzodioxoles; Brain; Disease Models, Animal; Humans; Mice; Neurons; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fyn; PrPC Proteins; Pyridines; Quinazolines; Receptor, Metabotropic Glutamate 5; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin; Synapses; Thiazoles | 2016 |
An Update on Calcineurin Inhibitor-Free Regimens: The Need Persists, but the Landscape has Changed.
Topics: Abatacept; Animals; Calcineurin Inhibitors; Drug Therapy, Combination; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Molecular Targeted Therapy; Organ Transplantation; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Risk Assessment; Risk Factors; Signal Transduction; Time Factors; Treatment Outcome | 2016 |
The safety of vandetanib for the treatment of thyroid cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease-Free Survival; Humans; Piperidines; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Rate; Thyroid Neoplasms | 2016 |
The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Child; Disease Progression; Disease-Free Survival; Humans; Piperidines; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Thyroid Neoplasms | 2016 |
Systemic treatment and management approaches for medullary thyroid cancer.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Genotype; Humans; Molecular Targeted Therapy; Phenotype; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Receptors, Fibroblast Growth Factor; Thyroid Neoplasms; Thyroidectomy; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Kinase Inhibitors in Multitargeted Cancer Therapy.
Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2017 |
CD30+ lymphoproliferative disorder in a patient with metastatic papillary thyroid carcinoma.
Topics: Aged; Carcinoma; Carcinoma, Papillary; Humans; Immunohistochemistry; Ki-1 Antigen; Lymphoma, Large-Cell, Anaplastic; Lymphoproliferative Disorders; Male; Neoplasms, Multiple Primary; Piperidines; Quinazolines; Skin Neoplasms; Thoracic Wall; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2016 |
The use of kinase inhibitors in solid organ transplantation.
Topics: Aminopyridines; Humans; Immunosuppressive Agents; Indoles; Morpholines; Organ Transplantation; Oxazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Syk Kinase | 2017 |
Genetics of medullary thyroid cancer: An overview.
Topics: Anilides; Carcinoma, Medullary; Codon; Exons; Humans; Male; Middle Aged; Multiple Endocrine Neoplasia Type 2a; Mutation; Piperidines; Polymorphism, Genetic; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Thyroid Neoplasms; Thyroidectomy | 2017 |
Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials as Topic; High-Throughput Nucleotide Sequencing; Humans; Molecular Targeted Therapy; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Thyroid Neoplasms | 2017 |
Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Disease-Free Survival; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Thyroid Neoplasms | 2017 |
Angiogenesis Inhibitors in NSCLC.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids | 2017 |
Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Non-Small-Cell Lung; Exanthema; Humans; Incidence; Inflammatory Breast Neoplasms; Neoplasm Staging; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Severity of Illness Index | 2017 |
Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Mutation; Neoplasm Proteins; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Rituximab; Signal Transduction; Splenic Neoplasms; Survival Rate; Thalidomide | 2017 |
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Topics: Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Tegafur | 2018 |
Chemical synthesis of febrifugine and analogues.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Cyclization; Cycloaddition Reaction; Humans; Piperidines; Plasmodium falciparum; Quinazolines; Quinazolinones; Stereoisomerism | 2018 |
The 6π-azaelectrocyclization of azatrienes. Synthetic applications in natural products, bioactive heterocycles, and related fields.
Topics: Alkaloids; Aza Compounds; Biological Products; Chemistry Techniques, Synthetic; Cyclization; Histamine Agonists; Piperidines; Pyridines; Pyrroles; Quinazolines; Quinolizines; Sesquiterpenes | 2019 |
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Progression-Free Survival; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2018 |
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.
Topics: Anilides; Carcinoma, Neuroendocrine; Cardiotoxicity; Humans; Hypertension; Indazoles; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sulfonamides; Thyroid Neoplasms | 2018 |
Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Network Meta-Analysis; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic | 2019 |
Incidence and risk of developing photosensitivity with targeted anticancer therapies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Immunological; Clinical Trials as Topic; Humans; Incidence; Molecular Targeted Therapy; Neoplasms; Nivolumab; Photosensitivity Disorders; Piperidines; Quinazolines; Risk Assessment; Vemurafenib | 2019 |
Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cost-Benefit Analysis; England; Humans; Models, Economic; Piperidines; Pyridines; Quality-Adjusted Life Years; Quinazolines; Technology Assessment, Biomedical; Thyroid Neoplasms | 2019 |
Vandetanib photoinduced cutaneous toxicities.
Topics: Aged; Antineoplastic Agents; Dermatitis, Phototoxic; Drug Eruptions; Female; Humans; Male; Middle Aged; Piperidines; Quinazolines | 2019 |
Progress on the Prevention and Treatment of Hantavirus Disease.
Topics: Adrenal Cortex Hormones; Amides; Animals; Antiviral Agents; Clinical Trials as Topic; Hantavirus Infections; Hantavirus Pulmonary Syndrome; Hemorrhagic Fever with Renal Syndrome; Humans; Immunotherapy; Lactoferrin; Models, Animal; Nucleosides; Orthohantavirus; Piperidines; Pyrazines; Quinazolines; Recombinant Proteins; Ribavirin; Triazoles; Vaccines, Synthetic; Viral Vaccines | 2019 |
Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer.
Topics: Acute Disease; Adult; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease-Free Survival; Follow-Up Studies; France; Humans; Pancreatitis; Piperidines; Quinazolines; Thyroid Neoplasms | 2021 |
Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Humans; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2020 |
95 trial(s) available for quinazolines and piperidines
| Article | Year |
|---|---|
Influence of phased inclusion of halofuginone on broiler skin tensile strength and growth performance.
Topics: Animals; Chickens; Coccidiostats; Piperidines; Quinazolines; Quinazolinones; Skin; Skin Physiological Phenomena; Tensile Strength | 1992 |
Influence of continuous dietary halofuginone on broiler skin tensile strength and growth performance.
Topics: Animals; Chickens; Coccidiostats; Female; Food Additives; Male; Piperidines; Quinazolines; Quinazolinones; Skin; Skin Physiological Phenomena; Tensile Strength | 1992 |
Prevalence and control of bovine cryptosporidiosis in German dairy herds.
Topics: Animals; Anti-Infective Agents; Cattle; Cattle Diseases; Coccidiostats; Cryptosporidiosis; Cryptosporidium; Dairying; Diarrhea; Feces; Female; Germany; Oocysts; Piperidines; Prevalence; Quinazolines; Quinazolinones; Sulfamethazine; Surveys and Questionnaires | 2003 |
Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.
Topics: Acute Disease; Adult; Calcitonin Gene-Related Peptide Receptor Antagonists; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Piperazines; Piperidines; Quinazolines; Time Factors | 2004 |
A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Bridged-Ring Compounds; Diarrhea; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Piperidines; Quinazolines; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2005 |
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2005 |
A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma--NCIC CTG IND.145.
Topics: Administration, Oral; ErbB Receptors; Female; Humans; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2006 |
Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Fatigue; Humans; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Piperidines; Quinazolines; Quinazolinones; Vomiting | 2006 |
Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Niacinamide; Pemetrexed; Phenylurea Compounds; Piperidines; Probability; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors.
Topics: Administration, Oral; Adult; Aged; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Survival Analysis; Thoracic Neoplasms; Treatment Outcome | 2006 |
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Placebos; Quinazolines; Taxoids | 2007 |
Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20.
Topics: Adult; Aged; Carcinoma, Small Cell; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Placebos; Quality of Life; Quinazolines; Treatment Outcome | 2007 |
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; ErbB Receptors; Female; Humans; Japan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Recurrence, Local; Piperidines; Prognosis; Quinazolines | 2008 |
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Piperidines; Quinazolines; Treatment Outcome | 2009 |
An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Piperidines; Quinazolines | 2009 |
Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperidines; Quinazolines | 2009 |
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Piperidines; Quinazolines | 2009 |
A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Piperidines; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Taxoids; Treatment Outcome | 2009 |
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cytokines; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Medullary; Disease-Free Survival; Drug Administration Schedule; Female; France; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pedigree; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines; Risk Factors; Thyroid Neoplasms; Time Factors; Treatment Outcome; United States; Young Adult | 2010 |
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Cystadenocarcinoma, Serous; Drug Administration Schedule; ErbB Receptors; Female; Humans; Middle Aged; Ovarian Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Recurrence; Signal Transduction; Treatment Failure; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Diverticulitis; Drug Administration Schedule; ErbB Receptors; Female; Gastrointestinal Hemorrhage; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Piperidines; Quinazolines; Temozolomide; Thrombocytopenia; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Topics: Adult; Aged; Antineoplastic Agents; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Medullary; Codon; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms; Tomography, X-Ray Computed; Young Adult | 2010 |
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Proportional Hazards Models; Quinazolines; Survival Analysis; Taxoids | 2010 |
A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Piperidines; Quinazolines; Survival Rate; Tissue Distribution; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Europe; Female; Humans; Infusions, Intravenous; Logistic Models; Middle Aged; Patient Selection; Piperidines; Placebos; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Risk Factors; South Africa; Taiwan; Taxoids; Time Factors; Treatment Outcome | 2012 |
Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Agents; Brain Stem Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Piperidines; Quinazolines; Radiotherapy, Adjuvant; Treatment Outcome; Young Adult | 2010 |
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Cohort Studies; Combined Modality Therapy; Dacarbazine; Dexamethasone; Drug Administration Schedule; Female; Glioma; Glucocorticoids; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide; Tumor Burden; Vincristine; Young Adult | 2012 |
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Contrast Media; Epidermal Growth Factor; Female; Humans; Lymphoma; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Piperidines; Quinazolines; Signal Transduction; Time Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Australia; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Mexico; Middle Aged; Pemetrexed; Piperidines; Proportional Hazards Models; Quinazolines; Risk Assessment; Risk Factors; South Africa; Time Factors; Treatment Outcome | 2011 |
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Europe; Female; Humans; Lung Neoplasms; Male; Middle Aged; North America; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2011 |
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Piperidines; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
Topics: Adult; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Interactions; Enzyme Induction; Humans; Itraconazole; Male; Piperidines; Quinazolines; Rifampin | 2011 |
Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Breast Neoplasms; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Middle Aged; Neovascularization, Pathologic; Nitric Oxide; Piperidines; Prospective Studies; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Tumor Cells, Cultured; Vasodilation | 2011 |
Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; China; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Piperidines; Quinazolines; Young Adult | 2011 |
Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenocarcinoma, Papillary; Adult; Aged; Aged, 80 and over; Blood Glucose; Calcium; Cross-Over Studies; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Male; Middle Aged; Parathyroid Hormone; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Testosterone; Thyroid Neoplasms; Treatment Outcome; Vitamin D | 2011 |
Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Piperidines; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Topics: Carcinoma, Neuroendocrine; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Piperidines; Placebos; Quinazolines; Thyroid Neoplasms | 2012 |
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Piperidines; Platinum Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Risk Factors; Taxoids; Treatment Failure; Urologic Neoplasms; Urothelium | 2012 |
Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biotransformation; Cross-Over Studies; Double-Blind Method; Feces; Female; Food-Drug Interactions; Half-Life; Humans; Male; Metabolic Clearance Rate; Metabolomics; Middle Aged; Models, Biological; Piperidines; Protein Kinase Inhibitors; Quinazolines; United Kingdom; Young Adult | 2012 |
Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; ErbB Receptors; Female; Humans; Liver Neoplasms; Male; Middle Aged; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Rate; Treatment Outcome | 2012 |
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Smoking; Treatment Outcome | 2012 |
Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.
Topics: Carcinoma, Neuroendocrine; Disease-Free Survival; Drug Approval; Humans; Piperidines; Quinazolines; Thyroid Neoplasms; United States; United States Food and Drug Administration | 2012 |
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Piperidines; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factors | 2012 |
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Topics: Adenocarcinoma, Follicular; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Papillary; Diarrhea; Disease-Free Survival; Double-Blind Method; Electrocardiography; ErbB Receptors; Female; Heart Conduction System; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Survival Analysis; Thyroid Cancer, Papillary; Thyroid Neoplasms; Young Adult | 2012 |
Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Blood Platelets; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Drug-Related Side Effects and Adverse Reactions; Female; Gene Expression Regulation, Neoplastic; Humans; Methotrexate; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Piperidines; Platelet Factor 4; Proteomics; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2012 |
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Rate; Tetrahydronaphthalenes | 2012 |
A phase I/II trial of vandetanib for patients with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Quinazolines; Young Adult | 2012 |
A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib.
Topics: Adult; Aged; Aged, 80 and over; Female; Folliculitis; Hand-Foot Syndrome; Humans; Hyperpigmentation; Male; Middle Aged; Photosensitivity Disorders; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2012 |
MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Agents; Blood Volume; Brain Stem Neoplasms; Child; Child, Preschool; Cohort Studies; Disease Progression; Echo-Planar Imaging; Female; Follow-Up Studies; Glioma; Humans; Image Enhancement; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Male; Neoadjuvant Therapy; Neuroimaging; Piperidines; Prospective Studies; Quinazolines; Radiotherapy, Conformal; Receptors, Vascular Endothelial Growth Factor; Survival Rate; Treatment Outcome | 2013 |
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Triazines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Brain Stem Neoplasms; Child; Child, Preschool; Dasatinib; Female; Follow-Up Studies; Glioma; Humans; Infant; Knee Joint; Magnetic Resonance Imaging; Male; Osteonecrosis; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Radiography; Thiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Child; Child, Preschool; Dasatinib; Female; Glioma; Humans; Male; Piperidines; Pyrimidines; Quinazolines; Thiazoles; Treatment Outcome | 2013 |
Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study.
Topics: Adult; Aged; Body Composition; Carcinoma, Neuroendocrine; Cross-Over Studies; Female; Humans; Male; Middle Aged; Muscle, Skeletal; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2013 |
A Phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Taxoids | 2013 |
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.
Topics: Acute-Phase Proteins; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gene Amplification; Genes, erbB-1; Humans; Interleukin-9; Kaplan-Meier Estimate; Lipocalin-2; Lipocalins; Lung Neoplasms; Male; Middle Aged; Mutation; Piperidines; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; TNF-Related Apoptosis-Inducing Ligand | 2013 |
Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2013 |
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperidines; Quinazolines; Taxoids | 2013 |
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
Topics: Adolescent; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Gene Expression Regulation, Neoplastic; Germ-Line Mutation; Humans; Multiple Endocrine Neoplasia Type 2b; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms | 2013 |
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13).
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Piperidines; Polyethylene Glycols; Protein Kinase Inhibitors; Quinazolines; Skin Diseases | 2013 |
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Exanthema; Female; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Piperidines; Platinum Compounds; Quinazolines; Vascular Endothelial Growth Factor A | 2013 |
Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Disease-Free Survival; Everolimus; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Quinazolines; Retrospective Studies; Sirolimus; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2013 |
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.
Topics: Aged; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Nitriles; Piperidines; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Quinazolines; Tosyl Compounds; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Quinazolines; Taxoids; Treatment Outcome | 2014 |
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Piperidines; Placebos; Quinazolines; Survival Rate | 2014 |
Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catheters, Indwelling; Humans; Lung Neoplasms; Middle Aged; Piperidines; Pleural Effusion, Malignant; Pleurodesis; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recurrence; Survival Rate; Time Factors; Treatment Outcome | 2014 |
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Peptides; Piperidines; Postmenopause; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2014 |
EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Female; Gene Dosage; Humans; Male; Mutation; Piperidines; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids | 2014 |
Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine.
Topics: Adolescent; Adult; Area Under Curve; Digoxin; Drug Interactions; Female; Humans; Male; Metformin; Midazolam; Middle Aged; Omeprazole; Piperidines; Quinazolines; Ranitidine; Young Adult | 2014 |
Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Squamous Cell Carcinoma of Head and Neck | 2016 |
Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Quinazolines; Sirolimus | 2015 |
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Piperidines; Quinazolines | 2015 |
A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Prevalence; Proto-Oncogene Proteins c-ret; Quinazolines; Retrospective Studies; Translocation, Genetic; Treatment Outcome | 2015 |
Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dermatitis, Photoallergic; Everolimus; Female; Humans; Middle Aged; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Thyroid Neoplasms | 2015 |
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Piperidines; Quinazolines; Temozolomide; Treatment Outcome | 2015 |
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Piperidines; Quinazolines; Treatment Outcome | 2016 |
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Fluorouracil; Humans; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Piperidines; Quinazolines; Treatment Outcome | 2017 |
A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease Progression; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Piperidines; Quinazolines; Small Cell Lung Carcinoma | 2017 |
RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain; Brain Neoplasms; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Female; Humans; Male; Melanoma; Middle Aged; Piperidines; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy | 2016 |
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Treatment Outcome; Tumor Burden | 2017 |
SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Neuroendocrine; Disease-Free Survival; ErbB Receptors; Female; Humans; Male; Middle Aged; Piperidines; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2017 |
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gene Order; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Treatment Outcome | 2017 |
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Double-Blind Method; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Piperidines; Prognosis; Quinazolines; Survival Rate | 2017 |
Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation.
Topics: Antineoplastic Agents; Brain Stem; Brain Stem Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dexamethasone; Diffusion Tensor Imaging; Disease Progression; Disease-Free Survival; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Piperidines; Prospective Studies; Quinazolines; Steroids; Vascular Endothelial Growth Factor A; White Matter | 2017 |
Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Brain; Brain Stem Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Female; Glioma; Humans; Leukoencephalopathies; Magnetic Resonance Imaging; Male; Piperidines; Quinazolines; Radiotherapy, Conformal; Stroke; Tumor Burden | 2017 |
Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
Topics: Antineoplastic Agents; Bortezomib; Carcinoma, Neuroendocrine; Female; Humans; Male; Piperidines; Proto-Oncogene Mas; Quinazolines; Thyroid Neoplasms | 2019 |
Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Neuroendocrine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms; Young Adult | 2019 |
A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor.
Topics: Adolescent; Adult; Child; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperidines; Progression-Free Survival; Proto-Oncogene Proteins c-kit; Quality of Life; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; Succinate Dehydrogenase; Young Adult | 2019 |
A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Double-Blind Method; Drug Combinations; Female; Gemcitabine; Humans; Male; Neoplasm Staging; Piperidines; Quinazolines; Treatment Outcome | 2020 |
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Everolimus; Humans; Neoplasms; Piperidines; Proto-Oncogene Mas; Quinazolines; Vascular Endothelial Growth Factor A | 2021 |
Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Lung Neoplasms; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines | 2021 |
A Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer.
Topics: Aged; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Ki-67 Antigen; Middle Aged; Pilot Projects; Piperidines; Preoperative Care; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Treatment Outcome | 2021 |
A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma.
Topics: Adenine; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrimidines; Quinazolines | 2022 |
Phase 3 Trial of Selpercatinib in Advanced
Topics: Antineoplastic Agents; Disease Progression; Humans; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Thyroid Neoplasms | 2023 |
658 other study(ies) available for quinazolines and piperidines
| Article | Year |
|---|---|
Chemotherapy of bovine theileriosis with Halofuginone. Short communication.
Topics: Animals; Apicomplexa; Body Temperature; Cattle; Piperidines; Quinazolines; Quinazolinones; Species Specificity; Theileriasis | 1979 |
Cardiovascular effects of UK 14,275: evaluation of a new phosphodiesterase inhibitor with inotropic properties in animals and human volunteers [proceedings].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Dogs; Hemodynamics; Humans; Male; Myocardial Contraction; Phosphodiesterase Inhibitors; Piperidines; Quinazolines | 1975 |
Efficacy of salinomycin and stenorol against various species of Eimeria and effect on chick performance.
Topics: Animals; Chickens; Coccidiosis; Coccidiostats; Ionophores; Male; Monensin; Piperidines; Poultry Diseases; Pyrans; Quinazolines; Quinazolinones; Roxarsone | 1979 |
Efficacy of Stenorol (halofuginone). I. Against recent field isolates of six species of chicken coccidia.
Topics: Animals; Body Weight; Chickens; Coccidiosis; Coccidiostats; Drug Resistance; Eimeria; Feeding Behavior; Piperidines; Poultry Diseases; Quinazolines; Quinazolinones | 1979 |
Efficacy of Stenorol (halofuginone). II. Plus roxarsone or bacitracin MD against selected strains of chicken Eimeria.
Topics: Animals; Arsenicals; Bacitracin; Body Weight; Chickens; Coccidiosis; Coccidiostats; Drug Combinations; Eimeria; Feeding Behavior; Piperidines; Poultry Diseases; Quinazolines; Quinazolinones; Roxarsone; Salicylates | 1979 |
Triazines and related products. Part 19. 4-Amino-2-[2-(piperid-n-1-ylazo)phenyl]quinazoline and its analogues.
Topics: Isomerism; Methods; Piperidines; Quinazolines; Triazenes; Triazines | 1977 |
Synthesis of some 2-styrylquinazoline derivatives structurally related to certain chemotherapeutic agents.
Topics: Amines; Chemical Phenomena; Chemistry; Formaldehyde; Piperidines; Quinazolines | 1978 |
Analysis of the anti-coccidial drug, halofunginone, in chicken feed using gas-liquid chromatography and high-performance liquid chromatography.
Topics: Animal Feed; Animals; Chickens; Chromatography, Gas; Chromatography, High Pressure Liquid; Coccidiostats; Food, Fortified; Methods; Minerals; Piperidines; Quinazolines; Quinazolinones | 1979 |
Some aspects of the cardiovascular pharmacology of UK 14,275 in patients with coronary artery disease.
Topics: Aged; Cardiac Output; Coronary Disease; Electrocardiography; Hemodynamics; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperidines; Quinazolines; Vascular Resistance | 1978 |
The inotropic effects of UK 14,275, a phosphodiesterase inhibitor, in man.
Topics: Adult; Drug Interactions; Humans; Isoproterenol; Male; Myocardial Contraction; Phosphodiesterase Inhibitors; Piperidines; Propranolol; Quinazolines; Stimulation, Chemical | 1978 |
Efficacy of new inotropic drugs in clinical coronary heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Catecholamines; Dobutamine; Heart Failure; Heart Rate; Hemodynamics; Humans; Infusions, Parenteral; Isoproterenol; Male; Middle Aged; Myocardial Contraction; Phonocardiography; Phosphodiesterase Inhibitors; Piperidines; Pressure; Quinazolines; Vascular Resistance | 1978 |
UK-14,275, a novel orally-active cardiac stimulant [proceedings].
Topics: Administration, Oral; Animals; Cats; Dogs; Guinea Pigs; Heart; Heart Rate; In Vitro Techniques; Myocardial Contraction; Piperidines; Quinazolines; Stimulation, Chemical | 1977 |
Cardiovascular effects of a new inotropic agent, U. K. 14275, in patients with coronary heart disease.
Topics: Coronary Disease; Hemodynamics; Humans; Male; Myocardial Contraction; Myocardial Infarction; Phosphodiesterase Inhibitors; Piperidines; Quinazolines | 1977 |
Structural similarity between febrifugine and chloroquine.
Topics: Antimalarials; Chloroquine; Models, Structural; Piperidines; Quinazolines; Structure-Activity Relationship | 1976 |
Laboratory studies with some recent anticoccidials.
Topics: Administration, Oral; Animal Feed; Animals; Chickens; Coccidiosis; Coccidiostats; Eimeria; Feces; Lasalocid; Monensin; Piperidines; Poultry Diseases; Quinazolines; Quinazolinones | 1975 |
Cardiovascular effects of a new inotropic drug in dog and normal man.
Topics: Animals; Blood Pressure; Cardiac Output; Dogs; Half-Life; Heart Rate; Hemodynamics; Humans; Male; Myocardial Contraction; Piperidines; Quinazolines | 1976 |
The diacylglycerol kinase inhibitor, R59949, potentiates secretion but not increased phosphorylation of a 47 kDalton protein in human platelets.
Topics: Blood Platelets; Diacylglycerol Kinase; Dose-Response Relationship, Drug; Humans; Phosphatidic Acids; Phosphorylation; Phosphotransferases; Piperidines; Protein Kinase C; Quinazolines; Quinazolinones; Serotonin; Thrombin | 1991 |
Determination of halofuginone in feedstuffs by the combination of capillary isotachophoresis and capillary zone electrophoresis in a column-switching system.
Topics: Animal Feed; Animals; Coccidiostats; Electrophoresis; Piperidines; Poultry; Quinazolines; Quinazolinones | 1991 |
Comparison of different anticoccidials on processing characteristics and parts yield of broiler chickens.
Topics: Animals; Body Weight; Chickens; Coccidiostats; Eating; Female; Male; Monensin; Muscle Development; Muscles; Piperidines; Pyrans; Quinazolines; Quinazolinones; Random Allocation | 1991 |
Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone.
Topics: Animals; Cells, Cultured; Chickens; Coccidiostats; Collagen; Dose-Response Relationship, Drug; Female; Fibroblasts; Monensin; Nicarbazin; Piperidines; Quinazolines; Quinazolinones; Random Allocation; Skin; Weight Gain | 1991 |
Influence of virginiamycin on growth and efficiency of large white turkeys.
Topics: Amebicides; Amprolium; Animal Feed; Animals; Arsanilic Acid; Drug Interactions; Eating; Energy Metabolism; Female; Male; Monensin; Mortality; Piperidines; Quinazolines; Quinazolinones; Sex Characteristics; Turkeys; Virginiamycin; Weight Gain | 1991 |
Predominant acetylcholine-induced vasoconstriction in isolated, perfused simian facial veins.
Topics: Acetylcholine; Adrenergic alpha-Antagonists; Animals; Atropine; Blood Pressure; Diltiazem; Face; Female; In Vitro Techniques; Macaca; Male; Muscle, Smooth, Vascular; Parasympatholytics; Physostigmine; Piperidines; Pirenzepine; Potassium Chloride; Quinazolines; Receptors, Muscarinic; Saponins; Vasoconstriction; Veins | 1990 |
Effects of different coccidiostats on performance of large white turkeys.
Topics: Amprolium; Animal Feed; Animals; Coccidiostats; Dietary Fats; Dinitolmide; Eating; Female; Male; Monensin; Organotin Compounds; Piperidines; Pyrimidines; Quinazolines; Quinazolinones; Random Allocation; Sulfadimethoxine; Turkeys; Weight Gain | 1991 |
Efficacy of different anticoccidials against experimental coccidiosis in large white turkeys.
Topics: Amprolium; Animals; Coccidiosis; Coccidiostats; Dinitolmide; Feces; Intestines; Male; Monensin; Organotin Compounds; Piperidines; Poultry Diseases; Pyrimidines; Quinazolines; Quinazolinones; Sulfadimethoxine; Turkeys; Weight Gain | 1991 |
Studies on cardiotonic agents. IV. Synthesis of novel 1-(6,7-dimethoxy-4-quinazolinyl)piperidine derivatives carrying substituted hydantoin and 2-thiohydantoin rings.
Topics: Animals; Cardiotonic Agents; Dogs; Hydantoins; Piperidines; Quinazolines; Thiohydantoins | 1990 |
Rate-dependent depression of maximal rate of depolarization in guinea pig papillary muscle action potentials by changrolin.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Benzeneacetamides; Female; Guinea Pigs; In Vitro Techniques; Male; Mexiletine; Papillary Muscles; Piperidines; Quinazolines; Quinidine | 1990 |
Elimination of Theileria buffeli infections from cattle by concurrent treatment with primaquine phosphate and halofuginone lactate.
Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Apicomplexa; Cattle; Drug Therapy, Combination; Fluorescent Antibody Technique; Piperidines; Primaquine; Quinazolines; Quinazolinones; Recurrence; Splenectomy; Theileriasis | 1990 |
Studies on cardiotonic agents. III. Synthesis of 1-[1-(6,7-dimethoxy-4-quinazolinyl)-4-piperidinyl]-3-substituted 2-imidazolidinone and 2-imidazolidinethione derivatives.
Topics: Animals; Cardiotonic Agents; Dogs; Female; Imidazoles; Male; Piperidines; Quinazolines; Thiones | 1990 |
The role of endogenously formed diacylglycerol in the propagation and termination of platelet activation. A biochemical and functional analysis using the novel diacylglycerol kinase inhibitor, R 59 949.
Topics: Blood Platelets; Calcium; Cell Membrane; Collagen; Cyclic AMP; Diacylglycerol Kinase; Diglycerides; Glycerides; Humans; Phosphates; Phosphatidylinositols; Phospholipids; Phosphoproteins; Phosphorylation; Phosphotransferases; Piperidines; Platelet Aggregation; Protein Kinase C; Quinazolines; Quinazolinones; Second Messenger Systems; Thromboxane B2; Vasopressins | 1989 |
Effects of afloqualone on vestibular nystagmus and the lateral vestibular nucleus.
Topics: Acetylcholine; Animals; Cats; Dose-Response Relationship, Drug; Female; gamma-Aminobutyric Acid; Histamine H1 Antagonists; Iontophoresis; Male; Muscle Relaxants, Central; Nystagmus, Physiologic; Piperidines; Propiophenones; Quinazolines; Reflex, Monosynaptic; Synaptic Transmission; Vestibular Nuclei | 1989 |
Determination of halofuginone in bovine plasma by competing-ion high performance liquid chromatography after solid phase extraction.
Topics: Administration, Oral; Animals; Cattle; Chromatography, High Pressure Liquid; Coccidiostats; Indicators and Reagents; Microchemistry; Piperidines; Quinazolines; Quinazolinones | 1989 |
Mechanism of the hypotensive effect of a novel phenylpiperazine derivative, SGB-1534: antagonism at alpha 1-adrenergic and 5-HT2 receptors.
Topics: Adrenergic alpha-Antagonists; Anesthesia; Animals; Antihypertensive Agents; Decerebrate State; Gastric Fundus; Guinea Pigs; In Vitro Techniques; Ketanserin; Male; Muscle Contraction; Muscle, Smooth; Muscle, Smooth, Vascular; Piperidines; Prazosin; Quinazolines; Rats; Rats, Inbred Strains; Serotonin Antagonists | 1985 |
Chemotherapy of East Coast fever. Treatment of infections induced by isolates of Theileria parva with halofuginone.
Topics: Animals; Antiprotozoal Agents; Body Weight; Carrier State; Cattle; Leukocyte Count; Lymph Nodes; Male; Piperidines; Quinazolines; Quinazolinones; Theileriasis; Ticks | 1986 |
2,4-Diamino-6,7-dimethoxyquinazolines. 2. 2-(4-Carbamoylpiperidino) derivatives as alpha 1-adrenoceptor antagonists and antihypertensive agents.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; In Vitro Techniques; Piperidines; Quinazolines; Rats; Rats, Inbred SHR; Receptors, Adrenergic, alpha; Structure-Activity Relationship | 1987 |
The effect of halofuginone on the excretion of Salmonella typhimurium by experimentally infected chickens.
Topics: Animal Feed; Animals; Chickens; Coccidiostats; Colony Count, Microbial; Feces; Piperidines; Poultry Diseases; Quinazolines; Quinazolinones; Salmonella Infections, Animal; Salmonella typhimurium; Specific Pathogen-Free Organisms | 1988 |
Anticoccidial evaluation of halofuginone, lasalocid, maduramicin, monensin and salinomycin.
Topics: Animals; Anti-Bacterial Agents; Body Weight; Chickens; Coccidiosis; Coccidiostats; Eimeria; Female; Ionophores; Lactones; Lasalocid; Male; Monensin; Piperidines; Poultry Diseases; Pyrans; Quinazolines; Quinazolinones | 1988 |
Determination of halofuginone in poultry feeds by high-performance liquid chromatography.
Topics: Animal Feed; Chromatography, High Pressure Liquid; Coccidiostats; Piperidines; Quinazolines; Quinazolinones; Solvents; Spectrophotometry, Ultraviolet | 1988 |
Efficacy of halofuginone as a coccidiostat for turkeys.
Topics: Animal Nutritional Physiological Phenomena; Animals; Body Weight; Coccidiosis; Coccidiostats; Male; Piperidines; Poultry Diseases; Quinazolines; Quinazolinones; Turkeys | 1987 |
Response of broiler chickens to addition of bacitracin methylene disalicylate and roxarsone to diets containing halofuginone.
Topics: Animal Feed; Animals; Arsenicals; Bacitracin; Body Weight; Chickens; Coccidiosis; Coccidiostats; Female; Food Additives; Male; Piperidines; Poultry Diseases; Quinazolines; Quinazolinones; Roxarsone | 1987 |
[Tolerance of halofuginone (Stenorol) by geese (Anser anser f. dom.), flight ducks (Cairina moschata f. dom.) and Peking ducks (Anas platyrhynchos f. dom.)].
Topics: Animals; Body Weight; Coccidiostats; Ducks; Eating; Geese; Piperidines; Quinazolines; Quinazolinones | 1986 |
Chemoprophylaxis of cryptosporidiosis in chickens, using halofuginone, salinomycin, lasalocid, or monensin.
Topics: Animals; Chickens; Coccidiostats; Cryptosporidiosis; Lasalocid; Monensin; Piperidines; Poultry Diseases; Pyrans; Quinazolines; Quinazolinones | 1987 |
Halofuginone: laboratory titration of anticoccidial activity in young turkeys.
Topics: Animals; Body Weight; Coccidiosis; Coccidiostats; Feeding Behavior; Piperidines; Poultry Diseases; Quinazolines; Quinazolinones; Turkeys | 1986 |
Eimeria tenella: stability of resistance to halofuginone, decoquinate and arprinocid in the chicken.
Topics: Adenine; Animals; Chickens; Coccidiosis; Coccidiostats; Decoquinate; Drug Resistance; Eimeria; Hydroxyquinolines; Piperidines; Quinazolines; Quinazolinones | 1986 |
Eimeria tenella: experimental studies on the development of resistance to halofuginone.
Topics: Animals; Chickens; Coccidiosis; Coccidiostats; Drug Resistance, Microbial; Eimeria; Piperidines; Poultry Diseases; Quinazolines; Quinazolinones | 1986 |
Synthesis of piperidine derivatives with a quinazoline ring system as potential antihypertensive agents.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Chemical Phenomena; Chemistry; Male; Piperidines; Quinazolines; Rats; Rats, Inbred SHR | 1986 |
Bovine theileriosis in Burundi: chemotherapy with halofuginone lactate.
Topics: Animals; Burundi; Cattle; Piperidines; Quinazolines; Quinazolinones; Theileriasis | 1986 |
Anticoccidial efficacy of halofuginone in turkeys reared to market weight.
Topics: Animals; Coccidiosis; Coccidiostats; Female; Male; Piperidines; Poultry Diseases; Quinazolines; Quinazolinones; Turkeys | 1986 |
The use of bambermycins (Flavomycin) and halofuginone (Stenorol) in diets for growing turkeys.
Topics: Animals; Anti-Bacterial Agents; Arkansas; Bambermycins; Body Weight; Coccidiostats; Colorado; Female; Food Additives; Male; Minnesota; Piperidines; Quinazolines; Quinazolinones; Sex Factors; Turkeys | 1985 |
Chemotherapeutic efficacy of sulphadimidine, amprolium, halofuginone and chloroquine phosphate in experimental Eimeria bareillyi coccidiosis of buffaloes.
Topics: Amprolium; Animals; Buffaloes; Chloroquine; Coccidiosis; Coccidiostats; Eimeria; Intestine, Small; Piperidines; Quinazolines; Quinazolinones; Sulfamethazine | 1985 |
Synthesis of 1- and 3-(1-substituted 4-piperidinyl)-1,2,3,4-tetrahydro-2-oxoquinazolines as potential antihypertensive agents.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Heart Rate; Male; Piperidines; Quinazolines; Rats; Rats, Inbred SHR; Rats, Inbred Strains; Structure-Activity Relationship | 1985 |
Treatment of field cases of East Coast fever with halofuginone lactate.
Topics: Animals; Cattle; Piperidines; Quinazolines; Quinazolinones; Theileriasis; Tick Infestations | 1985 |
[On the reactions of 4-substituted quinazoline with serveral nucleophilic reagents].
Topics: Aniline Compounds; Butylamines; Chemical Phenomena; Chemistry; Indicators and Reagents; Malonates; Phenylacetates; Piperidines; Quinazolines | 1973 |
[Aminomethylation of enamines of cyclic beta-dicarbonyl compounds].
Topics: Amines; Benzyl Compounds; Chemical Phenomena; Chemistry; Chlorides; Formaldehyde; Methods; Methylation; Piperidines; Quinazolines; Resorcinols; Spectrum Analysis | 1971 |
The chemistry of some new analgetics.
Topics: Analgesics; Chemistry, Pharmaceutical; Isoquinolines; Morphinans; Morphine; Piperidines; Quinazolines | 1969 |
Structural modification of febrifugine. Some methylenedioxy analogs.
Topics: Animals; Antimalarials; Female; Male; Mice; Piperidines; Plasmodium; Quinazolines | 1970 |
[Synthesis of quinazolinone derivatives].
Topics: Chemical Phenomena; Chemistry; Imidazoles; Piperidines; Quinazolines; Spectrum Analysis | 1970 |
Increased ouabain binding after repeated noradrenergic stimulation.
Topics: 4-Nitrophenylphosphatase; Animals; Cell Membrane; Cerebral Cortex; Male; Ouabain; Phosphoric Monoester Hydrolases; Piperidines; Piperoxan; Prazosin; Protein Binding; Quinazolines; Rats | 1981 |
An in vitro assay system for the identification of potential antimalarial drugs.
Topics: Animals; Antimalarials; Cattle; Chloramphenicol; Chloroquine; Clindamycin; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Erythrocytes; Humans; Hypoxanthine; Hypoxanthines; Piperidines; Plasmodium falciparum; Quinazolines; Quinazolinones; Rabbits | 1983 |
Development by genetic recombination of a line of Eimeria tenella resistant to robenidine, decoquinate and amprolium.
Topics: Adenine; Amprolium; Animals; Chickens; Clopidol; Coccidiostats; Decoquinate; Drug Resistance, Microbial; Eimeria; Guanidines; Hydroxyquinolines; Picolines; Piperidines; Quinazolines; Quinazolinones; Recombination, Genetic; Robenidine | 1984 |
The effect of halofuginone, Wellcome 993 C, oxytetracycline, and diminazene diaceturate on Babesia equi-infected lymphoblastoid cell cultures.
Topics: Amidines; Animals; Antiprotozoal Agents; Babesia; Cell Line; Diminazene; DNA; Lymphocytes; Naphthoquinones; Oxytetracycline; Piperidines; Quinazolines; Quinazolinones; Thymidine | 1984 |
Chemotherapy of bovine tropical theileriosis: Theileria annulata infection.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Cattle; Drug Administration Schedule; Injections, Intramuscular; Piperidines; Quinazolines; Quinazolinones; Theileriasis | 1984 |
Determination of halofuginone hydrobromide in medicated animal feeds.
Topics: Animal Feed; Chromatography, High Pressure Liquid; Coccidiostats; Piperidines; Quinazolines; Quinazolinones | 1983 |
Haemodynamic response to ketanserin in rabbits with Page hypertension: comparison with prazosin.
Topics: Animals; Blood Pressure; Dose-Response Relationship, Drug; Heart Rate; Hemodynamics; Hypertension; Ketanserin; Male; Methoxamine; Piperidines; Prazosin; Quinazolines; Rabbits; Receptors, Serotonin; Serotonin Antagonists | 1983 |
Collaborative study of a method for the determination of residues of halofuginone in chicken tissue. Analytical Methods Committee, Royal Society of Chemistry.
Topics: Animals; Chickens; Chromatography, High Pressure Liquid; Coccidiostats; Meat; Piperidines; Quinazolines; Quinazolinones | 1984 |
Chemotherapy of Sarcosporidiosis and theileriosis in domestic animals.
Topics: Animals; Cattle; Coccidiostats; Drug Combinations; Goats; Oxytetracycline; Piperidines; Quinazolines; Quinazolinones; Sarcocystosis; Sheep; Sheep Diseases; Sulfadoxine; Theileriasis; Trimethoprim | 1981 |
Comparison of the antitheilerial effect of Wellcome 993C and halofuginone.
Topics: Animals; Antiprotozoal Agents; Apicomplexa; Cattle; Coccidiostats; Lymph Nodes; Male; Naphthoquinones; Piperidines; Quinazolines; Quinazolinones; Theileriasis | 1982 |
Electron microscopical study on the effect of halofuginone on Theileria parva.
Topics: Animals; Apicomplexa; Cattle; Cattle Diseases; Lymphocytes; Piperidines; Quinazolines; Quinazolinones; Theileriasis | 1981 |
Chemotherapy of Theileria parva lawrencei infections in cattle with halofuginone.
Topics: Animals; Cattle; Coccidiostats; Piperidines; Quinazolines; Quinazolinones; Theileriasis | 1983 |
Diphenylhydantoin protection of centpiperalone induced insulin release from beta-cells.
Topics: Animals; Blood Glucose; Cytoplasmic Granules; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Phenytoin; Piperazines; Piperidines; Quinazolines; Quinazolinones; Rats | 1980 |
Drug responsiveness of field isolates of chicken Coccidia.
Topics: Amprolium; Animals; Chickens; Coccidiostats; Drug Resistance; Eimeria; Intestines; Manure; Nicarbazin; Piperidines; Quinazolines; Quinazolinones; Robenidine | 1982 |
Anticoccidial drugs: growth and performance depressing effects in young chickens.
Topics: Adenine; Animal Feed; Animals; Body Weight; Chickens; Coccidiostats; Growth; Lasalocid; Male; Monensin; Nicarbazin; Piperidines; Quinazolines; Quinazolinones | 1982 |
Effects of prazosin and piperoxan on central cardiovascular actions of St 91 in cats.
Topics: Animals; Atropine; Blood Pressure; Brain; Cats; Clonidine; Female; Heart Rate; Hemodynamics; Injections, Intra-Arterial; Injections, Intravenous; Male; Piperidines; Piperoxan; Prazosin; Quinazolines; Vertebral Artery | 1982 |
[Studies on antimalarials. VII. Synthesis and antimalarial activities of some derivatives of 2, 4-dipiperidino- or 2, 4-dipyrrolidino- 6-(substituted) amino-quinazolines].
Topics: Animals; Antimalarials; Malaria; Mice; Piperidines; Pyrrolidines; Quinazolines | 1982 |
Anticoccidial activity of arprinocid and halofuginone.
Topics: Adenine; Animals; Chickens; Coccidiosis; Coccidiostats; Eimeria; Piperidines; Poultry Diseases; Quinazolines; Quinazolinones; Species Specificity | 1981 |
[The development of weaned piglets experimentally infected with Isospora suis as a model for the effect of lasalocid and halofuginone on coccidia (author's transl)].
Topics: Animals; Body Weight; Coccidiosis; Feces; Isospora; Lasalocid; Piperidines; Quinazolines; Quinazolinones; Swine; Weaning | 1981 |
Analysis of the anti-coccidial drug, halofuginone, in chicken tissue and chicken feed using high-performance liquid chromatography.
Topics: Animal Feed; Animals; Chickens; Chromatography, High Pressure Liquid; Coccidiostats; Piperidines; Quinazolines; Quinazolinones; Tissue Distribution | 1981 |
Scientific evidence on the role of Ayurvedic herbals on bioavailability of drugs.
Topics: Abortifacient Agents; Alkaloids; Animals; Benzodioxoles; Biological Availability; Drug Synergism; Female; India; Medicine, Ayurvedic; Pharmaceutical Preparations; Phytotherapy; Piperidines; Plant Extracts; Plants, Medicinal; Polyunsaturated Alkamides; Quinazolines; Rats; Sparteine | 1981 |
Anticoccidial drugs for preventive therapy in intensively reared pheasants.
Topics: Animals; Bird Diseases; Birds; Clopidol; Coccidiosis; Coccidiostats; Piperidines; Quinazolines; Quinazolinones | 1981 |
The effects of halofuginone and salinomycin, alone and in combination, on live performance and skin characteristics of female broilers: influence of a high-proline diet supplemented with ascorbic acid and zinc.
Topics: Animals; Ascorbic Acid; Body Weight; Chickens; Coccidiostats; Female; Food, Fortified; Piperidines; Proline; Pyrans; Quinazolines; Quinazolinones; Skin; Skin Physiological Phenomena; Tensile Strength; Zinc | 1995 |
The effects of halofuginone and salinomycin, alone and in combination, on live performance and skin characteristics of broilers.
Topics: Animals; Body Weight; Chickens; Coccidiostats; Female; Food, Fortified; Male; Piperidines; Pyrans; Quinazolines; Quinazolinones; Sex Factors; Skin; Skin Physiological Phenomena; Tensile Strength | 1995 |
The activity of halofuginone in immunosuppressed rats infected with Cryptosporidium parvum.
Topics: Animals; Colonic Diseases; Common Bile Duct; Cryptosporidiosis; Cryptosporidium parvum; Dexamethasone; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Feces; Female; Immunosuppression Therapy; Intestine, Large; Intestine, Small; Parasite Egg Count; Piperidines; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Treatment Outcome | 1995 |
Effects of a novel, selective and potent phosphodiesterase type V inhibitor, E4021, on myocardial ischemia in guinea pigs.
Topics: Animals; Drug Interactions; Electrocardiography; Guinea Pigs; Injections, Intravenous; Isosorbide Dinitrate; Male; Myocardial Ischemia; Niacinamide; Nicorandil; Nitro Compounds; Phosphodiesterase Inhibitors; Piperidines; Quinazolines; Vasodilator Agents; Vasopressins | 1994 |
A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery.
Topics: Animals; Coronary Vessels; Cyclic GMP; Dose-Response Relationship, Drug; In Vitro Techniques; Isoenzymes; Isosorbide Dinitrate; Male; Phosphodiesterase Inhibitors; Piperidines; Quinazolines; Rabbits; Swine; Vasodilation | 1995 |
Halofuginone, a specific collagen type I inhibitor, reduces anastomotic intimal hyperplasia.
Topics: Anastomosis, Surgical; Animals; Blotting, Northern; Carotid Artery, Common; Cell Division; Cells, Cultured; Collagen; Dose-Response Relationship, Drug; Hyperplasia; Muscle, Smooth, Vascular; Piperidines; Procollagen; Quinazolines; Quinazolinones; Rabbits; RNA, Messenger; Tropoelastin; Tunica Intima | 1995 |
Modulation of nucleocytosolic [Ca2+] gradient in smooth muscle by protein phosphorylation.
Topics: Adenosine Triphosphate; Animals; Benzoquinones; Calcium; Cell Line; Cell Nucleus; Colforsin; Cricetinae; Cytosol; Diacylglycerol Kinase; Epidermal Growth Factor; Ethers, Cyclic; Homeostasis; Kinetics; Lactams, Macrocyclic; Leiomyosarcoma; Marine Toxins; Mesocricetus; Models, Biological; Muscle, Smooth; Okadaic Acid; Oxazoles; Phosphoproteins; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Piperidines; Protein Kinase C; Protein Kinases; Protein Tyrosine Phosphatases; Quinazolines; Quinazolinones; Quinones; Rifabutin; Tetradecanoylphorbol Acetate; Time Factors; Tumor Cells, Cultured | 1994 |
Effect of halofuginone on broiler skin strength when used in a shuttle anticoccidial program.
Topics: Animal Feed; Animals; Chickens; Coccidiostats; Diet; Drug Administration Schedule; Female; Piperidines; Pyrans; Quinazolines; Quinazolinones; Skin; Skin Physiological Phenomena; Tensile Strength | 1994 |
Halofuginone: an inhibitor of collagen type I synthesis.
Topics: Animals; Birds; Cell Division; Cells, Cultured; Coccidiostats; Collagen; Embryo, Mammalian; Embryo, Nonmammalian; Fibroblasts; Gene Expression; Growth Plate; Matrix Metalloproteinase Inhibitors; Mice; Piperidines; Proline; Quinazolines; Quinazolinones; Rats; Species Specificity | 1993 |
The effects of shuttle programs upon the growth of broilers and the development of immunity to eimeria species.
Topics: Animals; Body Weight; Chickens; Coccidiosis; Coccidiostats; Diet; Eimeria; Feces; Immunity; Male; Nicarbazin; Parasite Egg Count; Piperidines; Poultry Diseases; Quinazolines; Quinazolinones; Robenidine | 1993 |
Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta: characterization and the effects of E4021.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Aorta; Calcium-Calmodulin-Dependent Protein Kinases; Cytosol; Dinoprost; Humans; In Vitro Techniques; Isoenzymes; Kidney; Kinetics; Muscle Contraction; Muscle Relaxation; Muscle, Smooth, Vascular; Phosphodiesterase Inhibitors; Piperidines; Quinazolines; Subcellular Fractions; Vasodilator Agents | 1995 |
Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Calcium Channel Blockers; Cyclic GMP; Diltiazem; Hemodynamics; Hypertension, Pulmonary; Hypoxia; In Vitro Techniques; Lung; Male; Nitric Oxide; Perfusion; Phosphodiesterase Inhibitors; Piperidines; Pulmonary Circulation; Purinones; Quinazolines; Rats; Rats, Sprague-Dawley; Vasodilation | 1996 |
Mitigating the effects of halofuginone on skin strength by feeding L-proline to broiler chickens.
Topics: Animals; Body Weight; Chickens; Coccidiostats; Collagen; Female; Food, Fortified; Male; Piperidines; Proline; Quinazolines; Quinazolinones; Skin; Skin Physiological Phenomena; Tensile Strength | 1995 |
Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone.
Topics: Animals; Collagen; Disease Models, Animal; Fibrosis; Graft vs Host Disease; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Mutant Strains; Osmolar Concentration; Piperidines; Quinazolines; Quinazolinones; Scleroderma, Localized; Skin | 1996 |
PKC-dependent reduction of the acetylcholine-evoked inward Na current in Aplysia D-neurons: effect of injected PKC and PKC activators.
Topics: Acetylcholine; Animals; Aplysia; Dimethyl Sulfoxide; Enzyme Activation; Evoked Potentials; Ganglia, Invertebrate; In Vitro Techniques; Membrane Potentials; Naphthalenes; Neurons; Phorbol Esters; Piperidines; Protein Kinase C; Quinazolines; Quinazolinones; Sodium Channels; Sulfonamides | 1996 |
Therapeutic efficacy of halofuginone and spiramycin treatment against Cryptosporidium serpentis (Apicomplexa: Cryptosporidiidae) infections in captive snakes.
Topics: Animals; Coccidiostats; Cryptosporidium; Feces; Intestine, Large; Intestine, Small; Piperidines; Quinazolines; Quinazolinones; Snails; Spiramycin; Stomach | 1996 |
Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone.
Topics: Adult; Coccidiostats; Collagen; Dose-Response Relationship, Drug; Female; Fibroblasts; Graft vs Host Disease; Humans; Middle Aged; Piperidines; Quinazolines; Quinazolinones; Time Factors | 1996 |
Reduction in pulmonary fibrosis in vivo by halofuginone.
Topics: Animals; Bleomycin; Collagen; Lung; Male; Piperidines; Pulmonary Fibrosis; Quinazolines; Quinazolinones; Rats; Rats, Inbred Strains | 1996 |
Topically applied halofuginone, an inhibitor of collagen type I transcription, reduces peritendinous fibrous adhesions following surgery.
Topics: Animals; Chickens; Collagen; Gene Expression Regulation; Hydroxyproline; Inflammation; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Statistics, Nonparametric; Tendon Injuries; Tissue Adhesions | 1996 |
A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension.
Topics: Animals; Disease Models, Animal; Heart Ventricles; Hypertension, Pulmonary; Male; Monocrotaline; Organ Size; Phosphodiesterase Inhibitors; Piperidines; Pulmonary Artery; Quinazolines; Rats; Rats, Wistar | 1996 |
Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Arteries; Blood Platelets; Cattle; Cell Division; Cyclic Nucleotide Phosphodiesterases, Type 5; Dogs; Enzyme Inhibitors; Humans; Hypertension; Imidazoles; Nucleotides, Cyclic; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperidines; Platelet Aggregation Inhibitors; Quinazolines; Rats; Rats, Inbred SHR | 1996 |
Effect of halofuginone (Stenorol) on Chukar partridge (Alectoris chukar).
Topics: Animals; Coccidiostats; Dose-Response Relationship, Drug; Feeding Behavior; Growth; Piperidines; Poultry; Quinazolines; Quinazolinones; Weight Gain | 1996 |
Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; 8-Bromo Cyclic Adenosine Monophosphate; Amrinone; Cells, Cultured; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 5; Heart Failure; Humans; Interleukin-1; Interleukin-6; Kinetics; Leukocytes, Mononuclear; Lipopolysaccharides; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperidines; Pyrazines; Pyridazines; Quinazolines; Quinolines; Tumor Necrosis Factor-alpha | 1996 |
Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone.
Topics: Animals; Arteries; Cattle; Cell Division; Cells, Cultured; Collagen; Humans; Hyperplasia; Muscle, Smooth, Vascular; Piperidines; Quinazolines; Quinazolinones; Rabbits; Tunica Intima | 1997 |
Inhibition of platelet adhesion and aggregation by E4021, a type V phosphodiesterase inhibitor, in guinea pigs.
Topics: Animals; Dose-Response Relationship, Drug; Guinea Pigs; Humans; Male; Phosphodiesterase Inhibitors; Piperidines; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Quinazolines | 1997 |
Characterization of the isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Blood Platelets; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; In Vitro Techniques; Isoenzymes; Molsidomine; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Phthalazines; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Quinazolines; Signal Transduction; Thromboxane A2; Tissue Distribution | 1996 |
Studies of resistance to anticoccidials in Eimeria field isolates and pure Eimeria strains.
Topics: Animals; Chickens; Coccidiosis; Coccidiostats; Drug Resistance; Drug Resistance, Multiple; Eimeria; Germany; Lactones; Male; Monensin; Nicarbazin; Nitriles; Piperidines; Poultry Diseases; Pyrans; Quinazolines; Quinazolinones; Robenidine; Triazines | 1997 |
Noradrenaline release and the effect of endogenous activation of the phospholipase C/protein kinase C signalling pathway in rat atria.
Topics: Androstadienes; Animals; Atrial Function; Diacylglycerol Kinase; Electric Stimulation; Enzyme Activation; Enzyme Inhibitors; Estrenes; Heart Atria; Male; Norepinephrine; Phosphotransferases (Alcohol Group Acceptor); Piperidines; Protein Kinase C; Pyrrolidinones; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Signal Transduction; Type C Phospholipases; Wortmannin | 1997 |
Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis.
Topics: Alkaline Phosphatase; Animals; Collagen; Dimethylnitrosamine; Gene Expression; In Situ Hybridization; Injections, Intraperitoneal; Liver; Liver Cirrhosis, Experimental; Male; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley | 1997 |
Sphingosine prevents diacylglycerol signaling to mitogen-activated protein kinase in airway smooth muscle.
Topics: 1-Butanol; Animals; Bradykinin; Butanols; Calcium-Calmodulin-Dependent Protein Kinases; Cells, Cultured; Diacylglycerol Kinase; Diglycerides; Enzyme Activation; Enzyme Inhibitors; Guinea Pigs; Kinetics; Muscle, Smooth; Palmitic Acid; Phosphatidate Phosphatase; Phosphotransferases (Alcohol Group Acceptor); Piperidines; Platelet-Derived Growth Factor; Protein Kinase C; Quinazolines; Quinazolinones; Signal Transduction; Sphingosine; Tetradecanoylphorbol Acetate; Trachea | 1997 |
Role of Ca(2+)-independent PKC in alpha 1-adrenoceptor-mediated inotropic responses of neonatal rat hearts.
Topics: Adrenergic alpha-Agonists; Animals; Animals, Newborn; Calcium; Carbazoles; Diacylglycerol Kinase; Electric Stimulation; Enzyme Activation; Enzyme Inhibitors; Heart Ventricles; In Vitro Techniques; Indoles; Inositol Phosphates; Isoenzymes; Isoproterenol; Maleimides; Methoxamine; Myocardial Contraction; Myocardium; Phenylephrine; Phorbol 12,13-Dibutyrate; Phosphotransferases (Alcohol Group Acceptor); Piperidines; Protein Kinase C; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1 | 1997 |
Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone.
Topics: Animals; Carbon Radioisotopes; Cell Division; Cells, Cultured; Collagen; Extracellular Matrix; Gene Expression; Glomerular Mesangium; Piperidines; Proline; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Rats; Rats, Wistar; Sulfates; Tritium | 1997 |
Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats.
Topics: Animals; Blood Flow Velocity; Diabetes Mellitus, Experimental; Diacylglycerol Kinase; Diglycerides; Enzyme Inhibitors; Fluorescein Angiography; Hyperglycemia; Indoles; Isoenzymes; Male; Maleimides; Piperidines; Protein Kinase C; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Retina; Retinal Vessels | 1997 |
Residual activity of anticoccidial drugs in chickens after withdrawal of medicated feeds.
Topics: Amprolium; Animal Feed; Animals; Chickens; Coccidiosis; Coccidiostats; Eimeria tenella; Feces; Female; Lasalocid; Male; Monensin; Nicarbazin; Nitriles; Piperidines; Poultry Diseases; Pyrans; Quinazolines; Quinazolinones; Random Allocation; Triazines | 1998 |
Halofuginone--an inhibitor of collagen type I synthesis--prevents postoperative formation of abdominal adhesions.
Topics: Abdomen; Animals; Collagen; Histocytochemistry; In Situ Hybridization; Piperidines; Postoperative Complications; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Tissue Adhesions | 1998 |
[E 4021, a cGMP phosphodiesterase inhibitor, is a selective pulmonary vasodilator in chronically hypoxic pulmonary hypertensive rats].
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Blood Pressure; Chronic Disease; Hypertension, Pulmonary; Hypoxia; Lung; Male; Phosphodiesterase Inhibitors; Piperidines; Pulmonary Artery; Quinazolines; Rats; Rats, Sprague-Dawley; Vasodilator Agents | 1998 |
Comparative efficacy of anticoccidials under the conditions of commercial broiler production and in battery trials.
Topics: Animal Husbandry; Animals; Chickens; Clopidol; Coccidiosis; Coccidiostats; Drug Resistance; Eimeria; Feces; Food Industry; Ionophores; Monensin; Nicarbazin; Piperidines; Poultry Diseases; Predictive Value of Tests; Pyrans; Quinazolines; Quinazolinones; Quinolones | 1998 |
Type V phosphodiesterase inhibition modulates endogenous immunoreactivities of endothelin-1 and endothelial nitric oxide synthase in pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Administration, Oral; Animals; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Endothelin-1; Hypertension, Pulmonary; Immunohistochemistry; Male; Monocrotaline; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperidines; Pulmonary Artery; Quinazolines; Rats; Rats, Wistar; Receptors, Endothelin | 1998 |
Coronary artery diameter increase induced by a phosphodiesterase 5 inhibitor, E4021, in conscious pigs.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Arteries; Coronary Vessels; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Hemodynamics; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperidines; Quinazolines; Swine | 1998 |
Enhancement of NO production in activated macrophages in vivo by an antimalarial crude drug, Dichroa febrifuga.
Topics: Animals; Antimalarials; China; In Vitro Techniques; Macrophages; Male; Mass Spectrometry; Mice; Mice, Inbred ICR; Nitric Oxide; Piperidines; Plant Extracts; Plant Roots; Plants, Medicinal; Quinazolines; Spectrophotometry, Infrared; Spectrophotometry, Ultraviolet | 1998 |
Redescription of Babesia equi Laveran, 1901 as Theileria equi Mehlhorn, Schein 1998.
Topics: Animals; Antiprotozoal Agents; Arachnid Vectors; Babesia; Erythrocytes; Horse Diseases; Horses; Life Cycle Stages; Lymphocytes; Naphthoquinones; Piperidines; Quinazolines; Quinazolinones; Theileria; Theileriasis; Ticks | 1998 |
4-Benzylamino-1-chloro-6-substituted phthalazines: synthesis and inhibitory activity toward phosphodiesterase 5.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Blood Platelets; Coronary Vessels; Cyclic Nucleotide Phosphodiesterases, Type 5; Dinoprost; In Vitro Techniques; Muscle Contraction; Muscle Relaxation; Muscle, Smooth, Vascular; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Phthalazines; Piperidines; Quinazolines; Swine; Vasodilator Agents | 1998 |
Interleukin-2 stimulates a late increase in phosphatidic acid production in the absence of phospholipase D activation.
Topics: 3T3 Cells; Animals; Cell Line; Diacylglycerol Kinase; Enzyme Activation; Enzyme Inhibitors; Humans; Interleukin-2; Isoenzymes; Mice; Phosphatidic Acids; Phospholipase D; Piperidines; Quinazolines; Quinazolinones; Recombinant Proteins; Signal Transduction; T-Lymphocytes; Tetradecanoylphorbol Acetate | 1998 |
Increased adhesion of peripheral blood neutrophils from patients with localized juvenile periodontitis.
Topics: Adolescent; Adult; Aggressive Periodontitis; Case-Control Studies; Cell Adhesion; Child; Diacylglycerol Kinase; Enzyme Inhibitors; Female; Humans; Luminescent Measurements; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Piperidines; Quinazolines; Quinazolinones; Reactive Oxygen Species; Respiratory Burst; Zymosan | 1998 |
Sphingosine induces phospholipase D and mitogen activated protein kinase in vascular smooth muscle cells.
Topics: Animals; Aorta; Calcium-Calmodulin-Dependent Protein Kinases; Cells, Cultured; Diacylglycerol Kinase; Enzyme Activation; Ethanol; Glycerophospholipids; Muscle, Smooth, Vascular; Phosphatidic Acids; Phospholipase D; Piperidines; Protein Kinase C; Quinazolines; Quinazolinones; Rats; Signal Transduction; Sphingosine; Tetradecanoylphorbol Acetate; Time Factors; Type C Phospholipases | 1998 |
Halofuginone inhibits neointimal formation of cultured rat aorta in a concentration-dependent fashion in vitro.
Topics: Animals; Aorta; Coccidiostats; Culture Techniques; Dose-Response Relationship, Drug; Male; Muscle, Smooth, Vascular; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Rats; Rats, Wistar; Tunica Intima | 1998 |
Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney.
Topics: Adrenergic beta-Antagonists; Animals; Aorta, Thoracic; Benzopyrans; Celiprolol; Desoxycorticosterone; Dose-Response Relationship, Drug; Endothelium, Vascular; Ethanolamines; Hypertension; In Vitro Techniques; Kidney; Male; Metergoline; Muscle, Smooth, Vascular; Nebivolol; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Phenylephrine; Pindolol; Piperazines; Piperidines; Platelet Aggregation Inhibitors; Quinazolines; Rats; Rats, Wistar; Renal Circulation; Serotonin Antagonists; Vasoconstriction; Vasodilator Agents | 1999 |
Potency and mechanism of action of E4021, a type 5 phosphodiesterase isozyme-selective inhibitor, on the photoreceptor phosphodiesterase depend on the state of activation of the enzyme.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Binding, Competitive; Catalytic Domain; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Cyclic Nucleotide Phosphodiesterases, Type 6; Enzyme Activation; Holoenzymes; Isoenzymes; Phosphodiesterase Inhibitors; Photoreceptor Cells, Vertebrate; Piperidines; Quinazolines; Ranidae | 1999 |
Halofuginone, an inhibitor of collagen type I synthesis, prevents postoperative adhesion formation in the rat uterine horn model.
Topics: Administration, Oral; Animals; Collagen; Female; Gene Expression; In Situ Hybridization; Injections, Intraperitoneal; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Tissue Adhesions; Uterine Diseases | 1999 |
E4021, a selective phosphodiesterase 5 inhibitor, potentiates the vasodilator effect of inhaled nitric oxide in isolated perfused rat lungs.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 3',5'-Cyclic-GMP Phosphodiesterases; Administration, Inhalation; Animals; Bronchodilator Agents; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Synergism; Hypertension, Pulmonary; In Vitro Techniques; Isoproterenol; Lung; Male; Nitric Oxide; Nitroprusside; Perfusion; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperidines; Pulmonary Circulation; Quinazolines; Rats; Rats, Sprague-Dawley; Vasoconstriction; Vasodilation | 1999 |
Diacylglycerol kinase inhibition prevents IL-2-induced G1 to S transition through a phosphatidylinositol-3 kinase-independent mechanism.
Topics: Animals; Cell Cycle; Cell Cycle Proteins; Cell Line; Culture Media, Serum-Free; Cyclin D3; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Diacylglycerol Kinase; Enzyme Activation; Enzyme Inhibitors; G1 Phase; Gene Expression Regulation; Interleukin-2; Interleukin-4; Mice; Microtubule-Associated Proteins; Phosphatidylinositol 3-Kinases; Piperidines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogenes; Quinazolines; Quinazolinones; Retinoblastoma Protein; S Phase; T-Lymphocytes, Cytotoxic; Tumor Suppressor Proteins | 1999 |
Activation of human neutrophil NADPH oxidase by phosphatidic acid or diacylglycerol in a cell-free system. Activity of diacylglycerol is dependent on its conversion to phosphatidic acid.
Topics: Cell-Free System; Diacylglycerol Kinase; Diglycerides; Drug Synergism; Enzyme Activation; Humans; Kinetics; NADPH Oxidases; Neutrophils; Phosphatidic Acids; Piperidines; Quinazolines; Quinazolinones; Second Messenger Systems; Superoxides | 1999 |
Alpha 1-adrenergic receptor-mediated increase in the mass of phosphatidic acid and 1,2-diacylglycerol in ischemic rat heart.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Chromatography, Thin Layer; Desipramine; Diacylglycerol Kinase; Diglycerides; Estrenes; Male; Myocardial Ischemia; Myocardial Reperfusion; Myocardium; Norepinephrine; Perfusion; Phosphatidic Acids; Piperidines; Prazosin; Propranolol; Pyrrolidinones; Quinazolines; Quinazolinones; Rats; Rats, Wistar; Receptors, Adrenergic, alpha; Time Factors; Type C Phospholipases | 1999 |
New type of febrifugine analogues, bearing a quinolizidine moiety, show potent antimalarial activity against Plasmodium malaria parasite.
Topics: Animals; Antimalarials; Drugs, Chinese Herbal; Malaria; Male; Mice; Mice, Inbred ICR; Models, Molecular; Molecular Conformation; Piperidines; Plasmodium berghei; Plasmodium falciparum; Quinazolines; Quinazolinones; Quinolizines | 1999 |
Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone.
Topics: Animals; Antineoplastic Agents; Cell Division; Humans; Male; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Stromal Cells; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1999 |
The cGMP-specific phosphodiesterase inhibitor E4021 dilates the pulmonary circulation.
Topics: Analysis of Variance; Animals; Animals, Newborn; Cyclic GMP; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fetus; Humans; Infant, Newborn; Infusions, Intravenous; Nitric Oxide; Persistent Fetal Circulation Syndrome; Phosphodiesterase Inhibitors; Piperidines; Pregnancy; Pulmonary Artery; Pulmonary Circulation; Quinazolines; Sheep; Statistics, Nonparametric; Vasodilation | 1999 |
Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone.
Topics: Animals; Antineoplastic Agents; Carcinoma; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Gelatin; Humans; Laminin; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred C3H; Neoplasm Invasiveness; Neoplasm Transplantation; Piperidines; Promoter Regions, Genetic; Proteoglycans; Quinazolines; Quinazolinones; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1999 |
Potentiation by febrifugine of host defense in mice against Plasmodium berghei NK65.
Topics: Animals; Antimalarials; Drug Interactions; Enzyme Inhibitors; Malaria; Male; Mice; Mice, Inbred ICR; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Parasitemia; Piperidines; Plasmodium berghei; Quinazolines | 1999 |
Topical treatment of cutaneous chronic graft versus host disease with halofuginone: a novel inhibitor of collagen type I synthesis.
Topics: Administration, Topical; Adult; Animals; Collagen; Gene Expression; Graft vs Host Disease; Humans; Male; Neck; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Rabbits; Range of Motion, Articular; Sclerosis; Skin; Skin Transplantation | 1999 |
Selectivity of the diacylglycerol kinase inhibitor 3-[2-(4-[bis-(4-fluorophenyl)methylene]-1-piperidinyl)ethyl]-2, 3-dihydro-2-thioxo-4(1H)quinazolinone (R59949) among diacylglycerol kinase subtypes.
Topics: 3T3 Cells; Adenosine Triphosphate; Animals; Calcium; Catalytic Domain; COS Cells; Diacylglycerol Kinase; Enzyme Inhibitors; Isoenzymes; Mice; Piperidines; Quinazolines; Quinazolinones; Saccharomyces cerevisiae; Substrate Specificity | 2000 |
Use of epidermal growth factor and collagen synthesis inhibition as adjuvant to healing of ureteroureteral anastomosis.
Topics: Adjuvants, Pharmaceutic; Anastomosis, Surgical; Animals; Collagen; Drug Evaluation; Epidermal Growth Factor; Female; Piperidines; Quinazolines; Quinazolinones; Random Allocation; Swine; Ureter; Wound Healing | 2000 |
Relaxation of human ureteral smooth muscle in vitro by modulation of cyclic nucleotide-dependent pathways.
Topics: Colforsin; Cyclic AMP; Cyclic GMP; Humans; In Vitro Techniques; Isoquinolines; Muscle, Smooth; Nitroprusside; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperidines; Platelet Aggregation Inhibitors; Potassium Chloride; Purinones; Quinazolines; Rolipram; Tetrahydroisoquinolines; Ureter; Vasodilator Agents | 2000 |
4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Antihypertensive Agents; Biological Availability; Blood Pressure; Coronary Vessels; Cyclic Nucleotide Phosphodiesterases, Type 5; Dinoprost; Hypertension, Pulmonary; In Vitro Techniques; Male; Muscle Relaxation; Muscle, Smooth, Vascular; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Phthalazines; Piperidines; Quinazolines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Swine; Vasodilator Agents | 2000 |
Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antineoplastic Agents; Apoptosis; beta Catenin; Cadherins; Colonic Neoplasms; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cytoskeletal Proteins; Enzyme Activation; Humans; Isoenzymes; Kinetics; Phosphodiesterase Inhibitors; Piperidines; Protein Kinases; Quinazolines; Sulindac; Trans-Activators; Tumor Cells, Cultured | 2000 |
Nitric oxide-induced cGMP accumulation in the mouse bladder is not related to smooth muscle relaxation.
Topics: Animals; Arginine; Carbachol; Cyclic AMP; Cyclic GMP; Dose-Response Relationship, Drug; Electric Stimulation; Enzyme Inhibitors; Female; In Vitro Techniques; Mice; Mice, Inbred BALB C; Molsidomine; Muscle Relaxation; Muscle, Smooth; Nitric Oxide Donors; Nitric Oxide Synthase; Nitroarginine; Nitroprusside; Phosphodiesterase Inhibitors; Piperazines; Piperidines; Purines; Quinazolines; Sildenafil Citrate; Sulfones; Urethra; Urinary Bladder | 2000 |
Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis.
Topics: Animals; Antineoplastic Agents; Collagen; Dose-Response Relationship, Drug; In Situ Hybridization; Kinetics; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Time Factors; Tumor Cells, Cultured; Wound Healing | 1999 |
Functional identification of phosphodiesterase activity in human trabecular meshwork cells.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Adenylyl Cyclases; Cells, Cultured; Cyclic AMP; Cyclic GMP; Guanylate Cyclase; Humans; Isoproterenol; Nitroprusside; Piperidines; Quinazolines; Signal Transduction; Trabecular Meshwork | 2000 |
A diastereocontrolled synthesis of (+)-febrifugine: a potent antimalarial piperidine alkaloid.
Topics: Alkaloids; Antimalarials; Piperidines; Plants, Medicinal; Quinazolines; Stereoisomerism | 2000 |
The effect of halofuginone, an inhibitor of collagen type i synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model.
Topics: Animals; Collagen; Disease Models, Animal; Immunohistochemistry; In Situ Hybridization; Male; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Urethral Stricture | 2000 |
Novel therapeutic strategies for leiomyomas: targeting growth factors and their receptors.
Topics: Antineoplastic Agents; Blotting, Western; Chromatography, Liquid; Female; Growth Inhibitors; Growth Substances; Humans; Hysterectomy; Hysteroscopy; Immunohistochemistry; Interferon-alpha; Leiomyoma; Phenoxyacetates; Piperidines; Polymers; Protein Synthesis Inhibitors; Pyridones; Quinazolines; Quinazolinones; Receptors, Growth Factor; Uterine Neoplasms | 2000 |
Phosphatidic acid and diacylglycerol directly activate NADPH oxidase by interacting with enzyme components.
Topics: Cell-Free System; Diglycerides; Enzyme Activation; Humans; In Vitro Techniques; NADPH Oxidases; Neutrophils; Phosphatidic Acids; Phosphoproteins; Piperidines; Quinazolines; Quinazolinones; Recombinant Proteins | 2001 |
Halofuginone: a potent inhibitor of critical steps in angiogenesis progression.
Topics: Angiogenesis Inhibitors; Animals; Aorta; Capillaries; Cattle; Dose-Response Relationship, Drug; Endothelium, Vascular; Fibroblast Growth Factor 2; Matrix Metalloproteinase 2; Neovascularization, Physiologic; Piperidines; Quinazolines; Quinazolinones; Rats | 2000 |
Synthesis and analgesic activity of some quinazoline analogs of anpirtoline.
Topics: Aminopyridines; Analgesics; Animals; Hot Temperature; Male; Mice; Mice, Inbred Strains; Molecular Structure; Pain; Piperidines; Pyridines; Quinazolines; Reaction Time; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Structure-Activity Relationship; Tramadol | 2000 |
Evidence for the involvement of diacylglycerol kinase in the activation of hypoxia-inducible transcription factor 1 by low oxygen tension.
Topics: Cell Nucleus; Diacylglycerol Kinase; Diglycerides; DNA; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitors; HeLa Cells; Humans; Hypoxia; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Luciferases; Nuclear Proteins; Oxygen; Phosphatidic Acids; Phospholipids; Piperidines; Plasmids; Pyrimidinones; Quinazolines; Quinazolinones; Recombinant Proteins; Signal Transduction; Thiazoles; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transfection | 2001 |
Phosphodiesterase 5 inhibition restores impaired ACh relaxation in hypertensive conduit pulmonary arteries.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Acetylcholine; Animals; Chronic Disease; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Hypertension; Hypoxia; In Vitro Techniques; Male; Nitroprusside; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperidines; Pulmonary Artery; Quinazolines; Rats; Rats, Sprague-Dawley; Vasodilation; Vasodilator Agents | 2001 |
Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats.
Topics: Animals; Cell Division; Liver; Liver Cirrhosis; Male; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Rats; Rats, Wistar; Thioacetamide | 2001 |
Quinazolone-alkyl-carboxylic acid derivatives inhibit transmembrane Ca(2+) ion flux to (+)-(S)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid.
Topics: Acetates; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Binding Sites; Calcium; Calcium Channels; Cell Membrane; Cerebral Cortex; Excitatory Amino Acid Agents; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic Acid; Ion Channel Gating; Ligands; Male; Models, Molecular; Molecular Structure; Piperidines; Propionates; Quinazolines; Rats; Rats, Wistar; Receptors, AMPA; Structure-Activity Relationship | 2001 |
A concise enantioselective synthesis of antimalarial febrifugine alkaloids.
Topics: Alkaloids; Antimalarials; Indicators and Reagents; Molecular Conformation; Molecular Structure; Piperidines; Quinazolines; Stereoisomerism | 2001 |
Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system.
Topics: Aminobenzoates; Animals; DNA; DNA Damage; Electron Transport Complex IV; Energy Metabolism; Enzyme Inhibitors; Heart; In Vitro Techniques; Lipid Peroxidation; Male; Mitochondria; Myocardium; NAD; Oxidation-Reduction; Oximes; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Quinazolinones; Rats; Rats, Wistar; Reactive Oxygen Species; Reperfusion Injury | 2001 |
Synthesis and antimalarial activity of febrifugine derivatives.
Topics: Antimalarials; Piperidines; Quinazolines | 2001 |
Fatty acids inhibit growth-factor-induced diacylglycerol kinase alpha activation in vascular smooth-muscle cells.
Topics: Animals; Carotid Arteries; Cell Membrane; Cells, Cultured; Cytosol; Diacylglycerol Kinase; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; Escherichia coli; Fatty Acids, Nonesterified; Isoenzymes; Kinetics; Muscle, Smooth, Vascular; Oleic Acid; Palmitic Acid; Piperidines; Platelet-Derived Growth Factor; Quinazolines; Quinazolinones; Recombinant Proteins; Swine; Thrombin | 2001 |
Potassium channel blocker activates extracellular signal-regulated kinases through Pyk2 and epidermal growth factor receptor in rat cardiomyocytes.
Topics: 4-Aminopyridine; Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Channels, L-Type; Cells, Cultured; Cytochalasin D; Drug Evaluation, Preclinical; ErbB Receptors; Focal Adhesion Kinase 2; Mitogen-Activated Protein Kinases; Myocardium; Phosphorylation; Piperidines; Potassium Channel Blockers; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Quinidine; Rats; Rats, Wistar; Tetraethylammonium; Time Factors; Tyrphostins | 2001 |
Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone.
Topics: Administration, Topical; Animals; Cell Division; Collagen; Disease Models, Animal; Fibrosis; Male; Mast Cells; Mice; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Skin | 2001 |
Lewis acid-catalyzed ring-opening reactions of semicyclic N,O-acetals possessing an exocyclic nitrogen atom: mechanistic aspect and application to piperidine alkaloid synthesis.
Topics: Acetals; Acids; Alkaloids; Ethers, Cyclic; Nitrogen; Piperidines; Quinazolines; Stereoisomerism | 2001 |
Effects of calcitonin gene-related peptide and BIBN4096BS on myocardial ischemia in anesthetized rats.
Topics: Animals; Calcitonin Gene-Related Peptide; Cardiotonic Agents; Creatine Kinase; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Piperazines; Piperidines; Quinazolines; Rats; Rats, Wistar | 2001 |
Effects of intracavernous administration of adrenomedullin on erectile function in rats.
Topics: Adrenomedullin; Animals; Arginine; Cyclic GMP; Disease Models, Animal; Enzyme Inhibitors; Erectile Dysfunction; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Penile Erection; Peptides; Phosphodiesterase Inhibitors; Piperidines; Quinazolines; Rats; Rats, Wistar | 2001 |
Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats.
Topics: Animals; Antineoplastic Agents; Blood Proteins; Chromatography, High Pressure Liquid; Male; Mice; Piperidines; Protein Binding; Quinazolines; Quinazolinones; Rats; Rats, Inbred F344; Tissue Distribution | 2001 |
Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts.
Topics: Animals; Cells, Cultured; Collagen; Collagen Type I; DNA-Binding Proteins; Fibroblasts; Gene Expression; Hyperplasia; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Mutant Strains; Piperidines; Quinazolines; Quinazolinones; Receptors, Transforming Growth Factor beta; Sclerosis; Signal Transduction; Skin; Skin Diseases; Smad3 Protein; Trans-Activators; Transforming Growth Factor beta | 2002 |
Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biological Availability; Cell Division; Cells, Cultured; Dogs; Endothelium, Vascular; Enzyme Inhibitors; Humans; Male; Mice; Mice, Nude; Piperidines; Proto-Oncogene Proteins; Quinazolines; Rats; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-1 | 2002 |
A glutamate receptor subtype antagonist inhibits seizures in rat hippocampal slices.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Anticonvulsants; Electrophysiology; Excitatory Amino Acid Antagonists; In Vitro Techniques; Magnesium; Male; Membrane Potentials; Piperidines; Quinazolines; Rats; Rats, Wistar; Receptors, AMPA; Receptors, Glutamate; Seizures | 2002 |
Growth inhibition of prostate cancer xenografts by halofuginone.
Topics: Adenocarcinoma; Administration, Oral; Androgens; Animals; Antineoplastic Agents; Apoptosis; Collagen Type I; Disease Progression; DNA, Neoplasm; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization; Injections, Intraperitoneal; Male; Mice; Mice, SCID; Necrosis; Neovascularization, Pathologic; Phenotype; Piperidines; Prostatic Neoplasms; Quinazolines; Quinazolinones | 2002 |
Diacylglycerol kinase alpha activity promotes survival of CD4+ 8+ double positive cells during thymocyte development.
Topics: Animals; bcl-X Protein; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Differentiation; Cell Survival; Cells, Cultured; Diacylglycerol Kinase; Enzyme Inhibitors; Gene Expression Regulation; Genes, bcl-2; Isoenzymes; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Mice; Mice, Inbred BALB C; Mice, Transgenic; Piperidines; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Quinazolinones; Receptors, Antigen, T-Cell, alpha-beta; Signal Transduction; T-Lymphocytes | 2002 |
Analysis of the effect of halofuginone on bleomycin-induced scleroderma.
Topics: Animals; Bleomycin; Collagen; Disease Models, Animal; Female; Injections, Intraperitoneal; Injections, Subcutaneous; Mice; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Scleroderma, Systemic; Specific Pathogen-Free Organisms; Treatment Outcome | 2002 |
Potent antimalarial febrifugine analogues against the plasmodium malaria parasite.
Topics: Animals; Antimalarials; Cell Line; Malaria; Mice; Piperidines; Plasmodium berghei; Plasmodium falciparum; Quinazolines; Structure-Activity Relationship | 2002 |
Binding properties of the novel, non-peptide CGRP receptor antagonist radioligand, [(3)H]BIBN4096BS.
Topics: Animals; Binding, Competitive; Brain; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Callithrix; Cerebral Cortex; Dura Mater; Female; Humans; Hydrogen-Ion Concentration; Iodine Radioisotopes; Kinetics; Male; Piperazines; Piperidines; Quinazolines; Radioligand Assay; Receptors, Calcitonin Gene-Related Peptide; Spleen; Tritium; Tumor Cells, Cultured | 2002 |
Characterization of some novel alpha 1-adrenoceptor antagonists in human hyperplastic prostate.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Aorta; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Male; Piperazines; Piperidines; Prostatic Hyperplasia; Quinazolines; Rats; Receptors, Adrenergic, alpha-1; Spleen; Vas Deferens | 2002 |
Re-revision of the stereo structure of piperidine lactone, an intermediate in the synthesis of febrifugine.
Topics: Antimalarials; Indicators and Reagents; Lactones; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Piperidines; Quinazolines | 2002 |
Halofuginone does not reduce fibrosis in bleomycin-induced lung injury.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Bleomycin; Blotting, Northern; Bronchoalveolar Lavage Fluid; Cell Count; Collagen; Fibroblasts; Gene Expression Regulation; Hydroxyproline; Intubation, Intratracheal; Lung; Male; Piperidines; Pulmonary Fibrosis; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; RNA; Transforming Growth Factor beta | 2002 |
Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats.
Topics: Animals; Collagen Type I; Extracellular Matrix; Liver Cirrhosis; Liver Regeneration; Male; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Thioacetamide | 2002 |
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Division; Endothelial Growth Factors; Enzyme Inhibitors; Female; Humans; Lymphokines; Male; Mice; Neoplasms, Experimental; Neovascularization, Pathologic; Piperidines; Quinazolines; Rats; Rats, Wistar; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays | 2002 |
Effect of novel modulators of protein kinase C activity upon chemotherapy-induced differentiation and apoptosis in myeloid leukemic cells.
Topics: Antineoplastic Agents; Apoptosis; CD11c Antigen; CD4 Antigens; Cell Cycle; Cell Differentiation; Diacylglycerol Kinase; Enzyme Activators; Enzyme Inhibitors; Farnesol; Flow Cytometry; Genes, fos; Genes, jun; Humans; Immunoblotting; Isoenzymes; Leukemia, Myeloid; Naphthalenes; Oncogene Protein p21(ras); Piperidines; Protein Kinase C; Pyrimidinones; Quinazolines; Quinazolinones; Sulfonamides; Thiazoles; Triazoles; Tumor Cells, Cultured | 2002 |
Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism.
Topics: Administration, Topical; Animals; Cells, Cultured; Collagen; Collagen Type I; Drug Synergism; Fibroblasts; Gene Expression; Male; Mice; Mice, Mutant Strains; Mitogens; Phosphorylation; Piperidines; Promoter Regions, Genetic; Protein Synthesis Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-jun; Quinazolines; Quinazolinones; RNA, Messenger; Scleroderma, Systemic; Transcription Factor AP-1; Transcriptional Activation; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2002 |
Effect of halofuginone on the development of tight skin (TSK) syndrome.
Topics: Animals; Animals, Newborn; Collagen; Disease Models, Animal; Fibrosis; Humans; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Scleroderma, Systemic; Skin Diseases | 2002 |
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
Topics: 3T3 Cells; Animals; Carcinoma, Papillary; Cell Transformation, Neoplastic; Drosophila Proteins; Enzyme Inhibitors; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Piperidines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2002 |
p38 Inhibitors: piperidine- and 4-aminopiperidine-substituted naphthyridinones, quinolinones, and dihydroquinazolinones.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Biological Availability; Dogs; Enzyme Inhibitors; Half-Life; Macaca mulatta; Mitogen-Activated Protein Kinases; Naphthyridines; p38 Mitogen-Activated Protein Kinases; Piperidines; Quinazolines; Quinolones; Rats; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2003 |
Endothelial responses of the aorta from adrenomedullin transgenic mice and knockout mice.
Topics: Acetylcholine; Adrenomedullin; Animals; Aorta, Thoracic; Calcitonin Gene-Related Peptide; Endothelium, Vascular; Enzyme Inhibitors; Male; Mice; Mice, Knockout; Mice, Transgenic; Miotics; Muscle Contraction; NG-Nitroarginine Methyl Ester; Peptide Fragments; Peptides; Phosphodiesterase Inhibitors; Piperidines; Quinazolines; Vasoconstriction; Vasodilator Agents | 2003 |
Monocytic activation of protein tyrosine kinase, protein kinase A and protein kinase C induced by porins isolated from Salmonella enterica serovar Typhimurium.
Topics: Blotting, Western; Cyclic AMP-Dependent Protein Kinases; Electrophoresis, Polyacrylamide Gel; Electrophoretic Mobility Shift Assay; Enzyme Activation; Enzyme Inhibitors; Humans; Isoquinolines; L-Lactate Dehydrogenase; Lipopolysaccharides; Monocytes; Naphthalenes; Piperidines; Porins; Protein Kinase C; Protein-Tyrosine Kinases; Quinazolines; Quinazolinones; Salmonella typhimurium; Signal Transduction; Sulfonamides; Tyrphostins; U937 Cells | 2003 |
A medical compound derived from herbs.
Topics: Animals; Antineoplastic Agents; Coccidiosis; Coccidiostats; Drugs, Chinese Herbal; Humans; Phytotherapy; Piperidines; Poultry; Poultry Diseases; Quinazolines; Quinazolinones; Veterinary Drugs | 2003 |
Development and validation of a method for the confirmation of halofuginone in chicken liver and eggs using electrospray tandem mass spectrometry.
Topics: Calibration; Coccidiostats; Eggs; Liver; Piperidines; Quinazolines; Quinazolinones; Spectrometry, Mass, Electrospray Ionization | 2003 |
Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs?
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; ErbB Receptors; Humans; Inhibitory Concentration 50; Neoplasms; Piperidines; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
Topics: Agar; Animals; Antibodies, Monoclonal; Apoptosis; Blotting, Western; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; NIH 3T3 Cells; Paclitaxel; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
Activation of mitogen-activated protein kinase by cholinergic agonists and EGF in human compared with rat cultured conjunctival goblet cells.
Topics: Adult; Aged; Aged, 80 and over; Animals; Blotting, Western; Carbachol; Cells, Cultured; Cholinergic Agonists; Conjunctiva; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Goblet Cells; Humans; Male; Middle Aged; Mitogen-Activated Protein Kinases; Muscarinic Antagonists; Piperidines; Quinazolines; Rats; Rats, Sprague-Dawley; Time Factors; Tyrphostins | 2003 |
Different responses of three rodent Plasmodia species, Plasmodium yoelii 17XL, P. berghei NK65 and P. chabaudi AS on treatment with febrifugine and isofebrifugine mixture from Hydrangea macrophylla var. Otaksa leaf in ICR mice.
Topics: Administration, Oral; Animals; Antimalarials; Hydrangea; Malaria; Male; Mice; Mice, Inbred ICR; Parasitic Sensitivity Tests; Phytotherapy; Piperidines; Plant Extracts; Plant Leaves; Plasmodium; Plasmodium berghei; Plasmodium chabaudi; Plasmodium yoelii; Quinazolines | 2003 |
Metabolites of febrifugine and its synthetic analogue by mouse liver S9 and their antimalarial activity against Plasmodium malaria parasite.
Topics: Administration, Oral; Animals; Antimalarials; Antineoplastic Agents; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Liver; Mammary Neoplasms, Experimental; Mice; Nuclear Magnetic Resonance, Biomolecular; Piperidines; Plasmodium berghei; Plasmodium falciparum; Quinazolines; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 2003 |
[The antineoplastic activity of the alkaloid febrifugine in experiments on animals].
Topics: Alkaloids; Animals; Antineoplastic Agents; Piperidines; Quinazolines | 1960 |
Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo.
Topics: Animals; Antineoplastic Agents; Cell Division; Collagen; Collagen Type I; Disease Progression; Electrophoresis, Polyacrylamide Gel; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Pheochromocytoma; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Rats; Temperature; Time Factors; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein | 2003 |
The use of halofuginone in limiting urethral stricture formation and recurrence: an experimental study in rabbits.
Topics: Administration, Oral; Animals; Electrocoagulation; Fibrosis; Male; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Rabbits; Secondary Prevention; Urethra; Urethral Stricture | 2003 |
Hormonal regulation and functional role of vascular endothelial growth factor a in the rat testis.
Topics: Animals; Capillary Permeability; Chorionic Gonadotropin; Male; Piperidines; Quinazolines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Signal Transduction; Testis; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours.
Topics: Adenocarcinoma; Animals; Capillary Permeability; Contrast Media; Dose-Response Relationship, Drug; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Mice; Neoplasms, Experimental; Piperidines; Prostatic Neoplasms; Quinazolines; Reproducibility of Results; Signal Transduction; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2003 |
Combination effects of chloroquine with the febrifugine and isofebrifugine mixture against a blood-induced infection with chloroquine-resistant Plasmodium berghei NK65 in ICR mice.
Topics: Animals; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Malaria; Male; Mice; Mice, Inbred ICR; Parasitic Sensitivity Tests; Phytotherapy; Piperidines; Plasmodium berghei; Quinazolines | 2003 |
Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone.
Topics: Animals; Blotting, Northern; Blotting, Western; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Cells, Cultured; COS Cells; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Fibrosis; Gene Deletion; Genes, Reporter; Humans; Immunoblotting; MAP Kinase Signaling System; Mice; Mice, Inbred C3H; Microscopy, Confocal; Microscopy, Fluorescence; Piperidines; Plasmids; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Radiation Pneumonitis; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Smad3 Protein; Time Factors; Trans-Activators; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2004 |
Halofuginone, an inhibitor of collagen synthesis by rat stellate cells, stimulates insulin-like growth factor binding protein-1 synthesis by hepatocytes.
Topics: Animals; Cell Movement; Collagen Type I; Hepatocytes; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Protein 3; Male; Oligonucleotide Array Sequence Analysis; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Rats; Rats, Wistar; Thioacetamide; Tissue Inhibitor of Metalloproteinase-2 | 2004 |
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Topics: Adenocarcinoma; Agar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Cell Division; Cell Line, Tumor; Cell Membrane; Cetuximab; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Humans; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Piperidines; Precipitin Tests; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors | 2004 |
The effect of halofuginone, a specific inhibitor of collagen type 1 synthesis, in the prevention of esophageal strictures related to caustic injury.
Topics: Animals; Burns, Chemical; Caustics; Collagen Type I; Esophageal Stenosis; Esophagus; Fibrosis; Injections, Intraperitoneal; Male; Models, Animal; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Sodium Hydroxide | 2004 |
CGRP-receptor antagonists--a fresh approach to migraine therapy?
Topics: Acute Disease; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Female; Humans; Male; Migraine Disorders; Piperazines; Piperidines; Quinazolines; Receptors, Calcitonin Gene-Related Peptide | 2004 |
Diacylglycerol kinase gamma serves as an upstream suppressor of Rac1 and lamellipodium formation.
Topics: Animals; Blotting, Western; cdc42 GTP-Binding Protein; Cell Movement; COS Cells; Diacylglycerol Kinase; Fibronectins; Genes, Dominant; Glutathione Transferase; Green Fluorescent Proteins; Humans; Luminescent Proteins; Mice; Microscopy, Fluorescence; Mutation; NIH 3T3 Cells; Piperidines; Plasmids; Platelet-Derived Growth Factor; Precipitin Tests; Protein Binding; Pseudopodia; Quinazolines; Quinazolinones; rac1 GTP-Binding Protein; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Transfection | 2004 |
Inhibition of VEGFR2 prevents DMBA-induced mammary tumor formation.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Base Sequence; Carcinoma in Situ; DNA Primers; Female; Humans; Hyperplasia; Mammary Neoplasms, Experimental; Neovascularization, Pathologic; Piperidines; Quinazolines; Rats; Rats, Sprague-Dawley; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells.
Topics: Cell Cycle Proteins; Cell Line, Tumor; Cyclin D; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Cysteine Endopeptidases; Enzyme Inhibitors; Gene Rearrangement; Humans; MAP Kinase Signaling System; Multienzyme Complexes; Oncogene Proteins, Fusion; Piperidines; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Thyroid Neoplasms; Tumor Suppressor Proteins; Up-Regulation | 2004 |
Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone.
Topics: alpha-Fetoproteins; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Coccidiostats; Drug Screening Assays, Antitumor; Humans; Interferon-gamma; Interleukin-2; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Piperidines; Quinazolines; Quinazolinones | 2004 |
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.
Topics: Carcinoma, Medullary; Catalytic Domain; Cell Line; Drug Resistance; Enzyme Inhibitors; Mitogens; Piperidines; Point Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Thyroid Neoplasms; Valine | 2004 |
Ureteral replacement using small-intestinal submucosa and a collagen inhibitor in a porcine model.
Topics: Animals; Collagen Type I; Female; Intestinal Mucosa; Intestine, Small; Piperidines; Postoperative Complications; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Swine; Ureter; Ureteral Obstruction | 2004 |
The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Division; Disease Models, Animal; Enzyme Inhibitors; Glioma; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Rats | 2004 |
Phospholipid mediators and MgATPase modulation causes changes in the cardiovascular effects of vasopressin in lithium carbonate-induced polyuric rats.
Topics: Animals; Arginine Vasopressin; Blood Pressure; Ca(2+) Mg(2+)-ATPase; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Heart Rate; Injections, Intraperitoneal; Injections, Intravenous; Lithium Carbonate; Lypressin; Mice; Motor Activity; Neomycin; Phospholipids; Piperidines; Polyuria; Quinazolines; Quinazolinones; Rats; Rats, Wistar; Sphingosine | 2004 |
Determination of halofuginone in eggs by liquid chromatography/tandem mass spectrometry after cleanup with immunoaffinity chromatography.
Topics: Animals; Chickens; Chromatography, Affinity; Chromatography, High Pressure Liquid; Coccidiostats; Eggs; Piperidines; Quinazolines; Quinazolinones; Spectrometry, Mass, Electrospray Ionization | 2004 |
Cytokine and antibody production during the course of resolution in Plasmodium yoelii 17XL-infected BALB/c mice treated with febrifugine and isofebrifugine mixture from leaves of Hydrangea macrophylla var. Otaksa.
Topics: Animals; Antibodies, Protozoan; Cytokines; Female; Hydrangea; Malaria; Mice; Mice, Inbred BALB C; Phytotherapy; Piperidines; Plant Leaves; Plasmodium yoelii; Quinazolines | 2004 |
Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of halofuginone in plasma.
Topics: Animals; Chromatography, Liquid; Coccidiostats; Dogs; Indicators and Reagents; Mass Spectrometry; Molecular Weight; Piperidines; Quinazolines; Quinazolinones; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization | 2004 |
ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Capillaries; Cell Proliferation; Endothelial Cells; ErbB Receptors; Humans; Mice; Neovascularization, Pathologic; Pericytes; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Stomach Neoplasms; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
Studies in human malaria. XXV. Trial of febrifugine, an alkaloid obtained from Dichroa febrifuga lour., against the Chesson strain of Plasmodium vivax.
Topics: Alkaloids; Malaria; Piperidines; Plants; Plasmodium vivax; Quinazolines | 1950 |
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.
Topics: Angiogenesis Inhibitors; Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Disease Progression; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Melanoma; Mice; Mice, Inbred BALB C; Necrosis; Neoplasm Metastasis; Neovascularization, Pathologic; Oligonucleotides, Antisense; Phenotype; Piperidines; Placebos; Quinazolines; RNA; Transfection; Treatment Outcome; Vascular Endothelial Growth Factor A | 2004 |
Halofuginone can worsen liver fibrosis in bile duct obstructed rats.
Topics: Aminopyrine; Animals; Bile Ducts; Breath Tests; Cholestasis, Extrahepatic; Collagen Type I; Collagen Type III; Disease Models, Animal; Ligation; Liver; Liver Cirrhosis, Biliary; Liver Cirrhosis, Experimental; Male; Piperidines; Portal Pressure; Quinazolines; Quinazolinones; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2004 |
In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blood Vessels; Cell Line, Transformed; Disease Models, Animal; Female; Liver Neoplasms; Mice; Mice, SCID; Microscopy, Video; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Organophosphorus Compounds; Piperidines; Quinazolines | 2004 |
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Female; Humans; Kidney Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Organophosphorus Compounds; Piperidines; Quinazolines; Sarcoma, Kaposi | 2004 |
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gefitinib; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Tyrosine; Xenograft Model Antitumor Assays | 2004 |
Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.
Topics: Base Sequence; Cell Line, Tumor; Gefitinib; Gene Deletion; Genes, erbB-1; Humans; Molecular Sequence Data; Neoplasms; Piperidines; Quinazolines; Transfection; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Endothelial Cells; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Oxygen; Piperidines; Quinazolines; Radiotherapy; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2004 |
Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.
Topics: Androgens; Angiogenesis Inhibitors; Animals; Castration; Cell Division; Combined Modality Therapy; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Orchiectomy; Piperidines; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2004 |
Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer.
Topics: Carcinoma, Medullary; Carcinoma, Papillary; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Mutation; Piperidines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor Protein-Tyrosine Kinases; Sensitivity and Specificity; Thyroid Neoplasms; Treatment Outcome | 2004 |
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Piperidines; Pyrazoles; Quinazolines; Sulfonamides; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2005 |
Halofuginone inhibits collagen deposition in fibrous capsules around implants.
Topics: Animals; Collagen Type I; Colorimetry; Fibrosis; Male; Muscles; Piperidines; Prostheses and Implants; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Silicone Elastomers; Subcutaneous Tissue; Transforming Growth Factor beta | 2005 |
Antimalarial activities and therapeutic properties of febrifugine analogs.
Topics: Animals; Antimalarials; Cell Line; Macrophages; Mice; Mice, Inbred ICR; Piperidines; Quinazolines | 2005 |
Screening for the coccidiostats halofuginone and nicarbazin in egg and chicken muscle: development of an ELISA.
Topics: Animals; Antibodies; Carbanilides; Chickens; Coccidiostats; Cross Reactions; Drug Residues; Eggs; Enzyme-Linked Immunosorbent Assay; Food Contamination; Muscles; Nicarbazin; Piperidines; Quinazolines; Quinazolinones; Reproducibility of Results | 2005 |
Activation of HIF-prolyl hydroxylases by R59949, an inhibitor of the diacylglycerol kinase.
Topics: Cell Line; Diacylglycerol Kinase; Enzyme Activation; Enzyme Inhibitors; Humans; Immunoprecipitation; Piperidines; Procollagen-Proline Dioxygenase; Quinazolines; Quinazolinones; RNA, Messenger; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Von Hippel-Lindau Tumor Suppressor Protein | 2005 |
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.
Topics: Animals; Carcinoma, Lewis Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Endothelial Cells; Flow Cytometry; Immunohistochemistry; Leukocyte Common Antigens; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Neovascularization, Pathologic; Piperidines; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-kit; Quinazolines; Stem Cells; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2005 |
ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.
Topics: Animals; Carcinoma, Papillary; Disease Models, Animal; Drosophila; Drosophila Proteins; ErbB Receptors; Eye Abnormalities; Multiple Endocrine Neoplasia Type 2a; Multiple Endocrine Neoplasia Type 2b; Piperidines; Protein Isoforms; Proto-Oncogene Proteins c-ret; Quinazolines; raf Kinases; ras Proteins; Receptor Protein-Tyrosine Kinases; Thyroid Neoplasms | 2005 |
The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma.
Topics: Animals; Blood Vessels; Carcinoma, Renal Cell; Cell Division; Enzyme Inhibitors; Humans; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Microscopy, Electron, Scanning; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Quinazolines | 2004 |
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cetuximab; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Piperidines; Quinazolines; Taxoids | 2005 |
Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues.
Topics: Acetates; Animals; Antineoplastic Agents; Calibration; Chemistry, Pharmaceutical; Chromatography; Chromatography, Liquid; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; Ions; Liver; Mass Spectrometry; Mice; Mice, Inbred BALB C; Models, Chemical; Neoplasms; Pentanes; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Time Factors; Tissue Distribution; Trazodone | 2005 |
A novel Src kinase inhibitor, M475271, inhibits VEGF-induced human umbilical vein endothelial cell proliferation and migration.
Topics: Cell Line; Cell Movement; Cell Proliferation; Cells, Cultured; Endothelium, Vascular; Enzyme Inhibitors; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Piperidines; Quinazolines; src-Family Kinases; Vascular Endothelial Growth Factor A | 2005 |
The role of Akt and mitogen-activated protein kinase systems in the protective effect of poly(ADP-ribose) polymerase inhibition in Langendorff perfused and in isoproterenol-damaged rat hearts.
Topics: Animals; Energy Metabolism; Enzyme Inhibitors; Heart; Hydrogen Peroxide; Isoproterenol; Lipid Peroxidation; Male; Mitogen-Activated Protein Kinases; Myocardium; Perfusion; Phosphorylation; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Protective Agents; Proteins; Quinazolines; Rats; Rats, Sprague-Dawley | 2005 |
In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Coagulation; Cells, Cultured; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Endothelial Cells; Gemcitabine; Humans; Indoles; Oxindoles; Piperidines; Propionates; Pyrroles; Quinazolines; Thromboplastin | 2005 |
Concise synthesis of dl-febrifugine.
Topics: Antimalarials; Molecular Structure; Piperidines; Quinazolines | 2005 |
ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model.
Topics: Biomarkers, Tumor; Carcinoma, Signet Ring Cell; Gene Expression Profiling; Humans; Neoplasm Metastasis; Neoplasms, Experimental; Peritoneal Neoplasms; Piperidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Tumor Cells, Cultured | 2006 |
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Collagen; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Female; Glioblastoma; Humans; Immunohistochemistry; In Vitro Techniques; Laminin; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Proteoglycans; Quinazolines; Radiation, Ionizing; Time Factors; Vascular Endothelial Growth Factor A | 2005 |
Selective type 5 phosphodiesterase inhibition alters pulmonary hemodynamics and lung liquid production in near-term fetal lambs.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Blood Flow Velocity; Bronchoalveolar Lavage Fluid; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Extravascular Lung Water; Lung; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperidines; Pulmonary Circulation; Quinazolines; Sheep | 2005 |
The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice.
Topics: Animals; Body Weight; Dermatologic Surgical Procedures; Female; Mice; Mice, Inbred BALB C; Microcirculation; Neovascularization, Physiologic; Piperidines; Quinazolines; Signal Transduction; Skin; Stress, Mechanical; Vascular Endothelial Growth Factor Receptor-2; Wound Healing; Wounds and Injuries | 2005 |
Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression.
Topics: Angiogenesis Inhibitors; Animals; Cell Line; Child, Preschool; Collagen; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; Injections, Intraperitoneal; Kidney Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Proto-Oncogene Proteins c-met; Quinazolines; Quinazolinones; Receptor, ErbB-2; Transplantation, Heterologous; Wilms Tumor; WT1 Proteins | 2005 |
Prevention of esophageal strictures in a caustic burn model using halofuginone, an inhibitor of collagen type I synthesis.
Topics: Animals; Burns, Chemical; Caustics; Collagen Type I; Esophageal Stenosis; In Vitro Techniques; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Radiography; Rats; Sodium Hydroxide; Transforming Growth Factor beta; Wound Healing | 2005 |
SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; In Vitro Techniques; Injections, Subcutaneous; Lung Neoplasms; Male; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Piperidines; Proto-Oncogene Mas; Quinazolines; src-Family Kinases; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2005 |
Antinociceptive, brain-penetrating derivatives related to improgan, a non-opioid analgesic.
Topics: Algorithms; Analgesics; Animals; Behavior, Animal; Benzothiazoles; Brain; Cimetidine; Dose-Response Relationship, Drug; Histamine H2 Antagonists; Injections, Intraventricular; Male; Mice; Molecular Structure; Pain; Pain Measurement; Phenoxypropanolamines; Piperidines; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Thiazoles; Time Factors; Triazoles | 2005 |
A novel class of sodium/calcium exchanger inhibitors: design, synthesis, and structure-activity relationships of 4-phenyl-3-(piperidin-4-yl)-3,4-dihydro-2(1H)-quinazolinone derivatives.
Topics: Drug Design; Enzyme Inhibitors; Inhibitory Concentration 50; Piperidines; Quinazolines; Sodium-Calcium Exchanger; Structure-Activity Relationship | 2006 |
Antimalarials: shortages and searches.
Topics: Antimalarials; Artemisia; Artemisinins; History, 20th Century; History, 21st Century; Humans; Hydrangea; Methaqualone; Piperidines; Plant Extracts; Quinazolines; Quinine; World War II | 2005 |
Molecule-kinase interaction map.
Topics: Animals; Computational Biology; Drug Design; ErbB Receptors; Genetic Variation; Humans; Microchemistry; Mutation; Pharmaceutical Preparations; Piperidines; Programming Languages; Protein Interaction Mapping; Quinazolines; Software; Vascular Endothelial Growth Factor Receptor-2 | 2005 |
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Ependymoma; ErbB Receptors; Glioma; Humans; Immunohistochemistry; Ki-67 Antigen; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Phosphorylation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2005 |
ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Adhesion; Cell Adhesion Molecules; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Extracellular Matrix Proteins; Humans; Immunoprecipitation; Inhibitory Concentration 50; Kalinin; Liver Neoplasms; Neoplasm Invasiveness; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors | 2006 |
Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Small Cell; Cell Line, Tumor; Cell Proliferation; Endothelium, Vascular; Humans; Killer Cells, Natural; Lung Neoplasms; Lymphocyte Depletion; Mice; Mice, SCID; Neovascularization, Pathologic; Piperidines; Quinazolines; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Xenograft Model Antitumor Assays | 2005 |
ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy.
Topics: Angiogenesis Inhibitors; Animals; Combined Modality Therapy; ErbB Receptors; Humans; Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Up-Regulation; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
ZD6474 headed for phase III trials in the fall.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Humans; Lung Neoplasms; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction | 2005 |
Halofuginone inhibits tumor growth in the polyoma middle T antigen mouse via a thrombospondin-1 independent mechanism.
Topics: Animals; Antigens, Viral, Tumor; Antineoplastic Agents; Breast Neoplasms; Collagen Type I; Mice; Mice, Transgenic; Neovascularization, Pathologic; Piperidines; Polyomavirus; Quinazolines; Quinazolinones; Smad2 Protein; Smad3 Protein; Thrombospondin 1; Transforming Growth Factor beta; Tumor Burden | 2006 |
Synthesis and evaluation of febrifugine analogues as potential antimalarial agents.
Topics: Animals; Antimalarials; Drug Evaluation, Preclinical; Hepatocytes; Magnetic Resonance Spectroscopy; Piperidines; Plasmodium falciparum; Quinazolines; Rats | 2006 |
Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB.
Topics: Animals; Cell Line; Cell Movement; Cell Proliferation; Cells, Cultured; Collagenases; Enzyme Induction; Hepatocytes; Liver Cirrhosis; Male; MAP Kinase Signaling System; Matrix Metalloproteinase 13; Matrix Metalloproteinase 3; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Piperidines; Quinazolines; Quinazolinones; Rats; Rats, Wistar; RNA, Messenger; Signal Transduction | 2006 |
A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer.
Topics: Amino Acid Substitution; Animals; Cell Line; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Piperidines; Point Mutation; Protein Structure, Tertiary; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyrimidines; Quinazolines; Recombinant Proteins; Spodoptera; Thyroid Neoplasms | 2006 |
Suppression of neuronal network excitability and seizure-like events by 2-methyl-4-oxo-3H-quinazoline-3-acetyl piperidine in juvenile rat hippocampus: involvement of a metabotropic glutamate receptor.
Topics: Age Factors; Animals; Anticonvulsants; Binding Sites; Calcium Channels; Cell Membrane; Epilepsy; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic Acid; Guanosine Triphosphate; Hippocampus; Male; Nerve Net; Neural Inhibition; Organ Culture Techniques; Patch-Clamp Techniques; Piperidines; Protein Subunits; Pyramidal Cells; Quinazolines; Rats; Rats, Wistar; Receptors, Metabotropic Glutamate; Synaptic Transmission | 2006 |
Tissue distribution and metabolism of the tyrosine kinase inhibitor ZD6474 (Zactima) in tumor-bearing nude mice following oral dosing.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Area Under Curve; Chromatography, Liquid; Dose-Response Relationship, Drug; Drug Delivery Systems; Estradiol; Feces; Female; Liver; Mass Spectrometry; Mice; Mice, Inbred BALB C; Mice, Nude; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Reproducibility of Results; Tissue Distribution; Transplantation, Heterologous | 2006 |
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Evaluation, Preclinical; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Nude; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2006 |
PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.
Topics: Animals; Cardiomegaly; Collagen Type III; Electrocardiography; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Heart Failure; Isoproterenol; Male; Mitogen-Activated Protein Kinases; Myocardial Infarction; Natriuretic Peptide, Brain; Phosphorylation; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinase C; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Ventricular Remodeling | 2006 |
Inhibition of rat renal fibroblast proliferation by halofuginone.
Topics: Animals; Cell Proliferation; Cells, Cultured; Collagen Type I; Fibroblasts; Kidney Medulla; Male; Matrix Metalloproteinase Inhibitors; Piperidines; Platelet-Derived Growth Factor; Quinazolines; Quinazolinones; Rats; Rats, Wistar | 2006 |
Halofuginone prevents subglottic stenosis in a canine model.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Dogs; Fibroblasts; Follow-Up Studies; Humans; In Vitro Techniques; Laryngostenosis; Mitomycin; Nucleic Acid Synthesis Inhibitors; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Treatment Outcome | 2006 |
VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy.
Topics: Angiogenesis Inhibitors; Animals; Colorectal Neoplasms; Combined Modality Therapy; Enzyme Inhibitors; Female; HT29 Cells; Humans; Mice; Mice, Inbred Strains; Mice, Nude; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy Dosage; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Liver Neoplasms; Lung Neoplasms; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Matrix Metalloproteinases, Membrane-Associated; Neoplasm Metastasis; Piperidines; Quinazolines; Quinazolinones; Rats; Rats, Inbred F344 | 2006 |
Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells.
Topics: Apoptosis; Chemotaxis; Cytokines; Dose-Response Relationship, Drug; Humans; Lymphocyte Activation; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Piperidines; Quinazolines; Quinazolinones; Signal Transduction; T-Lymphocytes | 2006 |
ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Piperidines; Pleural Effusion, Malignant; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.
Topics: ADAM Proteins; ADAM17 Protein; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Gene Expression; Humans; Ligands; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Paclitaxel; Piperidines; Protease Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Signal Transduction; Spiro Compounds; Xenograft Model Antitumor Assays | 2006 |
Exploration of a new type of antimalarial compounds based on febrifugine.
Topics: Animals; Antimalarials; Cell Line; Malaria; Mice; Parasitic Sensitivity Tests; Piperidines; Plasmodium berghei; Plasmodium falciparum; Pyrimidinones; Quinazolines; Stereoisomerism; Structure-Activity Relationship; Thiophenes; Toxicity Tests, Acute | 2006 |
Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; ErbB Receptors; G2 Phase; Humans; Organoplatinum Compounds; Oxaliplatin; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2006 |
Two targets, one drug for new EGFR inhibitors.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; ErbB Receptors; Humans; Lapatinib; Piperidines; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor | 2006 |
Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts.
Topics: Animals; Cisplatin; Colonic Neoplasms; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Semaphorin-3A; Signal Transduction; Triazoles; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2006 |
Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chromatography, High Pressure Liquid; Colonic Neoplasms; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Piperidines; Quinazolines; Signal Transduction; Time Factors | 2006 |
The novel Src kinase inhibitor M475271 inhibits VEGF-induced vascular endothelial-cadherin and beta-catenin phosphorylation but increases their association.
Topics: beta Catenin; Cadherins; Cell Movement; Cell Proliferation; Electrophoresis, Polyacrylamide Gel; Endothelium, Vascular; Humans; Intercellular Junctions; Microscopy, Confocal; Neovascularization, Physiologic; Phosphorylation; Piperidines; Quinazolines; Signal Transduction; src-Family Kinases; Vascular Endothelial Growth Factor A | 2006 |
ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Proliferation; Drug Therapy, Combination; Gastrointestinal Stromal Tumors; Humans; Indoles; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphoproteins; Phosphorylation; Piperidines; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Ribosomal Protein S6 Kinases, 70-kDa; STAT3 Transcription Factor; Sunitinib; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2006 |
Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer.
Topics: Carcinoma; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms; Vascular Endothelial Growth Factor A | 2006 |
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Deoxycytidine Kinase; Disease Models, Animal; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gemcitabine; Gene Expression Profiling; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Piperidines; Polymerase Chain Reaction; Predictive Value of Tests; Quinazolines; Radiation, Ionizing; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Transplantation, Heterologous | 2006 |
Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclin D; Cyclin-Dependent Kinases; Cyclins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutant Proteins; Mutation, Missense; Oligonucleotide Array Sequence Analysis; Piperidines; Quinazolines; Signal Transduction; Transcription, Genetic; Transfection | 2006 |
Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma; Castration; Combined Modality Therapy; Dose-Response Relationship, Drug; Male; Piperidines; Prostatic Neoplasms; Quinazolines; Rats; Xenograft Model Antitumor Assays | 2006 |
Antitumor effects of ZD6474 on head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Models, Chemical; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Quinazolines | 2007 |
Pharmacological characterisation of capsaicin-induced relaxations in human and porcine isolated arteries.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Animals; Arteries; Calcitonin Gene-Related Peptide; Capsaicin; Coronary Vessels; Cyclic AMP; Dipeptides; Dose-Response Relationship, Drug; Female; Humans; In Vitro Techniques; Male; Middle Aged; NG-Nitroarginine Methyl Ester; Piperazines; Piperidines; Potassium Channel Blockers; Potassium Chloride; Protein Kinase Inhibitors; Quinazolines; Swine; Vasodilation | 2007 |
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Endothelium, Vascular; ErbB Receptors; Flow Cytometry; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Inbred CBA; Neovascularization, Pathologic; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2007 |
Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening.
Topics: Amino Acid Sequence; CCR5 Receptor Antagonists; Models, Molecular; Molecular Sequence Data; Molecular Structure; Piperazines; Piperidines; Protein Structure, Tertiary; Pyridazines; Pyrrolidines; Quantitative Structure-Activity Relationship; Quinazolines; Receptors, CCR5; Sequence Homology, Amino Acid; Triazoles | 2007 |
Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Piperidines; Pulmonary Embolism; Quinazolines; Skin Neoplasms; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2007 |
ZD6474 induces growth arrest and apoptosis of human leukemia cells, which is enhanced by concomitant use of a novel MEK inhibitor, AZD6244.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Proliferation; Drug Synergism; Humans; Leukemia; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Piperidines; Quinazolines; Tumor Cells, Cultured | 2007 |
Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
Topics: Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2008 |
Angiogenic inhibition reduces germinal matrix hemorrhage.
Topics: Aborted Fetus; Angiopoietin-2; Animals; Blotting, Western; Brain; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Endothelial Cells; Humans; Immunohistochemistry; Infant, Newborn; Infant, Premature; Intracranial Hemorrhages; Neovascularization, Physiologic; Piperidines; Pyrazoles; Quinazolines; Rabbits; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Piperidines; Quinazolines; Regional Blood Flow; Signal Transduction; Skin; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).
Topics: Animals; Calibration; Cell Proliferation; Colonic Neoplasms; Contrast Media; Disease Models, Animal; Heart Ventricles; Hemodynamics; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Male; Neoplasm Transplantation; Organometallic Compounds; Piperidines; Quinazolines; Rats; Rats, Nude | 2008 |
Novel inhibitors of VEGF receptors-1 and -2 based on azole-5-carboxamide templates.
Topics: Adenosine Triphosphate; Amides; Azoles; Binding, Competitive; Caco-2 Cells; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Models, Chemical; Phthalazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Survival Rate; Xenograft Model Antitumor Assays | 2007 |
A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.
Topics: Aged; Animals; Calcitonin; Carcinoma, Medullary; Cell Line, Tumor; Cell Transformation, Neoplastic; Chromogranin A; Disease Models, Animal; ErbB Receptors; Humans; Karyotyping; Male; Mice; Mice, Nude; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays | 2007 |
Suppression of spike-wave discharge activity and c-fos expression by 2-methyl-4-oxo-3H-quinazoline-3-acetyl piperidine (Q5) in vivo.
Topics: Animals; Anticonvulsants; Brain Chemistry; Dose-Response Relationship, Drug; Electroencephalography; Epilepsy, Absence; Gene Expression; Genes, fos; Immunohistochemistry; Nerve Net; Pain; Piperidines; Quinazolines; Rats; Rats, Inbred Strains; Stress, Psychological | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Biomedical Research; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Molecular Structure; Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Piperidines; Prednisolone; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2007 |
Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions.
Topics: Animals; Antibodies; Cell Line; Endothelial Cells; Gene Expression Regulation; Health; Humans; Hypertension; Kidney; Kidney Function Tests; Male; Microscopy, Electron, Transmission; Phosphorylation; Piperidines; Quinazolines; Rats; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; DNA Repair; Epidermal Growth Factor; ErbB Receptors; Feasibility Studies; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Pleural Effusion; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2007 |
ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein.
Topics: Adenosine Triphosphatases; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Proliferation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Piperidines; Quinazolines; Rhodamine 123; Tumor Cells, Cultured | 2007 |
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Administration Schedule; ErbB Receptors; Female; Humans; Irinotecan; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2007 |
Paucity of pericytes in germinal matrix vasculature of premature infants.
Topics: Animals; Antigens; Antigens, CD34; Autopsy; Blood-Brain Barrier; Cadherins; Cerebral Cortex; Female; Fetus; Gestational Age; Humans; Infant, Newborn; Lysophospholipids; Pericytes; Piperidines; Pregnancy; Premature Birth; Proteoglycans; Quinazolines; Rabbits; Sphingosine; Time Factors; Transforming Growth Factor beta1 | 2007 |
ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Multiple; Humans; Piperidines; Quinazolines | 2007 |
SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Colorimetry; Drug Synergism; Flow Cytometry; Humans; Indicators and Reagents; Lapatinib; Mutation; Oncogene Protein v-akt; Piperidines; Prenylation; Pyridines; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT3 Transcription Factor | 2008 |
8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes.
Topics: Administration, Oral; Animals; Caco-2 Cells; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Humans; Hypoglycemic Agents; Linagliptin; Macaca fascicularis; Macaca mulatta; Male; Models, Molecular; Piperidines; Purines; Quinazolines; Rats; Rats, Wistar; Stereoisomerism; Structure-Activity Relationship | 2007 |
Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Blood-Brain Barrier; Brain Neoplasms; Contrast Media; Dextrans; Ferrosoferric Oxide; Gadolinium DTPA; Glioma; Immunohistochemistry; Iron; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; Microcirculation; Oxides; Piperidines; Predictive Value of Tests; Quinazolines; Transplantation, Heterologous | 2008 |
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Humans; Mice; Neovascularization, Pathologic; Piperidines; Quinazolines; Temozolomide; Xenograft Model Antitumor Assays | 2008 |
Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.
Topics: Aminoquinolines; Animals; Biological Availability; Blood-Brain Barrier; Cell Line; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Fibroblasts; Folic Acid Antagonists; Heterozygote; Humans; Mice; Models, Molecular; Molecular Conformation; Muscular Atrophy, Spinal; Nerve Tissue Proteins; Permeability; Piperidines; Promoter Regions, Genetic; Quinazolines; RNA-Binding Proteins; SMN Complex Proteins; Spinal Muscular Atrophies of Childhood; Stereoisomerism; Structure-Activity Relationship; Survival of Motor Neuron 1 Protein; Survival of Motor Neuron 2 Protein; Tetrahydrofolate Dehydrogenase | 2008 |
Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; ErbB Receptors; Glioma; Neoplasm Transplantation; Piperidines; Quinazolines; Rats; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide | 2008 |
Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Drug Delivery Systems; Endothelium; ErbB Receptors; Humans; Male; Mice; Mice, Nude; Neuroblastoma; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2008 |
EGFR and VEGFR as potential target for biological therapies in HCC cells.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2008 |
Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Base Sequence; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Rearrangement; Humans; Male; Mesothelioma; Mice; Mice, SCID; Molecular Sequence Data; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Pleural Neoplasms; Proto-Oncogene Proteins c-ret; Quinazolines; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Piperidines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Signal Transduction | 2008 |
Differentiation of the diastereomeric synthetic precursors of isofebrifugine and febrifugine by electrospray ionization tandem mass spectrometry.
Topics: Antimalarials; Hydrangea; Isomerism; Molecular Structure; Piperidines; Plants, Medicinal; Quinazolines; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2008 |
Synthesis and evaluation of heteroaryl-ketone derivatives as a novel class of VEGFR-2 inhibitors.
Topics: Administration, Oral; Animals; Combinatorial Chemistry Techniques; Inhibitory Concentration 50; Ketones; Mice; Molecular Structure; Piperidines; Quinazolines; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
Asymmetric synthesis of (+)-isofebrifugine and (-)-sedacryptine from a common chiral nonracemic building block.
Topics: Alkaloids; Piperidines; Piperidones; Quinazolines; Stereoisomerism | 2008 |
Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib.
Topics: Animals; Base Sequence; Cell Line, Tumor; DNA Primers; Lymphatic Metastasis; Mice; Piperidines; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2008 |
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Immunoprecipitation; Neoplasms; Piperidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Transfection; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.
Topics: Animals; Apoptosis; Carcinoma, Small Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; In Situ Nick-End Labeling; Lung Neoplasms; Mice; Necrosis; Neovascularization, Pathologic; Piperidines; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2008 |
Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Adenoid Cystic; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Fluorescent Antibody Technique; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Parotid Neoplasms; Phosphorylation; Piperidines; Quinazolines; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2008 |
Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation.
Topics: Aminopyridines; Animals; Antidepressive Agents, Second-Generation; Astrocytes; Butadienes; Calcium; Cells, Cultured; Chelating Agents; Dipeptides; Dose-Response Relationship, Drug; Egtazic Acid; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Fluorobenzenes; Fluoxetine; Gene Expression; Indoles; Maleimides; Mice; Nitriles; Phosphorylation; Piperidines; Protein Kinase C; Proto-Oncogene Proteins c-fos; Quinazolines; Receptor, Serotonin, 5-HT2B; RNA, Messenger; Signal Transduction; Substrate Specificity; Transcriptional Activation; Tyrphostins; Up-Regulation; Urea | 2008 |
Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Muscle Neoplasms; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Tumor Cells, Cultured; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2008 |
Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Docetaxel; Endothelial Cells; Female; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Piperidines; Quinazolines; Taxoids; Xenograft Model Antitumor Assays | 2008 |
Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomegaly; Disease Models, Animal; Echocardiography; Enalapril; Enzyme Inhibitors; Fibrosis; Heart Failure; Male; Myocardial Infarction; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Ventricular Remodeling | 2008 |
Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.
Topics: Amino Acid Sequence; Drug Resistance, Neoplasm; HeLa Cells; Humans; Kidney; Molecular Sequence Data; Mutagenesis, Site-Directed; Neoplasms; Piperidines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-ret; Quinazolines; Structure-Activity Relationship; Tyrosine | 2009 |
Possible involvement of IFN-gamma in early mortality of Plasmodium berghei NK65-infected BALB/c mice after febrifugine treatment.
Topics: Animals; Antibodies, Protozoan; Antigens, Protozoan; Antimalarials; Interferon-gamma; Interleukin-4; Malaria; Male; Mice; Mice, Inbred BALB C; Parasitemia; Piperidines; Plasmodium berghei; Quinazolines | 2008 |
Potent and orally bioavailable CCR4 antagonists: Synthesis and structure-activity relationship study of 2-aminoquinazolines.
Topics: Administration, Oral; Amines; Animals; Anti-Inflammatory Agents; Chemotaxis; Dermatitis; Disease Models, Animal; Humans; Mice; Piperidines; Quinazolines; Receptors, CCR4; Structure-Activity Relationship | 2009 |
Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2.
Topics: Administration, Oral; Animals; Biological Availability; Female; Isoquinolines; Mice; Mice, Inbred Strains; Phthalazines; Piperidines; Quinazolines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Piperidines; Quinazolines; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factors | 2009 |
Synthesis and preclinical evaluation of [(11)C]PAQ as a PET imaging tracer for VEGFR-2.
Topics: Animals; Biological Transport; Carbon Radioisotopes; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Immunohistochemistry; Male; Mice; Microsomes; Neoplasms; Piperidines; Positron-Emission Tomography; Quinazolines; Radioactive Tracers; Radiochemistry; Rats; Tissue Distribution; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma.
Topics: Animals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Division; Cell Line, Tumor; Cholangiocarcinoma; ErbB Receptors; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Japan; Mice; Mice, Inbred BALB C; Mice, Nude; Piperidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function.
Topics: ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Multidrug Resistance-Associated Proteins; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2009 |
ZD6474 inhibits Src kinase leading to apoptosis of imatinib-resistant K562 cells.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Benzamides; Cell Cycle; DNA Primers; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Immunohistochemistry; K562 Cells; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; src-Family Kinases; Transplantation, Heterologous | 2009 |
Quinazolin-4-piperidin-4-methyl sulfamide PC-1 inhibitors: alleviating hERG interactions through structure based design.
Topics: Drug Design; Enzyme Inhibitors; Ether-A-Go-Go Potassium Channels; Humans; Long QT Syndrome; Osteoarthritis; Phosphoric Diester Hydrolases; Piperidines; Protein Binding; Pyrophosphatases; Quinazolines; Sulfonamides | 2009 |
Synthesis and comparison of antimalarial activity of febrifugine derivatives including halofuginone.
Topics: Animals; Antimalarials; Benzoates; Cell Line; Piperidines; Plasmodium falciparum; Quinazolines; Quinazolinones | 2009 |
PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats.
Topics: Administration, Oral; Animals; Blood Pressure; Cardiovascular Agents; Disease Models, Animal; Disease Progression; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Heart Failure; Hypertension; Hypertrophy, Left Ventricular; Isoenzymes; JNK Mitogen-Activated Protein Kinases; Male; Myocardium; Natriuretic Peptide, Brain; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinase C; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Rats, Inbred SHR; Signal Transduction; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2009 |
Quinazolindione derivatives as potent 5-HT3A receptor antagonists.
Topics: Animals; Mice; Molecular Structure; Oocytes; Piperidines; Quinazolines; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Small Molecule Libraries; Structure-Activity Relationship; Xenopus | 2009 |
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; NIH 3T3 Cells; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Transfection; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Enzyme-Linked Immunosorbent Assay; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Meta-Analysis as Topic; Piperidines; Predictive Value of Tests; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Synthesis and biological evaluation of febrifugine analogues as potential antimalarial agents.
Topics: Animals; Antimalarials; Drug Evaluation, Preclinical; Hydrangeaceae; Malaria; Mice; Molecular Structure; Parasitic Sensitivity Tests; Piperidines; Plasmodium falciparum; Quinazolines; Structure-Activity Relationship | 2009 |
Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Base Sequence; Cell Line, Tumor; DNA Primers; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Phosphorylation; Piperidines; Polymerase Chain Reaction; Quinazolines; Receptor, IGF Type 1; Signal Transduction | 2009 |
Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Line; Cell Line, Tumor; Dogs; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gefitinib; Humans; Irinotecan; Mitoxantrone; Neoplasm Proteins; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Time Factors | 2010 |
Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma.
Topics: Astrocytoma; Brain Neoplasms; Cellulase; Corneal Diseases; Corneal Opacity; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ointments; Piperidines; Quinazolines; Retrospective Studies; Sodium Chloride; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).
Topics: Animals; Carcinoma, Squamous Cell; Cell Movement; Colonic Neoplasms; Endothelium, Vascular; Female; Humans; Mice; Mice, Inbred C3H; Mice, Nude; Neovascularization, Pathologic; Piperidines; Quinazolines; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |
Severe photosensitivity reaction to vandetanib.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Photosensitivity Disorders; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2009 |
Complementary chemoenzymatic routes to both enantiomers of febrifugine.
Topics: Catalysis; Piperidines; Quinazolines; Stereoisomerism; Substrate Specificity | 2009 |
A concise approach to the core structures of pinnaic acid and halichlorine.
Topics: Alkaloids; Crystallography, X-Ray; Nitrogen Oxides; Oxidation-Reduction; Piperidines; Quinazolines; Spiro Compounds; Stereoisomerism | 2009 |
Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells.
Topics: Apoptosis; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Glioma; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Vorinostat | 2009 |
Lung cancer trials probe effects of maintenance therapy, targeted agents.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2009 |
A new reaction motif: "homo-S(N)2'-like" direct nucleophilic addition to neutral eta(3)-allylmolybdenum complexes. total synthesis of the antimalarial (+)-isofebrifugine.
Topics: Antimalarials; Molybdenum; Organometallic Compounds; Piperidines; Pyridines; Quinazolines; Stereoisomerism; Substrate Specificity | 2009 |
Cutaneous pigmentation after photosensitivity induced by vandetanib therapy.
Topics: Aged; Antineoplastic Agents; Dermatitis, Phototoxic; Female; Humans; Hyperpigmentation; Middle Aged; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Skin | 2009 |
Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Dose Fractionation, Radiation; ErbB Receptors; Humans; Irinotecan; Mice; Mice, Nude; Piperidines; Protein Kinase Inhibitors; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Piperidines; Quinazolines; Tissue Distribution; Xenograft Model Antitumor Assays | 2009 |
Decrease in tumor cell oxygen consumption after treatment with vandetanib (ZACTIMA; ZD6474) and its effect on response to radiotherapy.
Topics: Animals; Contrast Media; Electron Spin Resonance Spectroscopy; Liver Neoplasms, Experimental; Magnetic Resonance Imaging; Male; Mice; Neoplasm Transplantation; Oxygen Consumption; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2009 |
The Ca2+-calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC.
Topics: Amino Acid Sequence; Animals; Calcium Signaling; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calmodulin; Carcinoma, Papillary; Cell Division; Enzyme Activation; Estrenes; Extracellular Signal-Regulated MAP Kinases; Humans; MAP Kinase Signaling System; Molecular Sequence Data; Mutation; Neoplasm Proteins; Oncogene Protein p21(ras); Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-ret; Pyrrolidinones; Quinazolines; Rats; Thyroid Neoplasms; Type C Phospholipases | 2010 |
Dihydroxylation of vinyl sulfones: stereoselective synthesis of (+)- and (-)-febrifugine and halofuginone.
Topics: Catalysis; Hydroxylation; Molecular Structure; Piperidines; Quinazolines; Quinazolinones; Stereoisomerism; Sulfones | 2010 |
Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Cells, Cultured; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Endothelium, Vascular; ErbB Receptors; Esophageal Neoplasms; Flow Cytometry; Humans; Indoles; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Stomach Neoplasms; Sunitinib; Umbilical Veins; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2010 |
ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; ErbB Receptors; Female; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2010 |
Vascular endothelial growth factor concentration as a predictive marker: ready for primetime?
Topics: Biomarkers, Tumor; Blood Chemical Analysis; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Piperidines; Predictive Value of Tests; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2010 |
ZD6474 coerces breast cancer for an apoptotic journey.
Topics: Apoptosis; Breast Neoplasms; Female; Humans; Piperidines; Quinazolines | 2010 |
A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Binding Proteins; ErbB Receptors; Humans; Isotretinoin; Mice; Neovascularization, Pathologic; Neuroblastoma; Phosphorylation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2010 |
Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Autoradiography; Benzoxazoles; Brain; Cabergoline; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Female; Imidazoles; Levodopa; Ligands; Macaca fascicularis; MPTP Poisoning; Piperidines; Quinazolines; Receptors, AMPA; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate | 2010 |
Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
Topics: Algorithms; Animals; Antimalarials; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Dantrolene; Erlotinib Hydrochloride; Flavonoids; Kinetics; Male; Mice; Mice, Knockout; Mitoxantrone; Muscle Relaxants, Central; Neoplasm Proteins; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinidine; Testis; Tissue Distribution; Xenobiotics | 2010 |
[Inhibitory effect of ZD6474 combined with adriamycin on MCF-7 human breast cancer cells in vitro].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; Female; Humans; Piperidines; Quinazolines | 2010 |
Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrases; Carcinoma, Renal Cell; Drug Synergism; Female; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Mice; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2011 |
ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain.
Topics: Animals; bcl-X Protein; Brain; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Glioma; Humans; Magnetic Resonance Imaging; Mice; Mutant Proteins; Neovascularization, Pathologic; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Protein-Tyrosine Kinases; STAT3 Transcription Factor; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Neurilemmoma; Neurofibromatosis 2; Neurofibromin 2; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A | 2010 |
A novel PARP inhibitor L-2286 in a rat model of impact acceleration head injury: an immunohistochemical and behavioral study.
Topics: Animals; Anxiety; Axons; Behavior, Animal; Brain Injuries; Disease Models, Animal; Enzyme Inhibitors; Immunohistochemistry; Infusions, Intraventricular; Male; Neuroprotective Agents; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolines; Rats; Rats, Wistar | 2010 |
One more fallen star--ZODIAC and its implications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Endpoint Determination; Humans; Lung Neoplasms; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Taxoids | 2010 |
Epidermal growth factor receptor transactivation by the cannabinoid receptor (CB1) and transient receptor potential vanilloid 1 (TRPV1) induces differential responses in corneal epithelial cells.
Topics: Benzoxazines; Blotting, Western; Capsaicin; Cell Movement; Cell Proliferation; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Epithelium, Corneal; ErbB Receptors; Fluorescent Antibody Technique, Indirect; Humans; Interleukin-6; Interleukin-8; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; Morpholines; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Piperidines; Pyrazoles; Quinazolines; Receptor, Cannabinoid, CB1; Transcriptional Activation; TRPV Cation Channels; Tyrphostins | 2010 |
Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Disease Models, Animal; ErbB Receptors; Flow Cytometry; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Paclitaxel; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Random Allocation; Sensitivity and Specificity; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2011 |
Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinogens; Chemoprevention; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Mice; Molecular Targeted Therapy; Neovascularization, Pathologic; Piperidines; Protein Kinase Inhibitors; Quinazolines; Urethane; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytoskeleton; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Paclitaxel; Piperidines; Quinazolines | 2011 |
Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Topics: Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Female; Humans; Kidney Diseases; Liver Diseases; Male; Middle Aged; Piperidines; Quinazolines | 2010 |
VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Cadherins; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Epithelial Cells; Epithelial-Mesenchymal Transition; Humans; Mesoderm; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Urinary Bladder Neoplasms; Vimentin | 2010 |
Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc(MIN/+) mouse model.
Topics: Adenoma; Animals; Antineoplastic Agents; beta Catenin; Colitis; Colonic Neoplasms; Dextran Sulfate; Disease Models, Animal; ErbB Receptors; Genes, APC; Intestine, Small; Mice; Mice, Inbred C57BL; Piperidines; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Administration Schedule; ErbB Receptors; Glioma; Multivariate Analysis; Nerve Tissue Proteins; Piperidines; Protein Kinase Inhibitors; Proteomics; Quinazolines; Rats; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Time Factors | 2010 |
Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Colonic Neoplasms; Contrast Media; Humans; Image Enhancement; Kinetics; Male; Neovascularization, Pathologic; Piperidines; Quinazolines; Rats; Rats, Nude; Time Factors; Tomography, X-Ray Computed; Xenograft Model Antitumor Assays | 2010 |
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Electrophoresis, Polyacrylamide Gel; ErbB Receptors; Female; Flavonoids; Fluorescent Antibody Technique; Gene Knockout Techniques; Humans; Indoles; Lapatinib; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Piperidines; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrroles; Quinazolines; Roscovitine | 2010 |
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.
Topics: Carcinoma, Medullary; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Mutation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Signal Transduction; Thyroid Neoplasms; Transforming Growth Factor alpha; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Dual inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO model of oral carcinogenesis.
Topics: 4-Nitroquinoline-1-oxide; Animals; Antineoplastic Agents; Carcinogens; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Immunohistochemistry; Mice; Mice, Inbred CBA; Mouth Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Quinolones; Receptors, Vascular Endothelial Growth Factor | 2010 |
Targeted therapies: Molecular selection for 'smart' study design in lung cancer.
Topics: Antineoplastic Agents; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Genetic Markers; Humans; Lung Neoplasms; Pharmacogenetics; Piperidines; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2010 |
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Proliferation; Cell Survival; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia; Methotrexate; Piperidines; Protein Kinase Inhibitors; Quinazolines; Topoisomerase II Inhibitors | 2012 |
Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Chemoradiotherapy; Drug Administration Schedule; ErbB Receptors; Glioblastoma; Humans; Mice; Mice, Nude; Neoplasm Proteins; Piperidines; Quinazolines; Radiation Tolerance; Receptors, Vascular Endothelial Growth Factor; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Vandetanib improves anti-tumor effects of L19mTNFalpha in xenograft models of esophageal cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Models, Animal; Esophageal Neoplasms; Fibronectins; Humans; Mice; Mice, SCID; Piperidines; Quinazolines; Recombinant Fusion Proteins; Single-Chain Antibodies; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2011 |
New vandetanib analogs: fused tricyclic quinazolines with antiangiogenic potential.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Movement; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; ErbB Receptors; Fibroblast Growth Factor 2; Human Umbilical Vein Endothelial Cells; Humans; Inhibitory Concentration 50; Mice; Mice, Inbred C57BL; Molecular Structure; Neovascularization, Physiologic; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Structure-Activity Relationship; Vascular Endothelial Growth Factor A | 2012 |
Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Humans; Immunoblotting; In Situ Nick-End Labeling; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Piperidines; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2011 |
Metabolic imaging allows early prediction of response to vandetanib.
Topics: Aged; Animals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclins; Dihydroxyphenylalanine; Down-Regulation; Female; Fluorodeoxyglucose F18; G1 Phase; Glucose; Humans; Male; Mice; Mice, SCID; Microarray Analysis; Piperidines; Positron-Emission Tomography; Proto-Oncogene Proteins c-ret; Quality Control; Quinazolines; Radiopharmaceuticals; Resting Phase, Cell Cycle; RNA, Neoplasm; Signal Transduction; Thymidine; Thyroid Neoplasms; Tomography, Emission-Computed | 2011 |
Stereoselective synthesis of 2,6-cis- and 2,6-trans-piperidines through organocatalytic aza-Michael reactions: a facile synthesis of (+)-myrtine and (-)-epimyrtine.
Topics: Catalysis; Molecular Structure; Piperidines; Quinazolines; Quinolizines; Stereoisomerism; Sulfur Compounds | 2011 |
[Pleural metastases from bronchial carcinoma: is a cure possible?].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Piperidines; Pleural Neoplasms; Quinazolines; Radiotherapy; Receptor Protein-Tyrosine Kinases; Retreatment; Survivors; Thoracotomy | 2011 |
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; Humans; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Phthalazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Glioma; Humans; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Pyrroles; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2011 |
Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cisplatin; Combined Modality Therapy; Drug Resistance, Neoplasm; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
NSCLC drug targets acquire new visibility.
Topics: Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Tetrahydronaphthalenes; Treatment Outcome | 2011 |
Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Combinations; ErbB Receptors; Fluorouracil; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Piperidines; Quinazolines; Tegafur; Tumor Cells, Cultured | 2011 |
Successful laser treatment of vandetanib-associated cutaneous pigmentation.
Topics: Adult; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Hyperpigmentation; Lasers, Solid-State; Piperidines; Protein Kinase Inhibitors; Quinazolines; Skin Pigmentation | 2011 |
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.
Topics: Anilides; Axitinib; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sunitinib; Thyroid Gland; Tumor Cells, Cultured | 2011 |
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Endothelial Cells; ErbB Receptors; Female; Humans; Mice; Mice, SCID; Neoplasms; Phenotype; Piperidines; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2011 |
Radiosynthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer.
Topics: Carbon Radioisotopes; Chlorine; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Methylation; Molecular Structure; Neoplasms; Piperidines; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Receptors, Vascular Endothelial Growth Factor | 2011 |
2011 ASCO Genitourinary Cancers Symposium.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Humans; Kidney Neoplasms; Male; Piperidines; Prostatic Neoplasms; Quinazolines; Urinary Bladder Neoplasms; Urogenital Neoplasms | 2011 |
Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.
Topics: Antibodies; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Ligands; Male; Neoplasms; Neurokinin-1 Receptor Antagonists; Piperidines; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptors, Neurokinin-1; Signal Transduction; Substance P; Trastuzumab | 2012 |
[New therapeutic options for advanced thyroid cancer].
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Indoles; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms | 2011 |
Updates in the management of medullary thyroid cancer.
Topics: Carcinoma, Neuroendocrine; Contraindications; Humans; Multiple Endocrine Neoplasia; Mutation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Research; Syndrome; Thyroid Neoplasms | 2011 |
Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Cyclic N-Oxides; Disease Models, Animal; Dose-Response Relationship, Drug; Doxorubicin; Heart Failure; HSP72 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Male; MAP Kinase Signaling System; Mice; Myocytes, Cardiac; Phosphorylation; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Rats; Spin Labels | 2011 |
Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gefitinib; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Models, Biological; Phenylbutyrates; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Tumor Stem Cell Assay | 2011 |
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
Vandetanib: first global approval.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Drug Approval; Drug Design; Humans; Neoplasm Metastasis; Piperidines; Quinazolines; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coloring Agents; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Male; Piperidines; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Taxoids; Tetrazolium Salts; Thiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).
Topics: Antineoplastic Agents; Brain Neoplasms; Chemical Fractionation; Child; Chromatography, Liquid; Drug Stability; Humans; Piperidines; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2011 |
Epidermal growth factor enhances the malignant phenotype in canine mammary carcinoma cell lines.
Topics: Animals; Apoptosis; Cell Line, Tumor; Dog Diseases; Dogs; Epidermal Growth Factor; ErbB Receptors; Female; Mammary Neoplasms, Animal; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.
Topics: Apoptosis; Blotting, Western; Carboplatin; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Glutamates; Guanine; Humans; Immunohistochemistry; Mesothelioma; Pemetrexed; Phosphorylation; Piperidines; Pleural Neoplasms; Polymerase Chain Reaction; Polymorphism, Genetic; Proto-Oncogene Proteins c-akt; Quinazolines | 2011 |
Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Cornea; Corneal Diseases; Diagnosis, Differential; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lung Neoplasms; Microscopy, Acoustic; Piperidines; Quinazolines; Visual Acuity | 2011 |
Progress in molecular targeted therapy for thyroid cancer: vandetanib in medullary thyroid cancer.
Topics: Carcinoma, Neuroendocrine; Female; Humans; Male; Piperidines; Quinazolines; Thyroid Neoplasms | 2012 |
Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Lewis Lung; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Immunohistochemistry; Injections, Intraperitoneal; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; MicroRNAs; Neovascularization, Pathologic; Piperidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2012 |
Pharmacotherapy: vandetanib-a new therapeutic option in advanced medullary thyroid cancer.
Topics: Female; Humans; Male; Piperidines; Quinazolines; Thyroid Neoplasms | 2011 |
Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.
Topics: Animals; Area Under Curve; Cardiomyopathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Gene Expression Regulation; Glomerular Filtration Rate; Glucagon-Like Peptide 1; Heart; Humans; Kidney Failure, Chronic; Linagliptin; Myocardium; Natriuretic Peptide, Brain; Nephrectomy; Piperidines; Purines; Pyrazines; Quinazolines; Rats; Reverse Transcriptase Polymerase Chain Reaction; Sitagliptin Phosphate; Triazoles; Uracil; Uremia | 2011 |
Diffuse interstitial lung disease linked to vandetanib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Hypersensitivity; Drug Substitution; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines; Spirometry; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Completing the Arc: targeted inhibition of RET in medullary thyroid cancer.
Topics: Carcinoma, Neuroendocrine; Female; Humans; Male; Piperidines; Quinazolines; Thyroid Neoplasms | 2012 |
Unusual adverse event with vandetanib in metastatic medullary thyroid cancer.
Topics: Carcinoma, Neuroendocrine; Humans; Male; Middle Aged; Neoplasm Metastasis; Piperidines; Quinazolines; Thyroid Neoplasms | 2012 |
Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase.
Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Hep G2 Cells; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Models, Chemical; Neoplasm Transplantation; Piperidines; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Febrifugine analogue compounds: synthesis and antimalarial evaluation.
Topics: Animals; Antimalarials; Aotus trivirgatus; Drug Evaluation, Preclinical; Malaria; Piperidines; Plasmodium falciparum; Quinazolines | 2012 |
Drug approvals 2011: focus on companion diagnostics.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Brentuximab Vedotin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Approval; Female; Humans; Imidazoles; Immunoconjugates; Indazoles; Indoles; Ipilimumab; Lung Neoplasms; Male; Melanoma; Molecular Targeted Therapy; Neoplasms; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyridines; Quinazolines; Rare Diseases; Sulfonamides; Survival Analysis; United States; United States Food and Drug Administration; Vemurafenib | 2012 |
Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fluorescent Antibody Technique; Fulvestrant; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, SCID; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-3 | 2012 |
Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Head and Neck Neoplasms; Humans; Immunoprecipitation; In Vitro Techniques; Mice; Molecular Targeted Therapy; Piperidines; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2012 |
Synthesis and biological evaluation of quinazoline and quinoline bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors and EPR bio-probe agents.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Electron Spin Resonance Spectroscopy; ErbB Receptors; Humans; Models, Molecular; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Spin Labels | 2012 |
Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase.
Topics: Amino Acyl-tRNA Synthetases; Animals; Cell Differentiation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Mice; Mice, Inbred C57BL; Piperidines; Quinazolines; Quinazolinones; Structure-Activity Relationship; Th17 Cells | 2012 |
RET, ROS1 and ALK fusions in lung cancer.
Topics: 3T3 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Adult; Age Factors; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Animals; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cytoskeletal Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Middle Aged; Neoplasm Staging; Oncogene Proteins, Fusion; Piperidines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor Protein-Tyrosine Kinases; Sex Factors | 2012 |
KIF5B-RET fusions in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Animals; Cell Transformation, Neoplastic; ErbB Receptors; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; Japan; Kinesins; Lung Neoplasms; Mice; NIH 3T3 Cells; Norway; Oncogene Proteins, Fusion; Piperidines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; United States | 2012 |
Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluoresceins; Fluorescent Dyes; Humans; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Ovarian Neoplasms; Phenotype; Piperidines; Protein Kinase Inhibitors; Quinazolines; Rhodamine 123; Time Factors | 2012 |
Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Male; Mice; Mice, Inbred BALB C; Microvessels; Piperidines; Quinazolines; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Neoplasm Proteins; Piperidines; Protein Binding; Quinazolines; Quinolines | 2012 |
Treatment of metastatic medullary thyroid cancer with vandetanib: need to stratify patients on basis of calcitonin doubling time.
Topics: Female; Humans; Male; Piperidines; Quinazolines; Thyroid Neoplasms | 2012 |
A high-content biosensor-based screen identifies cell-permeable activators and inhibitors of EGFR function: implications in drug discovery.
Topics: Anti-Inflammatory Agents; Beclomethasone; Biosensing Techniques; Butyrophenones; Cell Line; Dose-Response Relationship, Drug; Drug Discovery; ErbB Receptors; Flurandrenolone; High-Throughput Screening Assays; Histamine H1 Antagonists; Humans; Permeability; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results; Signal-To-Noise Ratio | 2012 |
The receptor tyrosine kinase inhibitor vandetanib activates Akt and increases side population in a salivary gland tumor cell line (A253).
Topics: Antineoplastic Agents; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Salivary Gland Neoplasms; Side-Population Cells | 2012 |
False-negative MRI biomarkers of tumour response to targeted cancer therapeutics.
Topics: Animals; Benzodioxoles; Biomarkers, Tumor; Blood Vessels; Cell Hypoxia; Cell Line, Tumor; False Negative Reactions; Female; Humans; Magnetic Resonance Imaging; Male; Mammary Neoplasms, Experimental; Mice; Molecular Targeted Therapy; Neoplasm Transplantation; Piperidines; Prostatic Neoplasms; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Rats; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Ki-67 Antigen; Male; Mice; Mice, Inbred Strains; Piperidines; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2013 |
Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Mice; Mice, Nude; Neoplasms, Experimental; Phosphorylation; Piperidines; Prognosis; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Blood-Brain Barrier; Brain; Cell Line; Dogs; Drug Synergism; Everolimus; Male; Mice; Piperidines; Quinazolines; Sirolimus; Tissue Distribution; TOR Serine-Threonine Kinases | 2012 |
Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR-dependent mechanism.
Topics: Animals; Antioxidants; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Blotting, Western; Butylated Hydroxytoluene; Carcinogens; Cell Proliferation; Cytokines; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Hypoxia; Immunoenzyme Techniques; Lung Neoplasms; Methylcholanthrene; Mice; Neovascularization, Pathologic; Piperidines; Proto-Oncogene Proteins c-myc; Pulmonary Alveoli; Quinazolines; Sleep Apnea Syndromes; Urethane; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Fluorodeoxyglucose F18; Humans; Indoles; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Radiopharmaceuticals; Sorafenib; Sunitinib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed | 2012 |
[Therapeutic use and adverse events of incretin-related drugs].
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2012 |
[The role of Src kinase inhibitor ZD6474 on multi-drug resistant K562/A02 cells].
Topics: Animals; Apoptosis; Cell Cycle; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; K562 Cells; Mice; Mice, Inbred BALB C; Piperidines; Quinazolines; src-Family Kinases | 2012 |
Differential effects of calcitonin gene-related peptide receptor blockade by olcegepant on mechanical allodynia induced by ligation of the infraorbital nerve vs the sciatic nerve in the rat.
Topics: Activating Transcription Factor 3; Animals; Biomarkers; Calcitonin Gene-Related Peptide Receptor Antagonists; Dipeptides; Hyperalgesia; Interleukin-6; Locomotion; Male; Maxillary Nerve; Neuralgia; Pain Measurement; Piperazines; Piperidines; Proto-Oncogene Proteins c-fos; Quinazolines; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptors, Calcitonin Gene-Related Peptide; RNA, Messenger; Rotarod Performance Test; Sciatic Nerve; Serotonin 5-HT1 Receptor Agonists; Tryptamines | 2012 |
Treating advanced radioresistant differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Female; Humans; Male; Piperidines; Quinazolines; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2012 |
First do no harm: counting the cost of chasing drug efficacy.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Female; Humans; Male; Piperidines; Quinazolines; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2012 |
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.
Topics: Anticoagulants; Antineoplastic Agents; Benzimidazoles; beta-Alanine; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Dabigatran; Drug Approval; Efficiency, Organizational; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Patient Safety; Piperidines; Propylene Glycols; Quinazolines; Risk; Sphingosine; Stroke; Thyroid Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2012 |
Hantavirus treatments advance amidst outbreak in US park.
Topics: Animals; California; Cricetinae; Disease Models, Animal; Disease Outbreaks; Hantavirus Pulmonary Syndrome; Humans; Mesocricetus; Orthohantavirus; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; United States; Viral Vaccines | 2012 |
Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cytoskeletal Proteins; Female; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Oncogene Proteins, Fusion; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transplantation, Heterologous; Tumor Cells, Cultured | 2012 |
Vandetanib: too dangerous in medullary thyroid cancer.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Evidence-Based Medicine; Humans; Patient Safety; Piperidines; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thyroid Neoplasms; Treatment Outcome | 2012 |
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
Topics: Alanine; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Cetuximab; Dasatinib; Doxorubicin; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Humans; Indoles; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridones; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Triazines | 2013 |
Comparative proteome profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an epithelial mesenchymal transition associated protein signature.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Epithelial Cells; Epithelial-Mesenchymal Transition; Female; Gene Expression; Gene Expression Profiling; Humans; Mesoderm; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperidines; Protein Interaction Maps; Protein Kinases; Proteome; Proteomics; Quinazolines; Sorafenib | 2013 |
ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase.
Topics: Adenosine Triphosphate; Amino Acyl-tRNA Synthetases; Antimalarials; Binding Sites; Crystallography, X-Ray; Herbal Medicine; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Ligands; Medicine, Chinese Traditional; Models, Molecular; Piperidines; Proline; Quinazolines; Quinazolinones; RNA, Transfer | 2013 |
Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Genes, erbB-1; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Piperidines; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Niacinamide; Phenylurea Compounds; Piperidines; Pregnane X Receptor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptors, Steroid; Sorafenib | 2013 |
Case records of the Massachusetts General Hospital. Case 5-2013. A 52-year-old woman with a mass in the thyroid.
Topics: Biopsy, Fine-Needle; Calcitonin; Carcinoma, Neuroendocrine; Diagnosis, Differential; Female; Humans; Lymph Nodes; Lymphatic Diseases; Middle Aged; Neck; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Gland; Thyroid Neoplasms; Thyroid Nodule; Thyrotropin; Tomography, X-Ray Computed; Ultrasonography | 2013 |
Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Chromatography, Liquid; Doxorubicin; Humans; Piperidines; Protein Kinase Inhibitors; Quinazolines; Tandem Mass Spectrometry | 2013 |
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Transformation, Neoplastic; Diphenylamine; Feedback, Physiological; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis.
Topics: Adult; Carcinoma, Neuroendocrine; Cardiomyopathies; Clinical Trials, Phase III as Topic; Fatal Outcome; Female; Heart Failure; Humans; Male; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2013 |
Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Survival; Cyclic N-Oxides; Drug Delivery Systems; Female; Humans; Mice; Mice, Nude; Mitochondria; Nitrogen Oxides; Organophosphorus Compounds; Piperidines; Proto-Oncogene Mas; Quinazolines; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytoskeletal Proteins; Down-Regulation; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Nude; Mutation; Phosphorylation; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Quinazolines; RNA, Messenger; Signal Transduction; Transcriptome | 2013 |
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
Topics: Adenocarcinoma; Antineoplastic Agents; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Oncogene Proteins, Fusion; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2013 |
Total synthesis of (-)-hippodamine by stereocontrolled construction of azaphenalene skeleton based on extended one-pot asymmetric azaelectrocyclization.
Topics: Aza Compounds; Cyclization; Molecular Structure; Piperidines; Quinazolines; Stereoisomerism | 2013 |
Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Animals; Basal Ganglia; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Imidazoles; Levodopa; Macaca fascicularis; Oximes; Parkinsonian Disorders; Phenols; Piperidines; Pyridines; Quinazolines; Radioligand Assay; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Tritium; Xanthenes | 2013 |
Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Drug Synergism; Female; Glioblastoma; Humans; Male; Middle Aged; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Piperidines; Prognosis; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2013 |
Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 7; Beclin-1; Cell Line, Tumor; Cell Survival; Chloroquine; ErbB Receptors; Glioblastoma; Humans; Membrane Proteins; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; TOR Serine-Threonine Kinases; Ubiquitin-Activating Enzymes; Xenograft Model Antitumor Assays | 2013 |
Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer.
Topics: Animals; Apoptosis; Benzazepines; Cell Proliferation; Drug Evaluation, Preclinical; Humans; Male; Mice; Mice, Nude; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Isolation and structure elucidation of the main UV-A photoproducts of vandetanib.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Kinetics; Magnetic Resonance Spectroscopy; Mass Spectrometry; Photochemistry; Photolysis; Piperidines; Quinazolines; Solutions; Solvents; Ultraviolet Rays | 2013 |
Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma.
Topics: Adrenocorticotropic Hormone; Calcitonin; Carcinoma, Neuroendocrine; Cushing Syndrome; Deamino Arginine Vasopressin; Humans; Lymphatic Metastasis; Male; Middle Aged; Paraneoplastic Syndromes; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms | 2013 |
Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?
Topics: Anilides; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Humans; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Thyroid Neoplasms | 2013 |
Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.
Topics: Animals; Crystallography, X-Ray; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Activation; Inhibitory Concentration 50; Linagliptin; Male; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Piperidines; Purines; Quinazolines; Rats; Rats, Sprague-Dawley; Uracil | 2013 |
Nitric oxide synthase, calcitonin gene-related peptide and NK-1 receptor mechanisms are involved in GTN-induced neuronal activation.
Topics: Animals; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Dipeptides; Disease Models, Animal; Enzyme Inhibitors; Humans; Male; Migraine Disorders; Neurokinin-1 Receptor Antagonists; Neurons; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type I; Nitroglycerin; Piperazines; Piperidines; Posterior Horn Cells; Proto-Oncogene Proteins c-fos; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Neurokinin-1; Trigeminal Nerve; Vasodilator Agents; Wakefulness | 2014 |
Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance.
Topics: 1-Methyl-4-phenylpyridinium; Cell Line; Cisplatin; Creatinine; HEK293 Cells; Humans; Kidney; Metformin; Organic Cation Transport Proteins; Piperidines; Quinazolines | 2013 |
Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Estrogen Receptor alpha; Female; Flow Cytometry; Humans; Indoles; Mammary Neoplasms, Experimental; MAP Kinase Signaling System; MCF-7 Cells; Mice; Piperidines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; Random Allocation; Signal Transduction; Sunitinib; Tamoxifen; Transcription Factor AP-2 | 2014 |
Role of the eNOS-NO system in regulating the antiproteinuric effects of VEGF receptor 2 inhibition in diabetes.
Topics: Animals; Blood Pressure; Diabetes Mellitus, Experimental; Hypertension; Kidney; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Piperidines; Proteinuria; Quinazolines; Rats; Receptors, Vascular Endothelial Growth Factor; Systole | 2013 |
Specific binding of modified ZD6474 (Vandetanib) monomer and its dimer with VEGF receptor-2.
Topics: Angiogenesis Inhibitors; Animals; Binding Sites; Cell Line; Cell Survival; Dimerization; Female; Heterografts; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Nude; Molecular Imaging; Molecular Structure; Neoplasm Transplantation; Piperidines; Protein Binding; Quinazolines; Substrate Specificity; Tissue Distribution; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cluster Analysis; Disease Models, Animal; Disease Progression; Female; Humans; Mice; Neoplasm Grading; Ovarian Neoplasms; Piperidines; Protein Kinase Inhibitors; Proteomics; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Triazines; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of UV-B phototherapy in breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Caspase 3; Caspase 7; Cell Movement; Cell Proliferation; Cell Survival; Combined Modality Therapy; Cytoskeleton; ErbB Receptors; Female; Humans; Matrix Metalloproteinase 9; MCF-7 Cells; Membrane Potential, Mitochondrial; Molecular Targeted Therapy; Phototherapy; Piperidines; Quinazolines; Ultraviolet Rays; Ultraviolet Therapy; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Inhibitory Concentration 50; Nucleoside Transport Proteins; Piperidines; Quinazolines; Saccharomyces cerevisiae; Uridine | 2014 |
Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by reverse phase protein array.
Topics: Adult; Animals; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Proliferation; Humans; MAP Kinase Signaling System; Mice; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Thyroid Neoplasms | 2014 |
Frequency dependent impedimetric cytotoxic evaluation of anticancer drug on breast cancer cell.
Topics: Antineoplastic Agents; Apoptosis; Biological Assay; Biosensing Techniques; Breast Neoplasms; Cell Proliferation; Dielectric Spectroscopy; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Equipment Design; Equipment Failure Analysis; Female; Humans; MCF-7 Cells; Piperidines; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2014 |
Differential pharmacological alleviation of oxaliplatin-induced hyperalgesia/allodynia at cephalic versus extra-cephalic level in rodents.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amines; Analgesics; Animals; Cold Temperature; Cyclohexanecarboxylic Acids; Dipeptides; Formaldehyde; Gabapentin; gamma-Aminobutyric Acid; Ganglia, Spinal; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Morphine; Organoplatinum Compounds; Oxaliplatin; Piperazines; Piperidines; Quinazolines; Rats; Rats, Sprague-Dawley; Spinal Cord; Touch; TRPA1 Cation Channel; TRPC Cation Channels; Tryptamines | 2014 |
Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.
Topics: Adenine; Baculoviral IAP Repeat-Containing 3 Protein; Base Sequence; Blotting, Western; CARD Signaling Adaptor Proteins; Cell Line; Cell Survival; DNA Primers; Guanylate Cyclase; Humans; Inhibitor of Apoptosis Proteins; Luminescent Measurements; Lymphoma, Mantle-Cell; Microarray Analysis; Molecular Sequence Data; NF-kappa B; NF-kappaB-Inducing Kinase; Piperidines; Protein Serine-Threonine Kinases; Pyrazoles; Pyrimidines; Pyrroles; Quinazolines; Real-Time Polymerase Chain Reaction; Receptors, Antigen, B-Cell; RNA Interference; Sequence Analysis, RNA; Signal Transduction; TNF Receptor-Associated Factor 2; TNF Receptor-Associated Factor 3; Trypan Blue; Ubiquitin-Protein Ligases | 2014 |
[Selection of a melanine concentrating hormone receptor-1 (MCHR1) antagonists' focused library and its biological screening with AequoScreen].
Topics: Aequorin; Chemistry, Pharmaceutical; Cyclohexylamines; Databases, Chemical; Databases, Pharmaceutical; Drug Design; Drug Discovery; High-Throughput Screening Assays; Humans; In Vitro Techniques; Inhibitory Concentration 50; Light; Models, Molecular; Molecular Structure; Piperidines; Quinazolines; Receptors, Somatostatin; User-Computer Interface | 2013 |
Vandetanib-induced inhibition of neuroblastoma cell migration and invasion is associated with downregulation of the SDF-1/CXCR4 axis and matrix metalloproteinase 14.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Down-Regulation; Drug Screening Assays, Antitumor; G1 Phase Cell Cycle Checkpoints; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Matrix Metalloproteinase 14; Neoplasm Invasiveness; Neuroblastoma; Phosphorylation; Piperidines; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, CXCR4 | 2014 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2014 |
Electrochemical monitoring of an important biomarker and target protein: VEGFR2 in cell lysates.
Topics: Animals; Biosensing Techniques; Cell Line; Chitosan; Electrochemical Techniques; Endothelial Cells; Graphite; Immunoassay; Macaca mulatta; Niacinamide; Oxidation-Reduction; Phenothiazines; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Retina; Sorafenib; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Humans; MCF-7 Cells; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Piperidines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Tamoxifen; Xenograft Model Antitumor Assays | 2014 |
Synthesis of febrifugine derivatives and development of an effective and safe tetrahydroquinazoline-type antimalarial.
Topics: Animals; Antimalarials; Magnetic Resonance Spectroscopy; Piperidines; Plasmodium falciparum; Quinazolines; Spectrometry, Mass, Fast Atom Bombardment | 2014 |
Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.
Topics: Adolescent; Adrenocorticotropic Hormone; Carcinoma, Neuroendocrine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cushing Syndrome; Humans; Male; Multiple Endocrine Neoplasia Type 2b; Neoplasms, Second Primary; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Thyroid Neoplasms | 2014 |
A quinazoline-derivative compound with PARP inhibitory effect suppresses hypertension-induced vascular alterations in spontaneously hypertensive rats.
Topics: Animals; Aorta; Blood Pressure; Cell Death; Collagen; Hypertension; Male; Mitochondria; Mitogen-Activated Protein Kinases; NF-kappa B; Oxidative Stress; Phosphatidylinositol 3-Kinase; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Rats, Inbred SHR; Rats, Wistar; Signal Transduction | 2014 |
Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mass Spectrometry; Mice; Mice, Nude; Multimodal Imaging; Phthalazines; Piperidines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2014 |
Vandetanib-induced phototoxicity in human keratinocytes NCTC-2544.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Survival; Dermatitis, Phototoxic; DNA Damage; Humans; Lysosomes; Mice; Mitochondria; Oxidation-Reduction; Piperidines; Protein Kinase Inhibitors; Quinazolines; Serum Albumin, Bovine; Thiobarbituric Acid Reactive Substances; Ultraviolet Rays | 2014 |
[Hydrangea Hydrangea macrophylla].
Topics: Adult; Female; Foodborne Diseases; Humans; Hydrangea; Male; Middle Aged; Piperidines; Quinazolines; Stereoisomerism | 2014 |
Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
Topics: Animals; Antineoplastic Agents; Cell Line; DNA Repair; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Humans; Isoquinolines; Lung Neoplasms; Lymphangioleiomyomatosis; Mice, Inbred C57BL; Mice, SCID; Molecular Targeted Therapy; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolines; Rats; Sirolimus; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
Extracellular signal-regulated kinase 5 and cyclic AMP response element binding protein are novel pathways inhibited by vandetanib (ZD6474) and doxorubicin in mesotheliomas.
Topics: Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Survival; Cyclic AMP Response Element-Binding Protein; Doxorubicin; Drug Synergism; Humans; MAP Kinase Signaling System; Mesothelioma; Mitogen-Activated Protein Kinase 7; Neoplasms, Connective Tissue; Phosphorylation; Piperidines; Quinazolines; RNA, Small Interfering; Sarcoma | 2014 |
A topical matter: toxic epidermal necrolysis.
Topics: Acetaminophen; Analgesics, Opioid; Anti-Inflammatory Agents; Anticonvulsants; Antiemetics; Antineoplastic Agents; Dacarbazine; Dexamethasone; Drug Combinations; Erythema; gamma-Globulins; Glioblastoma; Humans; Immunologic Factors; Levetiracetam; Male; Methylprednisolone; Middle Aged; Omeprazole; Oxycodone; Piperidines; Piracetam; Proton Pump Inhibitors; Quinazolines; Stevens-Johnson Syndrome; Temozolomide; Wound Healing | 2014 |
Synthesis and evaluation of salicylanilide derivatives as potential epidermal growth factor receptor inhibitors.
Topics: Antineoplastic Agents; Benzamides; Binding Sites; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Hydrogen Bonding; Molecular Docking Simulation; Piperidines; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Salicylanilides; Thermodynamics | 2015 |
Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Humans; Linagliptin; Models, Molecular; Piperidines; Protein Conformation; Purines; Quinazolines; Structure-Activity Relationship; Substrate Specificity; Uracil | 2014 |
PARP-inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, Akt-1/GSK-3β and several PKC isoforms.
Topics: Animals; Blood Pressure; Extracellular Signal-Regulated MAP Kinases; Forkhead Transcription Factors; Gene Expression Regulation; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Heart Failure; HSP90 Heat-Shock Proteins; Hypertension; Hypertrophy, Left Ventricular; Isoenzymes; Male; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Phosphorylation; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinase C; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction | 2014 |
Vandetanib-associated alopecia areata in a patient with metastatic medullary thyroid cancer.
Topics: Adult; Alopecia Areata; Carcinoma, Neuroendocrine; Humans; Male; Piperidines; Quinazolines; Thyroid Neoplasms | 2015 |
Structural and functional analysis of the anti-malarial drug target prolyl-tRNA synthetase.
Topics: Amino Acyl-tRNA Synthetases; Antimalarials; Catalytic Domain; Crystallography, X-Ray; Enzyme Inhibitors; Malaria, Falciparum; Piperidines; Plasmodium falciparum; Protozoan Proteins; Quinazolines | 2014 |
A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Carcinogenesis; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Oncogene Proteins, Fusion; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2014 |
Label-free single cell kinetics of the invasion of spheroidal colon cancer cells through 3D Matrigel.
Topics: Biosensing Techniques; Cell Culture Techniques; Cell Movement; Collagen; Colonic Neoplasms; Drug Combinations; Epidermal Growth Factor; HT29 Cells; Humans; Kinetics; Laminin; Microscopy; Piperidines; Protein Kinase Inhibitors; Proteoglycans; Quinazolines; Spheroids, Cellular | 2014 |
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.
Topics: Adenine; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Methionine; Mice; Mutation; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Threonine | 2014 |
Photo-induced erythema multiforme associated with vandetanib administration.
Topics: Aged; Biopsy, Needle; Carcinoma, Medullary; Erythema Multiforme; Follow-Up Studies; Humans; Immunohistochemistry; Male; Neoplasm Staging; Photosensitivity Disorders; Piperidines; Quinazolines; Risk Assessment; Thyroid Neoplasms; Thyroidectomy | 2014 |
Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat--and with which drug--those are the questions.
Topics: Anilides; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Humans; Male; Middle Aged; Piperidines; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Thyroid Neoplasms; Thyroidectomy | 2014 |
Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Cytoskeletal Proteins; Female; Humans; Lung Neoplasms; Neoplasm Metastasis; Oncogene Proteins, Fusion; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Treatment Outcome | 2016 |
Endothelial progenitor cells induce transplant arteriosclerosis via VEGFR-1/2 activity.
Topics: Animals; Aorta; Arteriosclerosis; Bone Marrow Cells; Endothelial Cells; Flow Cytometry; Graft Rejection; Graft Survival; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Phosphorylation; Piperidines; Quinazolines; Signal Transduction; Stem Cells; Transplantation, Homologous; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design.
Topics: Aged; Clinical Trials, Phase II as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Paclitaxel; Piperidines; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Urologic Neoplasms; Urothelium | 2015 |
DisABLing kidney cancers caused by fumarate hydratase mutations.
Topics: Animals; Fumarate Hydratase; Humans; Kidney Neoplasms; Oxidative Stress; Piperidines; Proto-Oncogene Proteins c-abl; Quinazolines | 2014 |
Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer.
Topics: Animals; Cell Line, Tumor; Cell Nucleus; Fumarate Hydratase; Fumarates; Gene Expression Regulation, Neoplastic; Glycolysis; HEK293 Cells; Humans; Kidney Neoplasms; Mice; Neoplasms, Experimental; NF-E2-Related Factor 2; Oxidative Stress; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-abl; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib.
Topics: Adenine; Afatinib; Animals; Area Under Curve; Cytosol; Dogs; Glutathione; Hepatocytes; Humans; Kidney; Liver; Macaca fascicularis; Male; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Quinolines; Rats | 2015 |
Differential Effects of Tumor Secreted Factors on Mechanosensitivity, Capillary Branching, and Drug Responsiveness in PEG Hydrogels.
Topics: Cell Line, Tumor; Coculture Techniques; Human Umbilical Vein Endothelial Cells; Humans; Hydrogels; Intercellular Signaling Peptides and Proteins; Mechanotransduction, Cellular; Neoplasms; Neovascularization, Pathologic; Piperidines; Polyethylene Glycols; Quinazolines | 2015 |
Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Neuroendocrine; Child; Female; France; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Thyroid Neoplasms; Time Factors; Treatment Outcome; Young Adult | 2015 |
Synthesis and biological evaluation of febrifugine analogues.
Topics: Antimalarials; Antineoplastic Agents; Cell Line, Tumor; Humans; Piperidines; Plasmodium falciparum; Quinazolines | 2014 |
Self-Terminating Ventricular Fibrillation in Vandetanib-Induced Torsades de Pointes.
Topics: Action Potentials; Aged; Antineoplastic Agents; Electrocardiography, Ambulatory; Heart Conduction System; Heart Rate; Humans; Male; Piperidines; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Time Factors; Torsades de Pointes; Ventricular Fibrillation | 2015 |
VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.
Topics: Adult; Aged; Angiogenesis Inhibitors; Animals; Benzylamines; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cyclams; Female; Glioblastoma; Heterocyclic Compounds; Humans; Interleukin-2 Receptor alpha Subunit; Male; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Middle Aged; Neoplasm Invasiveness; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptor Cross-Talk; Receptors, CXCR4; Receptors, Transforming Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Time Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells.
Topics: Actin Cytoskeleton; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Shape; Cell Survival; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; MAP Kinase Signaling System; Piperidines; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; rho GTP-Binding Proteins | 2015 |
Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Line, Tumor; Cytoskeletal Proteins; Drug Delivery Systems; ErbB Receptors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Essential; Humans; Lung Neoplasms; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; RNA; Sequence Analysis, RNA; Single-Cell Analysis; Transcriptome | 2015 |
Late epidermal growth factor receptor inhibitor-related papulopustular rash: a distinct clinical entity.
Topics: Adult; Aged; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pruritus; Quinazolines; Skin Diseases, Papulosquamous; Staphylococcal Infections; Staphylococcus aureus | 2016 |
Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
Topics: Apoptosis; Benzamides; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolines | 2015 |
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Everolimus; Female; Gene Amplification; Gene Rearrangement; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Neuroimaging; Oncogene Proteins, Fusion; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines | 2015 |
The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs.
Topics: Amino Acyl-tRNA Synthetases; Animals; Antimalarials; Computer-Aided Design; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Resistance; Enzyme Inhibitors; Erythrocytes; Liver; Malaria, Falciparum; Mice; Models, Molecular; Molecular Structure; Molecular Targeted Therapy; Piperidines; Plasmodium falciparum; Protozoan Proteins; Quinazolines; Quinazolinones; Structure-Activity Relationship; Time Factors | 2015 |
Use of molecular modeling aided design to dial out hERG liability in adenosine A(2A) receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Benzopyrans; Drug Design; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Molecular Docking Simulation; Piperidines; Quinazolines; Receptor, Adenosine A2A; Triazoles | 2015 |
ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; ErbB Receptors; Female; G1 Phase; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Osteosarcoma; Phosphorylation; Piperidines; Quinazolines; Xenograft Model Antitumor Assays | 2015 |
Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoni.
Topics: Animals; Antineoplastic Agents; Drug Repositioning; Inhibitory Concentration 50; Mice; Piperidines; Pyridones; Pyrimidinones; Quinazolines; Schistosoma mansoni; Schistosomiasis mansoni; Schistosomicides | 2015 |
Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome.
Topics: Adult; Carcinoma, Neuroendocrine; Cushing Syndrome; Disease Progression; Female; Humans; Neoplasm Staging; Piperidines; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2015 |
Interaction of a tyrosine kinase inhibitor, vandetanib with human serum albumin as studied by fluorescence quenching and molecular docking.
Topics: Binding Sites; Circular Dichroism; Humans; Ligands; Metals; Molecular Docking Simulation; Molecular Dynamics Simulation; Piperidines; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Serum Albumin; Spectrometry, Fluorescence; Thermodynamics | 2016 |
The dual-acting H3 receptor antagonist and AChE inhibitor UW-MD-71 dose-dependently enhances memory retrieval and reverses dizocilpine-induced memory impairment in rats.
Topics: Animals; Avoidance Learning; Benzothiazoles; Cholinesterase Inhibitors; Disease Models, Animal; Dizocilpine Maleate; Donepezil; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Histamine H3 Antagonists; Indans; Male; Memory; Memory Disorders; Nootropic Agents; Phenoxypropanolamines; Piperidines; Pyrilamine; Pyrroles; Quinazolines; Random Allocation; Rats, Wistar; Receptors, Histamine H3 | 2016 |
Use of Vandetanib in Metastatic Medullary Carcinoma of Thyroid in a Pediatric Patient With Multiple Endocrine Neoplasia 2B.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Child; Humans; Male; Multiple Endocrine Neoplasia Type 2a; Piperidines; Quinazolines; Thyroid Neoplasms | 2016 |
High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.
Topics: Angiogenesis Inhibitors; Anilides; Carcinoma, Neuroendocrine; Databases, Chemical; Drug Discovery; Humans; Imidazoles; Indoles; Molecular Docking Simulation; Molecular Structure; Niacinamide; Oligonucleotides; Piperidines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Piperidines; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Thyroid Neoplasms | 2015 |
Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging for Monitoring the Early Response to ZD6474 from Nasopharyngeal Carcinoma in Nude Mouse.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Diffusion Magnetic Resonance Imaging; Humans; Image Processing, Computer-Assisted; Ki-67 Antigen; Mice; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Piperidines; Quinazolines; Radiography; Transplantation, Heterologous | 2015 |
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Design; Drug Resistance, Neoplasm; Humans; Models, Molecular; Molecular Docking Simulation; Mutation; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Structure-Activity Relationship; Substrate Specificity; Thyroid Neoplasms | 2016 |
Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease Models, Animal; Female; Gene Expression; Humans; MAP Kinase Signaling System; Mice; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Neoplasm Metastasis; Neovascularization, Pathologic; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Estrogen; Receptors, Vascular Endothelial Growth Factor; RNA, Messenger; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Transcription Factor AP-2; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity.
Topics: Animals; Cell Line; Drug Design; Humans; Mice; Molecular Docking Simulation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines | 2016 |
Pd(II)-Catalyzed Aminofluorination of Alkenes in Total Synthesis 6-(R)-Fluoroswainsonine and 5-(R)-Fluorofebrifugine.
Topics: Alkaloids; Alkenes; Catalysis; Molecular Structure; Palladium; Piperidines; Pyridines; Quinazolines; Stereoisomerism; Swainsonine | 2016 |
Targeting protein kinase C in mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Death; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; MAP Kinase Signaling System; Molecular Targeted Therapy; Phosphorylation; Piperidines; Protein Kinase C; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrroles; Quinazolines; Tumor Cells, Cultured | 2016 |
Biometrical issues in the analysis of adverse events within the benefit assessment of drugs.
Topics: Adverse Drug Reaction Reporting Systems; Androstenes; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Drug Industry; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Germany; Humans; Male; Piperidines; Prostatic Neoplasms; Quinazolines; Survival Rate; Thyroid Neoplasms | 2016 |
cabozantinib (COMETRIQ⁰). In medullary thyroid cancer: more harmful than beneficial, as is vandetanib.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Neuroendocrine; Female; Humans; Male; Piperidines; Protein Kinase Inhibitors; Pyridines; Quality of Life; Quinazolines; Thyroid Neoplasms | 2016 |
Exploring dual inhibitory role of febrifugine analogues against Plasmodium utilizing structure-based virtual screening and molecular dynamic simulation.
Topics: Amino Acyl-tRNA Synthetases; Antimalarials; Aspartic Acid Endopeptidases; Drug Design; Drug Evaluation, Preclinical; Humans; Molecular Conformation; Molecular Dynamics Simulation; Molecular Structure; Piperidines; Plasmodium falciparum; Protein Binding; Protozoan Proteins; Quinazolines; Structure-Activity Relationship | 2017 |
MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Neuroendocrine; Cell Line; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Piperidines; Quinazolines; RNA Interference; Thyroid Neoplasms; Vesicular Transport Proteins | 2016 |
Febrifugine analogues as Leishmania donovani trypanothione reductase inhibitors: binding energy analysis assisted by molecular docking, ADMET and molecular dynamics simulation.
Topics: Antiprotozoal Agents; Binding Sites; Drug Design; Enzyme Inhibitors; Leishmania donovani; Ligands; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; NADH, NADPH Oxidoreductases; Piperidines; Protein Binding; Protein Multimerization; Quinazolines; ROC Curve; Structure-Activity Relationship | 2017 |
Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.
Topics: Adenocarcinoma; Animals; Cell Line; Cell Survival; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Middle Aged; NIH 3T3 Cells; Oncogene Proteins, Fusion; Piperidines; Protein Isoforms; Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Transplantation, Heterologous | 2016 |
A platinum-based hybrid drug design approach to circumvent acquired resistance to molecular targeted tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Brain Chemistry; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; K562 Cells; Lung Neoplasms; Mice; Molecular Targeted Therapy; Mutation; Piperidines; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core.
Topics: Allosteric Regulation; Animals; Brain; Humans; Microsomes, Liver; Piperidines; Pyrimidines; Quinazolines; Rats; Receptor, Muscarinic M4; Structure-Activity Relationship; Thiophenes | 2016 |
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.
Topics: Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Drug Resistance, Neoplasm; Everolimus; Female; Fibroblast Growth Factor 3; Fibroblast Growth Factors; Gene Amplification; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Methionine; Middle Aged; Molecular Targeted Therapy; Mutation; Piperidines; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Pyridines; Quinazolines; Threonine; Thyroid Neoplasms | 2016 |
Effect of Vandetanib on Andes virus survival in the hamster model of Hantavirus pulmonary syndrome.
Topics: Animals; Capillary Permeability; Cricetinae; Disease Models, Animal; Endothelial Cells; Hantavirus Pulmonary Syndrome; Orthohantavirus; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A; Viral Load | 2016 |
Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Epidermal Growth Factor; Female; Gene Expression; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Neuregulin-1; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Medullary; Female; Humans; Male; Middle Aged; Mutation; Piperidines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2016 |
[Metastatic medullary thyroid carcinoma in a child with multiple endocrine neoplasia 2B. Efficiency of medium-term treatment with vandetanib without thyroid surgery].
Topics: Carcinoma, Neuroendocrine; Child; Female; Humans; Lung Neoplasms; Multiple Endocrine Neoplasia Type 2b; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2016 |
iRGD-Decorated Polymeric Nanoparticles for the Efficient Delivery of Vandetanib to Hepatocellular Carcinoma: Preparation and in Vitro and in Vivo Evaluation.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Liver Neoplasms; Mice; Nanoparticles; Piperidines; Polymers; Quinazolines | 2016 |
Vascular endothelial growth factor signaling is necessary for expansion of medullary microvessels during postnatal kidney development.
Topics: Animals; Humans; Kidney; Mice; Mice, Knockout; Microvessels; Piperidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor A | 2016 |
Discovery, Synthesis, and Evaluation of 2,4-Diaminoquinazolines as a Novel Class of Pancreatic β-Cell-Protective Agents against Endoplasmic Reticulum (ER) Stress.
Topics: Apoptosis; Cell Death; Cell Line; Endoplasmic Reticulum Stress; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Piperidines; Quinazolines; Stereoisomerism; Structure-Activity Relationship; Unfolded Protein Response | 2016 |
Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation.
Topics: Animals; Antineoplastic Agents; Carcinogenesis; Carcinoma; ErbB Receptors; Gene Expression Regulation; Hyperplasia; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Piperidines; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2016 |
Discovery and Optimization of N-Substituted 2-(4-pyridinyl)thiazole carboxamides against Tumor Growth through Regulating Angiogenesis Signaling Pathways.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chick Embryo; Colony-Forming Units Assay; Drug Design; Drug Discovery; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Phosphorylation; Piperidines; Quinazolines; Rats, Sprague-Dawley; Signal Transduction; Stress Fibers; Thiazoles; Wound Healing | 2016 |
The Significant Role of Cyclin D1 in the Synergistic Growth-inhibitory Effect of Combined Therapy of Vandetanib with 5-Fluorouracil for Gastric Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Drug Synergism; E2F1 Transcription Factor; ErbB Receptors; Female; Fluorouracil; Humans; Mice; Mice, Nude; Piperidines; Quinazolines; Stomach Neoplasms; Thymidylate Synthase; Tumor Burden | 2016 |
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Topics: Adenocarcinoma; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; fms-Like Tyrosine Kinase 3; Gefitinib; Gene Rearrangement; Hepatocyte Growth Factor; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; RNA, Small Interfering; Signal Transduction; Sorafenib; Sunitinib | 2017 |
Inhibition of JAK3 and PKC via Immunosuppressive Drugs Tofacitinib and Sotrastaurin Inhibits Proliferation of Human B Lymphocytes In Vitro.
Topics: Apoptosis; B-Lymphocytes; CD40 Ligand; Cell Proliferation; Cells, Cultured; Humans; Immunosuppressive Agents; Interleukin-10; Interleukin-2; Interleukins; Janus Kinase 3; Leukocytes, Mononuclear; Lymphocyte Activation; Piperidines; Protein Kinase C; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Sirolimus | 2016 |
Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Consciousness; Hemodynamics; Indazoles; Losartan; Male; Niacinamide; Phenylurea Compounds; Piperidines; Propranolol; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Regional Blood Flow; Sorafenib; Sulfonamides | 2017 |
Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation.
Topics: Calcitonin; Carcinoma, Neuroendocrine; Cushing Syndrome; Cytoreduction Surgical Procedures; Humans; Hydrocortisone; Male; Middle Aged; Neck Dissection; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms; Thyroidectomy | 2017 |
Synthesis of Ofornine mimics from natural product l-vasicine as anti-hypertensive agents.
Topics: Alkaloids; Aminopyridines; Animals; Antihypertensive Agents; Biological Products; Blood Pressure; Dose-Response Relationship, Drug; Female; Hypertension; Injections, Intravenous; Mice; Molecular Structure; Piperidines; Quinazolines; Rats; Rats, Wistar; Structure-Activity Relationship | 2017 |
Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies.
Topics: Carcinoma, Hepatocellular; Contrast Media; Drug Carriers; ErbB Receptors; Humans; Liver Neoplasms; Microspheres; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A | 2017 |
The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cerebellar Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Humans; Indazoles; Medulloblastoma; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sulfonamides | 2017 |
Binding and functional pharmacological characteristics of gepant-type antagonists in rat brain and mesenteric arteries.
Topics: Aged; Aged, 80 and over; Animals; Azepines; Binding, Competitive; Bridged Bicyclo Compounds, Heterocyclic; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Calcitonin Receptor-Like Protein; Cerebellum; Cerebral Arteries; Dipeptides; Dose-Response Relationship, Drug; Endothelial Cells; Female; Humans; Imidazoles; In Vitro Techniques; Ligands; Male; Mesenteric Arteries; Muscle, Smooth, Vascular; Myography; Piperazines; Piperidines; Protein Binding; Pyridines; Quinazolines; Radioligand Assay; Rats, Sprague-Dawley; Receptor Activity-Modifying Protein 1; Receptors, Calcitonin Gene-Related Peptide; Spiro Compounds; Sus scrofa; Vasodilation; Vasodilator Agents | 2017 |
Chronic PARP-1 inhibition reduces carotid vessel remodeling and oxidative damage of the dorsal hippocampus in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Carotid Arteries; Hippocampus; Hypertension; Male; Oxidative Stress; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Vascular Remodeling | 2017 |
Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.
Topics: Anilides; Animals; Carcinoma, Neuroendocrine; Cell Cycle; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Membrane Potential, Mitochondrial; Mice; Mitochondria; Mitochondrial Dynamics; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2017 |
[Cabozantinib: Mechanism of action, efficacy and indications].
Topics: Anilides; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Everolimus; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Piperidines; Prostatic Neoplasms; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
VEGFR-2 inhibitors and apoptosis inducers: synthesis and molecular design of new benzo[g]quinazolin bearing benzenesulfonamide moiety.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Benzenesulfonamides; Breast; Caspase 3; Catalytic Domain; Cell Cycle Checkpoints; Cell Line; Drug Screening Assays, Antitumor; Enzyme Activation; Humans; Inhibitory Concentration 50; MCF-7 Cells; Molecular Docking Simulation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Spectrum Analysis; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Micellear Gold Nanoparticles as Delivery Vehicles for Dual Tyrosine Kinase Inhibitor ZD6474 for Metastatic Breast Cancer Treatment.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Gold; Humans; Metal Nanoparticles; Mice; Mice, Nude; Micelles; Piperidines; Polyethylene Glycols; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2017 |
Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Cell Adhesion; Cell Adhesion Molecules; Gefitinib; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Monocytes; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Receptors, IgG; Rituximab; Signal Transduction; ZAP-70 Protein-Tyrosine Kinase | 2017 |
Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson's Disease.
Topics: Animals; Male; Parkinsonian Disorders; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Rats; Rats, Sprague-Dawley; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Biophysical and computational characterization of vandetanib-lysozyme interaction.
Topics: Animals; Biophysical Phenomena; Chickens; Circular Dichroism; Cluster Analysis; Enzyme Stability; Ions; Kinetics; Metals; Molecular Docking Simulation; Molecular Dynamics Simulation; Muramidase; Piperidines; Protein Structure, Secondary; Quinazolines; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Thermodynamics | 2018 |
Enhanced glioma therapy by synergistic inhibition of autophagy and tyrosine kinase activity.
Topics: Animals; Antineoplastic Agents; Autophagy; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Endothelial Cells; Glioma; Hydroxychloroquine; Integrin alphaVbeta3; Liposomes; Male; Mice; Piperidines; Protein-Tyrosine Kinases; Quinazolines | 2018 |
[Simultaneous determination of febrifugine and isofebrifugine in Dichroa febrifuga root by HPLC method].
Topics: Chromatography, High Pressure Liquid; Hydrangea; Piperidines; Plant Roots; Quinazolines | 2017 |
[Investigation on stability and degradation kinetics of febrifugine].
Topics: Drug Stability; Hydrogen-Ion Concentration; Kinetics; Piperidines; Quinazolines; Temperature | 2017 |
Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.
Topics: Adolescent; Carcinoma, Medullary; Child; Disease Progression; Disease-Free Survival; Female; Germ-Line Mutation; Humans; Male; Multiple Endocrine Neoplasia Type 2a; Outcome Assessment, Health Care; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2018 |
Investigation of the binding characteristics between ligands and epidermal growth factor receptor by cell membrane chromatography.
Topics: Afatinib; Cell Membrane; Chromatography; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HEK293 Cells; Humans; Ligands; Molecular Docking Simulation; Morpholines; Piperidines; Protein Binding; Protein Kinase Inhibitors; Quinazolines | 2018 |
[Analysis of Time-to-onset of Interstitial Lung Disease after the Administration of Small Molecule Molecularly-targeted Drugs].
Topics: Adverse Drug Reaction Reporting Systems; Afatinib; Bortezomib; Carbazoles; Cluster Analysis; Crizotinib; Dasatinib; Databases as Topic; Datasets as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Japan; Lung Diseases, Interstitial; Molecular Targeted Therapy; Particle Size; Piperidines; Pyrazoles; Pyridines; Quinazolines; Time Factors | 2018 |
Synthesis and biological evaluation of novel quinazoline-4-piperidinesulfamide derivatives as inhibitors of NPP1.
Topics: Amides; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Molecular Structure; Phosphoric Diester Hydrolases; Piperidines; Pyrophosphatases; Quinazolines; Structure-Activity Relationship | 2018 |
A secondary RET mutation in the activation loop conferring resistance to vandetanib.
Topics: Adenocarcinoma; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Middle Aged; Mutation, Missense; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines | 2018 |
Vandetanib inhibits cisplatin‑resistant neuroblastoma tumor growth and invasion.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Neoplasm Invasiveness; Neuroblastoma; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, CXCR4; Signal Transduction | 2018 |
Cabozantinib and Vandetanib in medullary thyroid carcinoma: mitochondrial function and its potential as a therapeutic target towards novel strategies to design anti-CSCs drugs.
Topics: Anilides; Humans; Mitochondria; Piperidines; Pyridines; Quinazolines; Thyroid Neoplasms | 2018 |
Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B.
Topics: Adult; Carcinoma, Neuroendocrine; Female; Humans; Multiple Endocrine Neoplasia Type 2a; Mutation, Missense; Neoplasm Metastasis; Piperidines; Pregnancy; Quinazolines; Thyroid Neoplasms; Young Adult | 2018 |
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclin D1; Dose-Response Relationship, Drug; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Confocal Microscopy Observation of Cornea Verticillata After Vandetanib Therapy for Medullary Thyroid Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Corneal Diseases; Female; Humans; Male; Microscopy, Confocal; Piperidines; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2018 |
Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
Topics: Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Humans; Molecular Structure; Piperidines; Protein Kinase Inhibitors; Pyrrolidines; Quinazolines; Structure-Activity Relationship | 2018 |
[Quantitative determination of febrifugine by proton nuclear magnetic resonance spectroscopy with internal standard method].
Topics: Magnetic Resonance Spectroscopy; Piperidines; Protons; Quinazolines | 2018 |
Electrophysiological mechanisms of vandetanib-induced cardiotoxicity: Comparison of action potentials in rabbit Purkinje fibers and pluripotent stem cell-derived cardiomyocytes.
Topics: Action Potentials; Animals; Cardiotoxicity; Cardiotoxins; Electrophysiological Phenomena; ERG1 Potassium Channel; Female; HEK293 Cells; Humans; In Vitro Techniques; Induced Pluripotent Stem Cells; KCNQ1 Potassium Channel; Models, Molecular; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Piperidines; Potassium Channels, Inwardly Rectifying; Potassium Channels, Voltage-Gated; Protein Kinase Inhibitors; Purkinje Fibers; Quinazolines; Rabbits | 2018 |
Gray-bluish cutaneous pigmentation and ice-pick scars induced by vandetanib therapy.
Topics: Adult; Antineoplastic Agents; Cicatrix; Color; Drug Eruptions; Facial Dermatoses; Female; Humans; Pigmentation Disorders; Piperidines; Quinazolines | 2018 |
Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Catechin; Cell Line, Tumor; Cell Proliferation; Chemical Engineering; Drug Carriers; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gold; Humans; Metal Nanoparticles; Mice, Nude; Piperidines; Porosity; Proto-Oncogene Proteins c-akt; Quinazolines; Silicon Dioxide; Tamoxifen; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2018 |
Expression of VEGF with tumor incidence, metastasis and prognosis in human gastric carcinoma.
Topics: Adult; Aged; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neovascularization, Pathologic; Piperidines; Prognosis; Quinazolines; Stomach Neoplasms; Vascular Endothelial Growth Factor A | 2018 |
Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Female; Heterografts; Humans; Mice; Mice, Inbred NOD; Naphthalenes; Neovascularization, Pathologic; Phenylurea Compounds; Piperidines; Pyrimidines; Quinazolines; Quinolines; Receptor, Fibroblast Growth Factor, Type 1; Vascular Endothelial Growth Factor Receptor-1 | 2018 |
Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cyclic N-Oxides; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Drug Synergism; Enhancer Elements, Genetic; Gene Expression Regulation, Neoplastic; Humans; Indolizines; Introns; Molecular Targeted Therapy; Oncogene Addiction; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Pyridinium Compounds; Quinazolines; Thyroid Gland; Thyroid Neoplasms; Tissue Array Analysis; Transcription, Genetic | 2018 |
Appendix 2: Medullary Thyroid Cancer: eUpdate published online 19 February 2018 (http://www.esmo.org/Guidelines/Endocrine-and-Neuroendocrine-Cancers/Thyroid-cancer).
Topics: Administration, Oral; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Europe; Humans; Medical Oncology; Piperidines; Placebos; Practice Guidelines as Topic; Progression-Free Survival; Quinazolines; Randomized Controlled Trials as Topic; Societies, Medical; Thyroid Neoplasms | 2018 |
Vandetanib Tumor Shrinkage in Metastatic Medullary Thyroid Cancer Allowing Surgical Resection of the Primary Site: A Case Report.
Topics: Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Child; Humans; Lung Neoplasms; Male; Piperidines; Quinazolines; Thyroid Neoplasms; Treatment Outcome; Tumor Burden | 2019 |
Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines | 2018 |
Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy.
Topics: Addison Disease; Adult; Aged; Carcinoma, Neuroendocrine; Child; Cortisone; Dose-Response Relationship, Drug; Fatigue; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Thyroid Neoplasms; Treatment Outcome; Young Adult | 2019 |
RET rearrangements are actionable alterations in breast cancer.
Topics: Anilides; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; NIH 3T3 Cells; Nuclear Receptor Coactivators; Oncogene Proteins, Fusion; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; ras Guanine Nucleotide Exchange Factors; Receptor, ErbB-2; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
Traceless Solid-Phase Synthesis of 1' H-Spiro[Pyrrolidine-3,2'-quinazolin]-2-ones and 1' H-Spiro[Piperidine-3,2'-quinazolin]-2-ones via Lactamization of 1,2-Dihydroquinazoline-2-carboxylates.
Topics: Acetophenones; Aminobutyrates; Cyclization; Nitrobenzenes; Ornithine; Piperidines; Pyrrolidines; Quinazolines; Solid-Phase Synthesis Techniques; Spiro Compounds | 2019 |
Mechanisms underlying mechanical sensitization induced by complement C5a: the roles of macrophages, TRPV1, and calcitonin gene-related peptide receptors.
Topics: Acrylamides; Animals; Bridged Bicyclo Compounds, Heterocyclic; Complement C5a; Dipeptides; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Hyperalgesia; Macrophages; Male; Mice; Mice, Inbred C57BL; Nerve Growth Factor; Pain Measurement; Piperidines; Quinazolines; Quinuclidines; Receptors, Calcitonin Gene-Related Peptide; Repressor Proteins; TRPA1 Cation Channel; TRPV Cation Channels | 2019 |
Rare complications of multikinase inhibitor treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Medullary; Female; Follow-Up Studies; Heart Failure; Humans; Intestinal Perforation; Kaplan-Meier Estimate; Male; Middle Aged; Oophoritis; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Retrospective Studies; Risk Factors; Sorafenib; Thrombocytopenia; Thyroid Neoplasms; Time Factors; Young Adult | 2018 |
Single-Molecule Force Measurement Guides the Design of Multivalent Ligands with Picomolar Affinity.
Topics: Animals; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Humans; Ligands; Mice; Molecular Structure; Neoplasms, Experimental; Optical Imaging; Piperidines; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2019 |
Development of novel response surface methodology-assisted micellar enhanced synchronous spectrofluorimetric method for determination of vandetanib in tablets, human plasma and urine.
Topics: Humans; Hydrogen-Ion Concentration; Limit of Detection; Micelles; Piperidines; Quinazolines; Regression Analysis; Reproducibility of Results; Spectrometry, Fluorescence; Tablets | 2019 |
Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro.
Topics: Anilides; Animals; Cytochrome P-450 Enzyme Inhibitors; Ellipticines; Humans; Microsomes, Liver; Oxidation-Reduction; Peroxidases; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Quinolines; Rats | 2019 |
Tyrosine Kinase Inhibitor Use and Wound Healing in Tracheoesophageal Punctures.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Esophagus; Female; Humans; Laryngectomy; Male; Middle Aged; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Punctures; Quinazolines; Quinolines; Speech Disorders; Surgical Wound; Thyroid Neoplasms; Trachea; Wound Healing | 2019 |
Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.
Topics: Animals; Binding Sites; Cell Line, Tumor; Crystallography, X-Ray; Drug Resistance, Neoplasm; Humans; Hydrophobic and Hydrophilic Interactions; Indoles; Mice; Molecular Dynamics Simulation; Mutagenesis, Site-Directed; Piperidines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-ret; Quinazolines; Recombinant Proteins | 2019 |
Predicting pharmacokinetic behaviour of drug release from drug-eluting embolization beads using in vitro elution methods.
Topics: Animals; Chemoembolization, Therapeutic; Doxorubicin; Drug Delivery Systems; Drug Liberation; In Vitro Techniques; Irinotecan; Liver; Liver Neoplasms; Piperidines; Quinazolines; Swine | 2019 |
Long-term cardiovascular effects of vandetanib and pazopanib in normotensive rats.
Topics: Animals; Arterial Pressure; Disease Models, Animal; Drug Administration Schedule; Humans; Hypertension; Indazoles; Male; Piperidines; Pyrimidines; Quinazolines; Random Allocation; Rats; Rats, Sprague-Dawley; Sulfonamides | 2019 |
Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chlorophyllides; DNA Damage; DNA-Activated Protein Kinase; Down-Regulation; Drug Therapy, Combination; ErbB Receptors; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Photochemotherapy; Photosensitizing Agents; Piperidines; Porphyrins; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-2 | 2019 |
A rare cutaneous phototoxic rash after vandetanib therapy in a patient with thyroid cancer: A case report.
Topics: Adult; Antineoplastic Agents; Dermatitis, Phototoxic; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Piperidines; Quinazolines; Thyroid Neoplasms | 2019 |
Preparation and
Topics: Animals; Liposomes; Mice; Particle Size; Piperidines; Polyethylene Glycols; Quinazolines | 2020 |
Molecular dynamics simulation and 3D-pharmacophore analysis of new quinoline-based analogues with dual potential against EGFR and VEGFR-2.
Topics: A549 Cells; Aminoquinolines; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Piperidines; Protein Conformation; Quinazolines; Quinolines; Sorafenib; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Evolution of Transarterial Chemoembolization for the Treatment of Liver Cancer.
Topics: Animals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Liver Neoplasms; Piperidines; Quinazolines; Rabbits | 2019 |
Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response.
Topics: Adolescent; Adult; Aged; Carcinoma, Neuroendocrine; Female; Humans; Male; Middle Aged; Piperidines; Quinazolines; Thyroid Neoplasms; Young Adult | 2020 |
RET-rearranged non-small-cell lung cancer and therapeutic implications.
Topics: Australia; Carcinoma, Non-Small-Cell Lung; Female; Gene Rearrangement; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Middle Aged; Mutation; Piperidines; Precision Medicine; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines | 2019 |
Cytochrome P450 and flavin-containing monooxygenase enzymes are responsible for differential oxidation of the anti-thyroid-cancer drug vandetanib by human and rat hepatic microsomal systems.
Topics: Animals; Antineoplastic Agents; Cytochrome P-450 Enzyme System; Humans; Microsomes, Liver; Oxidation-Reduction; Oxygenases; Piperidines; Quinazolines; Rats | 2020 |
Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors.
Topics: Acrylamides; Adult; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Corneal Diseases; Drug-Related Side Effects and Adverse Reactions; Epithelium, Corneal; ErbB Receptors; Female; Humans; Immunoconjugates; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Retrospective Studies; Therapies, Investigational; Vision Disorders; Visual Acuity | 2020 |
Resveratrol improves the therapeutic efficacy of bone marrow-derived mesenchymal stem cells in rats with severe acute pancreatitis.
Topics: Animals; Apoptosis; Cell Proliferation; Disease Models, Animal; Endothelium, Vascular; Human Umbilical Vein Endothelial Cells; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Necrosis; Pancreas; Pancreatitis; Paracrine Communication; Phosphatidylinositol 3-Kinase; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Resveratrol; Severity of Illness Index; Signal Transduction; Taurocholic Acid; Vascular Endothelial Growth Factor A | 2020 |
Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gene Rearrangement; Genome, Human; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Republic of Korea; Treatment Outcome | 2020 |
Effect of isofebrifugine on the proliferation and invasion of human gastric cancer cells via MMP.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL12; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Piperidines; Quinazolines; RNA, Messenger; Stomach Neoplasms | 2020 |
Oral mucosal pigmentation induced by vandetanib therapy: First clinicopathological characterization.
Topics: Aged; Biopsy; Humans; Immunohistochemistry; Male; Mouth Mucosa; Pigmentation; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2020 |
YAP confers resistance to vandetanib in medullary thyroid cancer.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Silencing; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Mutation; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Signal Transduction; Thyroid Neoplasms; Transcription Factors; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2020 |
Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors.
Topics: Anilides; Animals; Carcinoma, Neuroendocrine; Chemoradiotherapy; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Piperidines; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Anti-migraine Calcitonin Gene-Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice.
Topics: Animals; Arteries; Brain Ischemia; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Dipeptides; Humans; Mice; Piperazines; Piperidines; Pyridines; Quinazolines; Vasodilation | 2020 |
Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial.
Topics: Adult; Carcinoma, Neuroendocrine; Disease Progression; Female; Humans; Male; Middle Aged; Piperidines; Quinazolines; Survival Analysis; Thyroid Neoplasms | 2020 |
Acute tubulointerstitial nephritis induced by the tyrosine kinase inhibitor vandetanib.
Topics: Aged; Humans; Male; Nephritis, Interstitial; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2021 |
Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both
Topics: Adolescent; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Neuroendocrine; Germ-Line Mutation; Homozygote; Humans; Male; Neurofibromatosis 1; Neurofibromin 1; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2021 |
Effects of adenosine triphosphate on vandetanib induced skin damage in rats.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Glutathione; Male; Malondialdehyde; Piperidines; Protein Kinase Inhibitors; Quinazolines; Rats, Wistar; Skin; Skin Diseases | 2020 |
Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Synergism; Female; Humans; Irinotecan; Male; Mutation; Pancreatic Neoplasms; Piperidines; Proto-Oncogene Proteins p21(ras); Quinazolines; Survival Rate; Tumor Suppressor Protein p53 | 2021 |
Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Carcinoma, Neuroendocrine; Female; Germany; Humans; Male; Middle Aged; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quinazolines; Registries; Retrospective Studies; Thyroid Neoplasms; Time Factors; Young Adult | 2021 |
Vandetanib inhibits cell growth in EGFR-expressing cutaneous squamous cell carcinoma.
Topics: Aged; Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Piperidines; Proto-Oncogene Mas; Quinazolines; Skin Neoplasms | 2020 |
Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
Topics: Carcinoma, Neuroendocrine; Disease-Free Survival; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Retrospective Studies; Thyroid Neoplasms | 2020 |
Trends in the Diagnosis and Treatment of Patients with Medullary Thyroid Carcinoma in Korea.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Carcinoma, Neuroendocrine; Child; Child, Preschool; Databases, Factual; Disease-Free Survival; Female; Forecasting; Humans; Infant; Infant, Newborn; Male; Middle Aged; National Health Programs; Piperidines; Quinazolines; Radiotherapy; Reoperation; Republic of Korea; Retrospective Studies; Sex Distribution; Thyroid Neoplasms; Thyroidectomy; Young Adult | 2020 |
Inhibitory effects of vandetanib on creatinine transport via renal organic cation transporter OCT2.
Topics: Cations; Creatinine; HEK293 Cells; Humans; Kidney; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A | 2021 |
Mitochondrial protective effects of PARP-inhibition in hypertension-induced myocardial remodeling and in stressed cardiomyocytes.
Topics: Animals; Cells, Cultured; Citrate (si)-Synthase; DNA, Mitochondrial; Electrocardiography; Glutathione; Hypertension; Hypertrophy, Left Ventricular; Male; Membrane Potential, Mitochondrial; Mitochondria, Heart; Mitochondrial Proteins; Myocytes, Cardiac; Natriuretic Peptide, Brain; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Rats, Inbred SHR; Rats, Wistar | 2021 |
Passive Diffusion vs Active pH-Dependent Encapsulation of Tyrosine Kinase Inhibitors Vandetanib and Lenvatinib into Folate-Targeted Ferritin Delivery System.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Cell Death; Cell Line; Cell Movement; Clone Cells; Diffusion; Drug Carriers; Drug Delivery Systems; Ferritins; Folic Acid; Horses; Humans; Hydrogen-Ion Concentration; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Surface Properties | 2021 |
Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.
Topics: Angiogenesis Inhibitors; Anilides; Animals; Apoptosis; Carcinoma, Neuroendocrine; Cell Cycle; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Embryo, Nonmammalian; Humans; Neovascularization, Pathologic; Neovascularization, Physiologic; Piperidines; Pyridines; Quinazolines; Thyroid Neoplasms; Zebrafish | 2021 |
Preparative separation of two isomeric antimalaria alkaloids febrifugine and isofebrifugine from Dichroa febrifuga roots by countercurrent chromatography.
Topics: Alkaloids; Countercurrent Distribution; Hydrangea; Piperidines; Plant Extracts; Plant Roots; Quinazolines | 2021 |
Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib.
Topics: Apoferritins; Cell Line, Tumor; Drug Stability; Humans; Hydrogen-Ion Concentration; Nanoparticles; Piperidines; Quinazolines | 2021 |
Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Chemoembolization, Therapeutic; Drug Liberation; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia; Liver Neoplasms; MAP Kinase Signaling System; Neovascularization, Pathologic; Piperidines; Quinazolines; Vascular Endothelial Growth Factors | 2021 |
Simple and efficient spectroscopic-based univariate sequential methods for simultaneous quantitative analysis of vandetanib, dasatinib, and sorafenib in pharmaceutical preparations and biological fluids.
Topics: Dasatinib; Humans; Pharmaceutical Preparations; Piperidines; Quinazolines; Sorafenib; Spectrophotometry | 2021 |
Research Note: Study on the residue depletion of febrifugine and isofebrifugine in broiler chicken.
Topics: Animals; Chickens; Drug Residues; Liver; Meat; Piperidines; Quinazolines | 2021 |
Development of novel univariate and multivariate validated chemometric methods for the analysis of dasatinib, sorafenib, and vandetanib in pure form, dosage forms and biological fluids.
Topics: Calibration; Dasatinib; Humans; Least-Squares Analysis; Piperidines; Quinazolines; Sorafenib; Spectrophotometry | 2022 |
An Unusual Case of Hypopituitarism as an Adverse Effect of Vandetanib and Remission of Breast Metastases in a Patient with Medullary Thyroid Cancer.
Topics: Carcinoma, Neuroendocrine; Female; Humans; Hypopituitarism; Piperidines; Quinazolines; Thyroid Neoplasms | 2021 |
[Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer].
Topics: Anilides; Antineoplastic Agents; Carcinoma, Medullary; Drug Approval; Humans; Mutation; Phenylurea Compounds; Piperidines; Precision Medicine; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Quinolines; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2021 |
A multidimensional biosensor system to guide LUAD individualized treatment.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biosensing Techniques; Biphenyl Compounds; Cell Culture Techniques; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Lignans; Lung Neoplasms; Male; Mice; Mice, Nude; Piperidines; Precision Medicine; Quinazolines; Tumor Cells, Cultured | 2021 |
Bisdemethoxycurcumin alleviates vandetanib-induced cutaneous toxicity in vivo and in vitro through autophagy activation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Diarylheptanoids; Disease Models, Animal; DNA Damage; HaCaT Cells; Humans; Keratinocytes; Membrane Potential, Mitochondrial; Mice, Inbred C57BL; Mitochondria; Piperidines; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; Skin; Skin Diseases | 2021 |
Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
Topics: Adult; Carcinoma, Neuroendocrine; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperidines; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Thyroid Neoplasms; Withholding Treatment; Young Adult | 2021 |
[Medullary thyroid carcinoma: current clinical progress].
Topics: Anilides; Antineoplastic Agents; Carcinoma, Neuroendocrine; Humans; Piperidines; Pyridines; Quinazolines; Thyroid Neoplasms | 2021 |
Novel vandetanib derivative inhibited proliferation and promoted apoptosis of cancer cells under normoxia and hypoxia.
Topics: Apoptosis; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; HeLa Cells; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasms; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2022 |
Phase 0 Study of Vandetanib-Eluting Radiopaque Embolics as a Preoperative Embolization Treatment in Patients with Resectable Liver Malignancies.
Topics: Adolescent; Adult; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2022 |
Downregulation of hERG channel expression by tyrosine kinase inhibitors nilotinib and vandetanib predominantly contributes to arrhythmogenesis.
Topics: Arrhythmias, Cardiac; Down-Regulation; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; HEK293 Cells; Humans; Induced Pluripotent Stem Cells; Myocytes, Cardiac; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2022 |
Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type-B receptor 4.
Topics: Antineoplastic Agents; Apoptosis; Drug Resistance, Neoplasm; Ephrins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphatidylinositol 3-Kinases; Piperidines; Quinazolines | 2022 |
Disseminated medullary thyroid cancer - an alternative therapeutic approach.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Humans; Piperidines; Quinazolines; Thyroid Neoplasms | 2022 |